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ABSTRACT 
 
Mechanistic Investigation of Tolfenamic Acid, Betulinic Acid, and Aspirin in Anti-
Cancer Therapy. 
 (August 2011) 
Xinyi Liu, B.MS., Chongqing Medical University 
Chair of Advisory Committee: Dr. Stephen H. Safe 
 
Tolfenamic acid (TA), betulinic acid (BA) and acetylsalicylic acid (aspirin) 
are anticancer drugs, and Sp1, Sp3, Sp4 (Sps) transcription factors and growth 
factor 2 (EGFR2, HER2 / ErbB2) are important molecular markers in cancer 
cells. In this study, the molecular mechanisms by which these anticancer drugs 
target downregulation of Sps and ErbB2 were investigated in breast cancer 
cells.  
TA inhibits growth of ErbB2-overexpressing BT474 and SKBR3 breast 
cancer cells by inhibiting ErbB2 expression. TA downregulates ErbB2 mRNA 
expression and promoter activity, and TA also decreased expression of the YY1 
and AP-2 transcription factors that are required for basal ErbB2 expression. 
These effects were accompanied by decreased ErbB2-dependent kinase 
activities, induction of p27, and decreased expression of cyclin D1. In addition, 
TA also inhibited tumor growth in BT474 cells orthotopic mouse model. 
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However, Sp proteins were not the major target of TA in these breast cancer 
cells. 
BA inhibits growth of ErbB2–overexpressing BT474 and MDA-MB-453 
and induced apoptosis in these cells. BA induced proteasome-independent 
downregulation of specificity protein (Sp) transcription factors Sp1, Sp3, Sp4 and 
Sp-regulated genes, and BA also decreased expression of ErbB2, ErbB2-
regulated kinases and YY1. Knockdown of Sp1, Sp3, Sp4 and their combination 
by RNA interference was accompanied by decreased expression of ErbB2, YY1. 
BA-dependent repression of Sp1, Sp3, Sp4 and Sp regulated genes was due in 
part to induction of the Sp repressor ZBTB10 and downregulation of microRNA-
27a (miR-27a) which constitutively inhibits ZBTB10 expression, and these 
effects is dependent on activation of the cannabinoid 1 (CB1) and CB2 receptors. 
Aspirin inhibits growth and induces apoptosis in BT474 and MDA-MB-453 
breast cancer cells. Aspirin downregulated expression of ErbB2, Sp1, Sp3, Sp4 
and Sp-regulated genes, and these effects were inhibited in part by proteasome 
inhibitior lactacystin and phosphatase inhibitors. Aspirin-induced downregulation 
of Sp proteins are reversed in cells transfected with an oligonucleotide (siMKP5) 
that knocks down MKP5 by RNA interference, demonstrating for the first time a 
linkage between a drug-induced phosphatase (MKP-5) and Sp downregulation. 
These results suggest that TA, BA and aspirin represent novel and 
promising new anticancer drugs for cancer treatment by targeting Sp proteins 
and ErbB2 oncogene. 
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1. INTRODUCTION  
 
1.1 Cancer  
1.1.1 Cancer statistics 
Cancer is the second leading cause of death after heart disease in the 
United States and for individuals between 40 and 79 years of age, cancer is the 
leading cause of death. Approximately 1.53 million new cases of cancer will be 
diagnosed in 2010 and 0.57 million people will die from this disease in the 
United States. The three most common tumor types among men are cancers of 
the prostate, lung and bronchus, and colorectum, and the cancers of breast, 
lung and bronchus, and colorectum are the 3 most commonly diagnosed tumor 
types among women. Cancers of the lung and bronchus, prostate, breast, and 
colorectum account for about 50% of all cancer deaths among men and women 
[1] . 
1.1.2 Causal factors of cancer 
Cancer is not associated with a single cause. Multiple factors including 
tobacco, infectious organisms, chemicals, radiation, inherited mutations, 
hormones, immune conditions, and metabolically-mediated mutations have been 
identified as risk factors for the development of cancer (Table 1) [2]. 
Cigarette smoking is one of the major risk factors for development of 
cancer. Almost one-third of all cancers are related to smoking even though 
tobacco consumption has decreased in recent years. The incidence of lung can- 
____________ 
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cer has increased rapidly in smoking populations particularly among individuals 
who started smoking at an early age and have continued smoking throughout 
their adult years [2]. Smoking is a risk factor for cancers of the lung, pancreas, 
bladder, kidney, larynx, mouth, pharynx and oesophagus, and there is also 
evidence indicating that smoking may contribute to development of stomach, 
liver and probably cervical cancers [3,4]. Different populations have different 
susceptibilities to various smoking-related diseases. For example, smoking 
causes more liver cancer and less heart disease in China than in the USA [5]. 
 
 
 
Diet and overweight can also affect cancer development. There is 
evidence showing that folate and aspirin reduce colon cancer incidence [6], and 
foods containing carotenoids, vitamins C and E decrease the incidence of some 
cancers. Cruciferous vegetables containing anticancer agents such as indole-3-
carbinol (I3C) reduce colon, breast and pancreatic cancer risk [7].  Obese men 
and women are at highest risk for post-menopausal breast cancer, cancers of 
the endometrium, and gall-bladder and kidney compared to individuals in the 
“normal” weight range [8,9]. It has been suggested that approximately one- third 
External Factors 
 
Tobacco  
Chemicals  
Occupational or 
environmental conditions  
Radiation  
Infectious organisms  
 
Internal Factors 
 
Gene-Polymorphisms  
Gene-Mutations  
Hormones  
immune states  
Aging  
Diet and exercise 
Table 1 Risk factors for cancer. 
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all cancers are associated with diet and obesity and these can be prevented in 
part by dietary changes [10].  
Reproductive and hormonal factors primarily affect the incidence of breast 
and ovarian cancers, and both endogenous and exogenous hormones account 
for these effects [11,12]. For example, hormone replacement therapy and 
oestrogens administered as oral contraceptives increase incidence of breast 
cancer; increased parity and oral contraceptives lower the incidence of 
endometrial and ovarian cancers. Later age at first childbirth, lower parity and 
shorter periods of breastfeeding are the major reasons that women in developed 
countries have a higher risk of breast cancer compared to women in developing 
countries [13,14].  
Epidemiology studies in the past two decades have demonstrated that 
infectious pathogens including viruses, bacteria and parasites are important risk 
factors for cancer.  For example, it has long been recognized that hepatitis-B 
virus contributes to liver cancer, and recently it was reported that smoking 
synergistically enhanced hepatitis-induced hepatocellular carcinomas [15]. A 
major factor for development of stomach cancer is Helicobacter pylori, a gastric 
bacteria that causes gastric ulcers [15]. Human papillomaviruses can also cause 
anogenital, skin, and neck cancers [16]. 
Inherited genetic alterations have also received attention as important 
factors that influence development of cancer. Many studies show gene 
polymorphisms that are involved in mutagen metabolism strongly influence 
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cancer incidence. For example, in workers exposed to high levels of certain 
aromatic amines, the N-acetyltransferase (NAT2) slow acetylator phenotype 
confers a higher risk of bladder cancer [17]. Mutations in  glutathione S-
transferase  genes are associated with increased lung cancer risk [18], and 
polymorphisms in oncogenes and tumor-suppressor genes  also increase 
cancer risk. For example, a single nucleotide polymorphism at I1307K in the 
APC gene doubles the risk of colon cancer [19]. 
1.1.3 Tumor progression, oncogenes and tumor-suppressor genes 
Human carcinogenesis is a multi-stage process, which can be divided into 
three basic steps, namely, initiation, promotion, and progression [20] (Fig. 1). In 
the initiation stage, pre-malignant lesions such as dysplasia and hyperplasia can 
be found in various organs prior to formation of malignant tumors. Environmental 
factors such as viral infections can induce polyclonal expansion of hyperplastic 
cells, and genetic alterations induce monoclonal expansion of the cells to give 
pre-malignant lesions. Subsequently, pre-malignant cells are converted into 
malignant cells of clonal origin which can form a primary tumor after 
accumulation of genetic alterations. This is called the promotion stage. The 
converted cells are not responsive to growth inhibitory factors and they expand 
into surrounding tissues; however, these cells are not invasive or metastatic at 
early stages of primary tumor formation. However, in the progression stage, 
primary tumors accumulate genetic alterations that result in formation of invasive 
and metastatic cells leading to the appearance of new clones. These highly 
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metastatic cells exhibit more gene alterations than non-metastatic cells [21] (Fig. 
1).   
Figure 1. Stepwise progression of human cancer (adapted from [21]). 
Genetic studies of human cancers suggest that multiple gene alterations 
occur during cancer progression and these include changes in expression of 
oncogenes and tumor-suppressor genes. If mutated or highly expressed, an 
oncogene can transform a normal cell into a tumor cell. A proto-oncogene is a 
normal gene that can be converted into an oncogene due to mutations or 
overexpression. Proto-oncogenes are involved in regulation of cell growth and 
differentiation, wound healing, regeneration of the liver, growth factor-induced 
stimulation of cells, and embryogenesis. Proto-oncogenes encode for various 
growth factors, growth factor receptors, tyrosine kinases, regulatory proteins in 
signal transduction, and nuclear regulatory proteins[22] (Table2). 
The mechanisms that activate proto-oncogenes to cancer-causing oncog- 
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enes can be classified as quantitative and qualitative. The quantitative 
mechanism is associated with gene amplifications, which result in increased 
expression of a proto-oncogene and its corresponding protein product. For 
example, amplification of the N-myc proto-oncogene has been linked to a 
number of human neuroblastomas, retinoblastomas, small cell lung carcinomas, 
and astrocytomas [23]; ErbB2 amplifications are associated with mammary 
carcinomas, salivary adenocarcinomas, and gastric adenocarcinomas [24].  The 
qualitative mechanism is due to DNA rearrangements, which lead to changes in 
nucleotide sequences that are pivotal for the activities of a gene. This 
mechanism may involve a reduction or increase in chromosome numbers, point 
mutations, deletions, translocations, inversions, isochromosomes, and ring 
chromosomes [25]. For example, as a consequence of a chromosomal 
rearrangement, c-myc and c-abl are activated by structural alterations in Burkitt’s 
lymphoma and chronic myelocytic leukemia, respectively [26,27]. Activation of 
the ras oncogene due to a structural mutation was the first example of an 
activated proto-oncogene in human tumors. The ras proto-oncogene family is 
Sis, int-2, hst-1                              Growth factor 
erbB, fms, met, ros, trk, ret           Growth factor receptor with tyrosine kinase activity 
src, abl, lck, yes                            Tyrosine kinase 
Ha-ras, K-ras, N-ras, gsp, gip       Regulatory protein in signal transduction 
Mos, raf                                         Serine/threonine kinase 
Myc, myb, fax, c-jun, rel                Nuclear regulatory protein 
 
 
 
 
 
Proto-oncogene                            Function 
Table 2. Proto-oncogenes and their functions. 
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interesting due to their importance in the development of many types of tumors. 
The K-, H-, and N-ras oncogenes are overexpressed and have point-mutations 
in more human tumors than any other oncogene. For example, a G35A point 
mutation of the K-ras gene is found in lung cancers; an A182T point mutation of 
the H-ras gene is detected in liver cancer, and G37C and C181A point mutations 
of N-ras gene are observed in skin cancers [28-30]. All the point mutations 
activate the ras oncogenes. The Philadelphia chromosome is an example of 
proto-oncogene activated by a chromosomal translocation. In 90% of patients 
with chronic myeloid leukemia, a balanced reciprocal 9:22 translocation occurs. 
Chromosome 9 acquires a breakpoint within an intron of the ABL oncogene, the 
translocation joins most of the ABL sequence with BCR gene on chromosome 
22 to create a fusion gene. This fusion gene produces an ABL gene protein 
product with high cell transforming activity [31]. 
Another important type of genetic alteration that leads to cancer is the 
inhibition of tumor-suppressor gene expression. The incidence of tumor-
suppressor gene mutations is higher than that of oncogene mutations in tumors. 
A tumor-suppressor gene protects cells from transformation, but in contrast with 
oncogenes which require activation, genetic alterations that inactivate tumor-
suppressor gene activities are important for tumor development. In addition, a 
recessive mutation in which both alleles of the gene are altered is required for 
genetic alterations of tumor-suppressor genes [32]. 
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The Human retinoblastoma gene was one of the first examples showing 
the importance of tumor-suppressor genes in carcinogenesis. Molecular studies 
show that the Rb gene prevents cells from entering into G1/S phase, and 
therefore mutation of this gene promotes cell proliferation [33]. Retinoblastoma, 
an embryonic neural retinal tumor that occurs in young children has heritable 
and non-heritable forms. The heritable form is a result of a chromosome deletion 
in which a germ-line mutation occurs on chromosome 13 at the Rb-1 locus. 
However, the result of this mutation is recessive, and is not sufficient to generate 
a tumor. Therefore a second mutation is required to un-mask the effects of the 
original Rb-1 mutation. Two somatic mutations are required to occur at each Rb-
1 locus in non-heritable cases [34].  
The p53 gene is another example of tumor-suppressor gene that is 
frequently mutated in human tumors and is associated with loss of 
heterozygocity (LOH) in high percentage of colon (70%), breast (30%-50%), and 
lung cancers (50%). Loss of heterozygosity is observed when one of the alleles 
of a gene is already inactivated and loss of function of the other allele results 
from mutations. This term is usually associated with tumor-suppressor gene 
inactivation and LOH can lead to dysfunction of a normal tumor-suppressor gene 
and thereby enhance tumor formation. Mutations of the p53 gene are detected in 
leukemias, lymphomas, sarcomas, and neurogenic tumors. There are two major 
functions of the normal p53 gene and one of them is to kill cells which have 
undergone DNA damage. The other function of p53 is to decelerate cells from 
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passing through the G0/G1 to S phase and thereby decrease cell proliferation. A 
mutation in only one tumor suppressor gene is usually not sufficient for a cell to 
become malignant. For example, functional defects in both the p53 and RB 
genes are observed in a number of human cancers, including small-cell lung 
carcinoma and osteosarcoma [35]. Rb and p53 regulate different pathways that  
inhibit cell proliferation and mutations of both genes enhance the likelihood that 
cells will evade growth inhibition. In some cancers, more than 3 tumor-
suppressor genes are mutated. For example, colorectal mutant cancer protein 
(MCC), adenomatous polyposis coli (APC), p53, and deleted in colorectal cancer 
(DCC) are tumor-suppressor genes  mutated in some colorectal cancers [36] 
and several combinations of tumor suppressor gene mutations are detected in 
diverse human tumors. 
1.2 Breast Cancer  
1.2.1  Breast cancer statistics 
Breast cancer occurs mainly in women, and is rarely observed in men. In 
the United States, breast cancer is the second most commonly diagnosed 
cancer in women and it is estimated that 1 in 8 women in the United States will 
develop this disease [37]. Breast cancer incidence increases with age and the 
lowest incidence rate is observed in women aged 20-24 (0.0014%). The highest 
incidence rate (0.44%) is in women aged 75-79 and the decrease in incidence  
in women over 80  has been attributed to decreased screening and incomplete 
detection [37]. Mortality from breast cancer for women in the United States is 
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higher than all other cancers except lung cancer. In 2010, approximately 
200,000 and 1970 new cases of breast cancer will be diagnosed in women and 
men respectively, and about 39840 female and 390 males are expected to die 
from this disease in 2010. 
 Fortunately, the incidence rates of breast cancer decreased by 2% 
between 1999 and 2006. This decrease is due to the reduced use of hormone 
replacement therapy (HRT) by women, suggesting that HRT is a risk factor for 
breast cancer. In addition, mortality rates for breast cancer have been 
decreasing since 1990 and from 1990-1995, the rates decreased by 1.8% 
annually, and from 1995-1998 and 1998-2006, the annual incidence rates 
decreased by 3.3%, and 1.9% respectively. These decreases are due to 
increased awareness, improved therapies and earlier detection of tumors due to 
increased use of mammography [2]. 
Incidence and mortality rates of breast cancer differ by race and ethnicity. 
During 2002-2006, Caucasian women in the United States had a higher 
incidence (0.12%) of breast cancer than African American women (0.11%) 
whereas African American women have higher mortality rates (0.033%) than 
Caucasians (0.023%) during the same period. This suggests that compared to 
African- American women, Caucasians are more likely to develop breast cancer, 
but less likely to die from this disease. One possible explanation is that African 
American women may develop more aggressive breast tumors than Caucasian 
woman, but the reasons for these differences are unclear. Compared with 
  
11 
1
1
 
Caucasian and African- American women, women with Asian, Hispanic, and 
American Indian ethnicity have lower rates of breast cancer incidence and 
mortality and the lowest among these groups are Asian women (0.08% 
incidence and 0.01% mortality) [38].  
1.2.2  Classification, grade and stage of breast cancer 
1.2.2.1 Structure of mammary gland 
A normal human mammary gland is composed of hollow cavities, namely 
alveoli, cuboidal cells which are responsible for milk secretion and are enclosed 
by myoepithelium. The alveoli assemble to form lobules which harbor a 
lactiferous duct that are connected to openings in the nipple. Oxytocin excretion 
in the brain induces the myoepithelial cells to contract and expel milk secreted 
from the alveoli to the lobule lumen and through the lactiferous duct to the 
nipple.  Tissues linked to a single lactiferous duct constitute a “simple mammary 
gland”, and all mammary glands serving one nipple are called a “complex 
mammary gland”. Humans normally have two complex mammary glands in each 
breast, and 10-20 simple mammary glands in each complex mammary gland 
[39]. Other components of the breast include mammary epithelial cells 
extracellular matrix (ECM) containing myoepithelial basement membrane and 
connective tissue, adipocytes, and fibroblasts. These structures are essential for 
maintenance of the polarized morphology of the lactiferous ducts, to support 
mammary structure, and to maintain connections between the mammary 
epithelium and their global environment [40] (Fig. 2). 
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1.2.2.2 Histopathological classification of breast cancer 
Breast cancer is primarily classified according to its histopathological 
appearance and can be divided into two major groups, noninvasive and invasive 
breast cancer. Noninvasive breast cancers include ductal carcinoma in situ 
(DCIS) and lobular carcinoma in situ (LCIS). Invasive breast cancers include 
invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), tubular 
carcinoma, and some types that are rarely seen in clinic such as medullary 
carcinoma, mucinous carcinoma, metaplastic carcinoma, invasive cribriform 
carcinoma, invasive papillary carcinoma, and invasive micropapillary carcinoma. 
There are also other types of breast cancer that do not fit into any of the two 
groups and these include inflammatory breast cancer, Paget’s disease of the 
nipple, and phylloides tumors (Table 3).  
Ductal carcinoma in situ (DCIS) accounts for about 15% of the new breast 
cancer cases in the United States and is the most common noninvasive breast 
cancer. DCIS is characterized as uncontrolled cell growth that is limited to the 
ductal structure of the breast [41] and DCIS is often classified as a precancerous 
change. However, others believe that any cell changes exceeding atypical 
hyperplasia should be considered as cancer [42]. DCIS is usually diagnosed by 
mammogram screening and treated with surgery or radiation. DCIS is not life-
threatening and the prognosis is good: the five-year survival rate is almost 100% 
when  detected and treated at an early stage [43]. However, the incidence of de- 
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Figure 2. Anatomy of breast (Adapted from [44]). 
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veloping invasive breast cancer in the same site of at the opposite breast is 
higher in women who have been previously diagnosed with DCIS compared to 
women without DCIS [45].  
 
 
 
 
 
 
Lobular carcinoma in situ (LCIS) is characterized by accumulation of 
abnormal cells in the milk-producing breast lobules. Under the microscope, the 
normal lobules are interrupted abruptly by abnormal lobule groups in which the 
cells are twice  the size of  normal lobules, and their nuclei are proportionally 
enlarged with an opaque cytoplasm [46]. Both the incidence and the risk of 
developing invasive cancer of LCIS are lower than those of DCIS. LCIS 
frequently harbors multiple lesions and is often detected in both breasts. 
Symptoms associated with LCIS cannot be detected by mammography and the 
diagnosis usually occurs after a breast biopsy for other reasons [47]. Typically, 
Noninvasive 
 
 
 
DCIS 
LCIS 
Invasive 
IDC 
ILC 
Tubular carcinoma 
Medullary carcinoma 
Mucinous carcinoma 
Metaplastic carcinoma 
Invasive cribriform carcinoma 
Invasive papillary carcinoma 
Invasive micropapillary carcinoma 
Other types 
 
 
Inflammatory breast cancer 
Paget’s disease of the nipple 
Phylloides tumors 
Table 3. Histopathological classification of breast cancer 
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LCIS is considered as a marker of increased risk for future development of 
invasive breast cancer. Thus, most women diagnosed with LCIS need to 
increase their surveillance have frequent physical examinations and a 
mammogram every 6 months. For LCIS patients with a family history of breast 
cancer, a mastectomy is recommended [48] whereas post-menopausal women 
with LCIS are treated with tamoxifen or a similar antiestrogenic drug such as 
raloxifene [49].  
Invasive ductal carcinoma (IDC) accounts for about 80% of invasive 
breast cancer, and also is the most common (70%) type of breast cancer. 
Histopathological studies show that the tumor appears as a peri and intra 
canalicular fibroadenoma with a number of atypical epithelial changes varying 
from atypical ductal hyperplasia to DCIS [50]. In addition to the in situ changes, 
infiltrating groups of malignant ductal epithelial cells are found in the surrounding 
breast tissues. Inflammatory responses are apparent around the DCIS and 
invasive carcinoma [51] and since the cells are metastatic they can migrate to 
other tissues through the lymphatic system or bloodstream. IDC tumors can 
cause retraction of the nipple or skin, and can easily be felt in a physical exam 
as an irregular-shaped hard lump and these are readily detected by 
mammography [52]. Treatment of IDC includes surgery, chemotherapy, 
hormonal and radiation therapy. Seventy percent of women diagnosed with IDC 
choose breast-conserving surgical treatments such as lumpectomy for relatively 
small tumor; mastectomy is used for large tumors to remove the entire breast 
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and some lymph nodes and thereby decrease the chance for tumor recurrence 
[53]. Most women with IDC are treated with chemotherapy and / or hormonal 
therapy after the surgery. Chemotherapy removes tumor cells that are rapidly 
proliferating, and hormonal therapy kills cells that require hormones for growth 
and both treatments inhibit tumor metastasis. In some cases, radiation therapy is 
used to remove remnants of cancer cells in the surgical area. Twenty year- 
survival rates of IDC patients range from 50%-98% depending on the tumor size 
[54]. 
Invasive lobular carcinoma (ILC) accounts for 10% invasive breast cancer 
and is the second most common types of breast cancer. ILC begins in the milk-
producing lobules and penetrates into the surrounding tissues and spreads to 
other parts of the body. About two thirds of women with invasive breast cancer 
are over 55 years of age, and ILC is often observed in older women (early 60s) 
compared to IDC [55]. Hormone replacement therapy (HRT) after menopause 
increases the risk of ILC. Microscopically, the tumor is formed by uniform 
rounded cells with light cytoplasm and large nuclei with single nucleoli. The 
tumor cells aggregate in the alveoli and are separated by collagen-rich fibrous 
tissues. IDC tumors pass though the lobules into the adipose tissues and can be 
observed in the skin [56]. Compared with IDC, ILC often attacks both breasts 
and is more difficult to identify by mammography. Treatment of ILC includes 
local and systemic therapy and local treatment includes surgery and radiation. 
Lumpectomy or mastectomy is based on tumor size, and radiation is 
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recommended after mastectomy if the tumor is larger than 5 cm and/or the 
lymph nodes are involved.  Chemotherapy and hormonal therapy are used as a 
systemic treatment to destroy any cancer cells that remain or have metastasized 
[57]. 
Tubular carcinoma is a rare invasive breast cancer that accounts for 
about 1-2% of all breast cancer cases. The average age of diagnosis of tubular 
carcinoma ranges between mid-40s to late-60s [58]. Tubular carcinoma is 
considered as a subtype of IDC; however, the microscopic appearance of tumor 
cells is quite different. In this case, the cancer cells are regular and highly 
differentiated, arranged in well-defined tubules. Tubular carcinoma is usually 
confined in the milk ducts and invasion to surrounding tissues is less likely than 
observed for other types of breast cancers [59]. Surgery can be conducted to 
remove the cancer and affected lymph nodes and procedures include 
lumpectomy which removes small size tumors, and mastectomy  to remove 
large tumors and affected lymph nodes. Adjuvant therapy includes 
chemotherapy, radiation and/or hormonal therapy. The main goal of 
chemotherapy and radiation is to kill any remaining cancer cells at the tumor site 
and cells that metastasize to other tissues. Hormonal therapy with tamoxifen 
blocks the growth promoting effects of estrogen and since almost all tubular 
carcinomas are estrogen receptor positive, tamoxifen is a highly effective 
treatment [60]. 
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Other sub-types of invasive breast cancer are very rare. For example, 
medullary carcinoma accounts for less than 5-7% of all invasive breast cancers; 
mucinous carcinoma is less than 5% of all invasive breast cancers; metaplastic 
carcinoma represents less than 5% of all breast cancers; invasive cribriform 
carcinoma comprises 5-6% of invasive breast cancers; invasive papillary 
carcinoma accounts for less than 1-2% of invasive breast cancers; and the 
incidence of invasive micropapillary carcinoma is less than 3% of invasive breast 
cancers [61]. 
Other types of breast cancers such as inflammatory breast cancer, 
Paget’s disease of the nipple, and phylloides tumors cannot be classified into 
either noninvasive or invasive breast cancers, and inflammatory breast cancer 
accounts for only 2% of breast cancer. Unlike other breast cancers, 
inflammatory breast cancer usually appears as redness, swollen, tenderness, 
and blockage of the lymph vessels in the skin of breasts. This type of mammary 
cancer does not grow like a solid tumor and cannot be detected by 
mammography or ultrasound resulting in a relatively poor prognosis [62]. Paget’s 
disease of the nipple accounts for only 1% of all breast cancers and begins in 
the milk ducts and appears like mild scaling, pain, and itching of the nipple. 
Paget’s disease can be in situ or invasive, and the prognosis is very good when 
the foci are in situ. Phylloides tumors start from the periductal stromal cells and 
accounts for less than 1% of breast cancers [63]. Phylloides tumors can be 
benign, borderline, or malignant and are composed of benign epithelium and 
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connective tissue, which determine whether the tumor is benign, borderline, or 
malignant. Total mastectomy is often used for treatment of phylloides tumors 
[64]. 
1.2.2.3 Grade of breast cancer 
Pathologists often use histological grades to identify the type of breast 
tumor and determine its prognosis. The most commonly used grading scheme is 
the Scarff-Bloom-Richardson system [65]. To determine the grade of a breast 
cancer, pathologists usually observe three features of the breast tumor under 
microscope. The first one is the frequency of cell mitosis, the second one is 
formation of cancers that consist of tubular structure, and the third one is nuclear 
pleomorphism, which accounts for changes of cell size and uniformity. A score 
ranging from 1 to 3 is assigned to each of the features; a lower score means 
slower cell growth, and a higher score indicates faster cell growth. Hence, the 
three scores are added to give a final score ranging between 3 and 9. A tumor 
with a final score between 3 and 5 is classified as a Grade 1 tumor, and is 
characterized by well differentiated tumor cells; a final score of 6 or 7 is 
considered to be a Grade 2 tumor, in which the cells are moderately 
differentiated; and a final score of 8 or 9 is a Grade 3 tumor with poorly 
differentiated cells. Necrosis is another factor that determines tumor grade [66]. 
When necrosis occurs in a high grade tumor close to the outside margin of 
breast, the tumor is more likely to recur after the treatment. 
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1.2.2.4 Classification according to receptor status 
Biological messengers such as hormones bind to receptors on the 
surface, in the nucleus or in the cytoplasm of the cells. Breast cancers can also 
be classified to subtypes according to their expression of receptors. Three 
important receptors: namely, the estrogen receptor (ER), progesterone receptor 
(PR), and human epidermal growth factor receptor 2 (HER2 / neu / ErbB2), may 
or may not be expressed in breast cancer cells and tumors. Breast cancer cells 
are classified as ER positive (ER+), ER negative (ER-), PR positive (PR+), PR 
negative (PR-), HER2 positive (HER2+), and HER2 negative (HER2-). Based on 
receptor status, breast cancers can be classified into four molecular groups: (1) 
basal-like breast cancer, which is ER-, PR- and HER2- (triple negative, TN); (2) 
luminal A, in which tumors are ER+ and considered to be low grade; (3) luminal 
B, which are ER+ and high grade and (4) HER2+ tumors, in which HER2  is 
amplified.   
1.2.2.4.1 Basal-like breast cancers 
Basal-like breast tumors express genes that are typically found in the 
normal basal myoepithelial cells of the breast. These genes include vimentin, αB 
crystalline, fasin, p-cadherin and cavelolin1 and 2, and basal cytokeratins (CKs) 
such as CK5 / 6, CK14 and CK17 [67-69]. Since CK expression is one of the 
most important features of basal-like tumors, they have been used in almost all 
immunohistochemistry studies as markers to define basal-like tumors. Basal-like 
breast cancer is often observed in young individuals and accounts for 15% of all 
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breast cancers. Over 60% of basal-like breast carcinomas show expression of 
epidermal growth factor receptor (EGFR) and unusually high levels of genes 
associated with cell proliferation, such as Ki-67 and PCNA [70,71]. Mutations in 
p53 are observed in about 85% of basal-like breast cancers [72].  
Basal-like breast carcinoma appears as high histological grade with a 
high percentage of cell mitosis and a central necrosis area which may reach the 
border of the tumor and infiltrate into lymphocytes [73]. Large portions of the 
tumors show typical ductal structures and occasional tubular foci. The tumor 
cells are usually pleomorphic with high nuclear-cytoplasmic ratio. Metaplastic 
features such as spindle cells and squamous cell metaplasia, and medullary 
characteristics are frequently observed in basal-like breast carcinomas, and 
almost all medullary breast carcinomas and over 90% of metaplastic breast 
carcinomas exhibit a basal-like phenotype [74,75].  
Basal-like breast cancers exhibit an aggressive clinical behavior and poor 
outcomes, and may develop a locoregional and distant metastasis within the first 
five years after initial diagnosis. Theses tumors often metastasize to the brain 
and lung [76], and rarely to the bone and liver [77]. 
Frequently, basal-like breast cancer are considered to be triple-negative 
(TN) breast cancer because of the absence of ER, PR and HER2 expression in 
almost all basal-like breast cancers. Triple-negative breast cancers constitute 
10-17% of all breast cancers, and the range depends on the standards used to 
assess receptor status [78,79]. Both basal-like breast cancer and triple negative 
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breast cancer preferentially affect young African-American women;  both of the 
two tumor types usually exhibit a  histological grade of 3, even though about 
10% of triple-negative breast cancers are in grade 1 [80]; both of the two tumor 
types are aggressive and patients have a poor prognosis [81].  
A major similarity between basal-like and triple-negative breast cancers is 
the occurrence of breast cancer 1(BRCA1) mutations. BRCA1 is a human 
tumor-suppressor gene and was identified in 1990 by King and coworkers [82] 
and cloned in 1994 [83]. The protein encoded by BRCA1 repairs damaged DNA 
and kills cells when the DNA damage cannot be repaired. Mutation of the 
BRCA1 gene leads to uncontrolled proliferation of cells with damaged DNA and 
this enhances tumor formation [84]. The protein product of BRCA1 is called 
breast cancer type 1 susceptibility protein. It binds to other proteins such as 
DNA damage sensors, signal tranducers and tumor suppressors to form a multi-
subunit protein complex, namely the BRCA1-associated genome surveillance 
complex (BASC) [85].The BASC complex is involved in transcription, double-
stranded break DNA repair, ubiquitination and transcriptional regulation. Many 
tumors with a BRCA1-mutation are triple-negative and also express basal CKs 
[86], and microarray profiling of RNAs from these tumors show that BRCA1 
mutations exhibit basal-like tumor mRNA expression [87], suggesting similar 
causes and / or signaling pathways in the two subtypes. 
Since basal-like and triple negative breast cancers exhibit many 
similarities, can they be combined as a single type of tumor? It has been 
  
23 
2
3
 
proposed by some investigators that the basal-like breast cancers are primarily 
triple-negative with respect to ER, PR and HER2 expression whereas this has 
been disputed by others [88]. Microarray-based expression profiling revealed 
that 15-54% of the basal-like subgroup of breast cancer expresses at least one 
of the ER, PR and HER2 receptors [89]. Furthermore, careful analyses of 
microarray-based expression profiles indicate that triple-negative breast cancer 
also includes other subtypes of breast tumors designated as normal-breast-like 
cancers. The so-called normal breast-like cancers are clustered with basal-like 
and are HER2+ / ER- [86]. Therefore, the basal-like and triple-negative breast 
tumor definitions cannot be simply combined to describe the same subtype of 
breast tumors due to their own distinctive characteristics. 
Basal-like / triple-negative breast tumors are one of the most challenging 
subtypes of breast cancers, since the hormone receptors and HER2 are not 
expressed and these tumors can only be treated with cytotoxic anticancer drugs. 
[90]. Triple-negative breast tumors do not respond to existing targeted therapies 
such as endocrine therapy and monoclonal antibodies such as trastuzumab, or 
tyrosine kinase inhibitors. Persistent follow-up of triple-negative breast cancer 
cases indicates a poor prognosis of this subtype compared to patients with 
tumors expressing hormone receptors [91]. Chemotherapeutic agents used for 
treatment include doxorubicin, cyclophosphamide, methotrexate, paclitaxel, 
fluorouracil, epirubicin, docetaxel, vinorelbine, gemcitabine, capecitabine, and 
carboplatin. Ixabepilone, an epothilone analog which binds tubulin, stabilize 
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microtubules, arrest cell cycles, and cause subsequent apoptosis of cells, 
appears to be reasonably effective for treating triple-negative breast tumors and 
other metastatic breast cancers [88]. Some new targeted therapies are emerging 
for treating TN cancers. Histological studies of basal-like / triple-negative tumors 
indicate extensive glomeruloid microvascular proliferation. Therefore, 
angiogenesis inhibitors such as bevacizumab, a human monoclonal antibody for 
vascular endothelial growth factor (VEGF), show some success in treatment of 
the triple-negative subtype of breast cancer [92]. Another emerging targeted 
therapeutic agent is cetuximab, a human monoclonal antibody against EGFR, 
which is overexpressed in these tumors, and it has been used with limited 
success in treatment of the triple-negative breast cancer. [93]. However, single 
agents are minimally effective for treating triple-negative cancers and ongoing 
studies with drug combinations may be more successful. 
1.2.2.4.2 Luminal breast cancers 
 Another subtype of breast cancer according to receptor status is hormone 
receptor positive breast cancers. Hormone receptors that are expressed in 
breast cancer cells include estrogen receptor (ER) and progesterone receptor 
(PR). 
The ER responds to the hormone 17 β - estradiol (E2, estrogen), and ER 
is a member of the nuclear hormone receptor family, and functions as a ligand-
activated transcription factor. ERα and ERβ are two forms of the receptor and 
are encoded by separate genes, ESR1 and ESR2, respectively [94]. In response 
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to estrogen, ER forms dimers which could include ERα/ERα and ERβ/ERβ 
homodimers, and ERα/ERβ heterodimers. ERα and ERβ have significant 
sequence homology, and both receptors contain five domains typical of nuclear 
receptors [95]. The N-terminal A/B domain exhibits ligand-independent 
transactivation activity. The DNA-binding domain (C) contain zinc finger motifs 
that bind to estrogen response element (ERE) in promoter regions of target 
genes and the D domain contains a flexible hinge region. The E domain, also 
known as ligand binding domain binds to estrogenic ligands and also interacts 
with coactivator and corepressor proteins. After ligand binding, the ER becomes 
transcriptionally active and this results in the induction of gene expression (Fig. 
3). The function of the C-terminal F domain is not clear [96]. Although both ERs 
are extensively expressed in various tissue types, they have different expression 
patterns: ERα is expressed in breast, ovarian stroma, endometrium and 
hypothalamus, while ERβ is distributed in lungs, intestine,  kidney, brain, bone, 
heart prostate, and endothelial cells [97].  
Ligands activate ER-dependent genomic and non-genomic pathways. In 
the classical genomic pathway, estrogen receptors reside in the nucleus and 
after binding ligand the bound complex binds to EREs or other motifs in E2-
responsive genes to activate transcription [94]. The ER also regulates 
transcription of genes that contain other motifs such as an AP-1 or GC-rich sites 
in which the ER binds fos/jun or Sp proteins respectively which are themselves 
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bound to DNA [98,99]. In non-genomic pathways, some estrogen receptors 
increased. This cross-talk between growth factors and estrogen receptors can r- 
 
 
Figure 3. Protein domains of estrogen receptor  (Adapted from [100]). 
eside in the cell surface membrane and  in lipid-rafts and caveolae where they 
may interact with growth factor receptors such as EGFR, HER2 and Insulin-like 
growth factor 1(IGFR1) . These cell surface-associated estrogen receptors can 
be rapidly activated when cells are exposed to estrogen [101]. The non-genomic 
ER pathway leads to rapid activation of mitogen-activated protein kinase 
(MAPK) and phosphatidylinositol 3-kinases (PI3K) signaling [102]. Nuclear 
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estrogen receptors are phosphorylated by activated extracellular-signal-
regulated kinase (ERK) and protein kinase B (AKT/PKB), and transcription 
activity and the stability of phosphorylated nuclear estrogen receptors are result 
in resistance to ER antagonists such as tamoxifen [103]. 
 The progesterone receptor is a member of the steroid-receptor 
superfamily of nuclear receptors. It is also named nuclear receptor subfamily 3 
(NR3C3).The PR is encoded by the PGR gene on chromosome 11 [104]. This 
single gene uses two different promoters and translational start sites to produce 
two isoforms, PR-A and PR-B. The PR protein also contains five domains,  and 
the transcriptional activation function-3 (TAF-3) domain  is only present in the 
amino acid terminal of the PR-B isoform [105]. The two isoforms of PR are 
functionally distinct. For example, PR-B induces proliferation of epithelial cells in 
the uterus in response to both progesterone and estrogen or estrogen alone, 
while the PR-A isoform inhibit estrogen-induced epithelium proliferation [106]. 
Hormone receptor positive breast cancers are also called luminal breast 
cancer. They have similar expression pattern as the luminal epithelium of the 
breast, in which luminal cyto-keratins 8/18, ER and ER activating genes such as 
LIV1 and cyclinD1 are expressed [89,107]. There are two subtypes within the 
luminal breast cancers, luminal A and luminal B. Luminal A subtype is 
characterized as expressing ER and PR, associated with low histological grade 
and cell proliferation rate, and good prognosis (>95% 5 year survival). Luminal B 
breast cancer is defined as expressing ER, PR and HER2 and often with high 
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histological grade; 50-70% of all breast cancers belong to the luminal subtype. 
Luminal A subtypes express more ER-associated genes such as GATA-3 and 
FOXA1, and less proliferative genes than luminal B subtype [108]. GATA-3 is a 
member of the GATA transcriptional factor family [109], and FOXA1 belongs to 
the “winged helix” transcriptional factor family [110]. FOXA1 binds to the 
condensed form of chromatin and increases chromatin accessibility to 
transcription factors such as ER to bind DNA and initiate transcription. GATA-3 
cooperates with FOXA1 to open chromatin efficiently and increase accessibility 
of DNA regulatory elements. Cooperation among GATA-3, FOXA1 and ER is 
essential for development of mammary gland, and loss of control of this 
cooperation may be an indicator for ER positive breast cancers [111]. 
Although both luminal subtypes have good prognosis, luminal A has a 
better outcome than luminal B and this is related to responsiveness to therapy 
[86]. Luminal breast cancers usually have good responses to hormone therapy 
and poor response to chemotherapy. However, recent studies suggest that 
luminal A subtype may receive sufficient benefit from endocrine therapy alone, 
and luminal B subtype may be adequately treated with combination of endocrine 
therapy and chemotherapy, considering that luminal B cells express more 
proliferative genes and less ER-related genes than luminal A tumors [112]. 
Recent studies show that targeted therapy may also work for treating luminal 
breast cancers. Combination usage of bevacizumab, a VEGF antibody, with 
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paclitaxel, a mitotic inhibitor used in chemotherapy, may improve prognosis of 
luminal breast cancer patients [113]. 
1.2.2.4.3 HER2+ breast cancers 
HER2 positive breast tumors account for 15%-20% of all breast cancers. 
Clinical detection of HER2 is conducted by immonuohistochemistry (IHC) for 
HER2 overexpression or by fluorescence in situ hybridization (FISH) for HER2 
gene amplification [114]. HER2 positive breast tumors often fall in high 
histological grades (grade2-3), and are associated with poor differentiation, high 
rate of cell proliferation, lymph-node involvement, and poor prognosis. The poor 
prognosis of HER2 positive breast cancer may due to its increased invasion, 
metastasis, and angiogenic activity [115]. HER2 overexpression is largely due to 
amplification at the DNA level, which is related to relapse and death even in 
cases of early-stage breast cancer [116]. Furthermore, HER2 is preferentially 
expressed in hormone receptor-negative breast cancer cells than hormone 
receptor-positive cases and this accounts for a decreased response of HER2 
positive cells to hormonal regulation through cross-talk with the estrogen 
receptor complex [117,118] (Fig. 4). In fact, HER2 amplification has been shown 
to negatively correlate with estrogen receptor expression in a number of breast 
cancer cell lines, and estrogen decreases HER2 mRNA and protein levels in ER 
positive breast cells [119,120]. Since HER2 positive breast cancersexhibit 
minimal ER expression, they are not the good candidate endocrine therapy. The 
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Figure 4. The pathologic stage of a tumor (adapted from [121]). 
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most important and efficient treatment for this subtype to date is passive 
immunotherapy. Heceptin (trastuzumab), a humanized monoclonal antibody 
against the extracellular domain of HER2, is extensively used to inhibit growth of 
HER2-overexpressing cancer cells. It can be used before, after, or in 
combination with different chemotherapy agents [122]. (Details of ErbB2 
targeted drugs will be elucidated at the end of chapter 1.2) When inflammation 
and invasion is observed in the tumor, overexpression of HER2 indicates a 
better prognosis, even though HER2 is usually a marker for poor outcome. In 
addition, HER2-responsive T-cells were identified in patients with HER2 positive 
tumors. This suggests a role for HER2 in immune-surveillance and this spurred 
an investigation of active immunotherapy for HER2 positive breast tumors [123]. 
HER2-directed vaccines have been generated and active immunotherapy 
strategies have been tested in animal studies and clinical trials [124]. Since 
proliferation of HER2 positive tumors depends on HER1 and HER2, tyrosine 
kinase inhibitors (TKIs) that specifically inhibit HER1 phosphorylation and 
function have also been developed. For example, ZD1839, one of the HER1 
TKIs, can effectively inhibit growth of HER2-overexpressing cells with normal or 
low HER1 levels [125]. There are many other HER2-derived antibodies and 
neoadjuvant therapies for treating HER2 positive breast tumors and these will be 
discussed in more detail in a separate subsection of this Introduction.  
Relationships between classification of receptor status and histological 
grade is shown in Figure 4. 
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1.2.2.5 Stages of breast cancers 
Clinicians have developed a staging system to determine the extent of 
tumor development and metastasis.  The clinical stage of a breast tumor is 
based on the physical exam, biopsy, and imaging test results, The pathologic 
stage of a tumor is based on the above tests and results of surgery which 
evaluates both the tumor and its spread to lymph nodes as indicated in Figure 4. 
Since it provides doctors with firsthand information on the extent of a cancer, the 
pathologist staging is more accurate than the clinical staging system. According 
to the American Joint Committee on Cancer (AJCC), the TNM system is the 
most common pathological staging system for assessing breast cancer. In the 
TNM system, T stands for tumor, which depicts the tumor size, and the extent 
that the tumor has spread within the breast and to surrounding organs; N stands 
for lymph nodes, which describes migration to lymph nodes; and M is for 
metastasis, which designates metastasis of the tumor to distant organs. 
Additional numbers or letters are used after T, N, M; a number from 0 to 4 
after the letter T defines the tumor size and extent of spreading to the skin or 
chest wall, and higher numbers correspond to an enhanced effect.  
A number from 0 to 3 following the letter N describes the extent of cancer 
metastasis to lymph nodes. A number of 0 or 1 after the letter M indicates the 
extent of metastasis to distant organs. 
In the T category, TX indicates that the primary tumor cannot be 
assessed, T0 suggests no evidence of a primary tumor, Tis is assigned to carci- 
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noma in situ (DCIS, LCIS, or Paget disease), T1 designates a tumor smaller 
than 2 cm, T2 indicates a tumor between 2 and 5 cm, T3 indicates a tumor 
bigger than 5 cm, and T4 means a tumor of any size growing into the chest wall 
or skin. In the N category, NX means nearby lymph nodes cannot be assessed, 
N0 indicates that cancer has not been detected in nearby lymph nodes, N1 
defines tumors spread to 1 to 3 axillary lymph nodes, N2 is defined as cancer 
that has spread to 4 to 9 axillary lymph nodes, and N3 is used to describe a 
cancer detected in more than 10 axillary lymph nodes with at least one area 
larger than 2 mm. In the M category, M0 means no distant spread of the tumor is 
observed in x-ray or physical examination, and M1 indicates tumor metastasis. 
Once the TNM categories have been determined, stage grouping with 
information from each category is combined, and an overall stage number is 
assigned for each breast cancer patient (Table 4). According to the National 
Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) 
database, the 5-year survival rate of breast cancer patient classified in various 
stage is summarized in Table 4. 
1.2.3 Breast cancer therapies 
Significant improvements have been made in breast cancer therapies, 
and patients have many treatment options, including surgery, radiation therapy, 
chemotherapy, endocrine therapy, and targeted therapy and these are 
discussed in the following subsections. 
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1.2.3.1 Surgery and radiation therapy 
Surgery is used for most patients to remove mammary tumors. In the 
early days of breast cancer treatment, radical mastectomy was used to remove 
the entire breast, pectoral muscles, all of the axillary lymph nodes, and the 
overlaying skin. More moderate surgical procedures termed modified radical 
mastectomy (MRM) are now used to remove the mammary tumors and most of 
the axillary lymph nodes; 5 year survival rates for patients who have undergone 
MRM is similar to that for women with radical mastectomy [126]. 
Breast-conserving surgery is a procedure that removes the cancer but 
leaves the breast intact and is widely prescribed for patients with early stage 
breast cancer, such as DCIS, or invasive breast cancer in stages I and II [127]. 
Breast-conserving surgery (lumpectomy / partial mastectomy) is normally 
followed by radiotherapy and this procedure preserves the breast structure and 
appearance compared to mastectomy. Radiation therapy following surgery 
eliminates microscopic tumors that remain after radiation [128].  
Radiotherapy can also be used with mastectomy [129] and the National 
Cancer Institute recommends that patients with metastasis in more than four 
axillary lymph nodes undergo postmastectomy radiotherapy. Breast cancer is 
often metastasized to lung, liver, bone and brain, and radiation therapy is also 
applied to relieve the pain from the metastasis [130]. 
1.2.3.2 Chemotherapy 
Antineoplastic chemicals are used in chemotherapies to treat malignant 
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tumors and these drugs are invariably cytotoxic compounds that impair mitosis 
and cause  extensive cell damage and death [131]. An important principle of ch-   
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Table 4. TNM stage grouping and 5-year survival rate. 
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emotherapy is that the cytotoxic chemicals effectively target rapidly-dividing cells 
and thus malignancies with high growth rates such as aggressive lymphomas 
and acute myelogenous leukemia are more sensitive to chemotherapy 
compared to tumors with lower growth rates such as indolent lymphomas and 
also normal tissues with even lower rates of cell proliferation [132]. Some solid 
tumors are also less responsive to chemotherapy, since cell division is relatively 
low and these are treated by surgery or radiation therapy. 
Most cancers are currently treated with surgery or radiation therapy along 
with various combinations of anticancer drugs. Neoadjuvant chemotherapy in 
which chemotherapeutic drugs are used to decrease the size of the primary 
tumor prior to surgery is highly effective for treating some tumors and 
postoperative adjuvant chemotherapy is useful for preventing tumor recurrence 
and killing cancer cells that have metastasized [133]. 
Cytotoxic chemotherapeutic drugs include alkylating agents, anti-
metabolites, microtubule disrupters derived from natural products, and 
topoisomerase inhibitors, all of which impair cell division or DNA synthesis. 
Alkylating agents include cisplatin, carboplatin, and oxaliplatin; these 
compounds alkylate nucleophilic groups and form covalent bonds with the 
amino, carboxyl, sulfhydryl, and phosphate moieties in macromolecules and this 
results in impaired cell function. Other alkylating agents such as 
mechlorethamine, cyclophosphamide, chlorambucil, and ifosfamide chemically 
modify DNA to disrupt cell function [134]. Anti-metabolites include purine 
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analogues (azathioprine, mercaptopurine, thioguanine), pyrimidine analogues ( 
5-fluorouracil (5FU), floxuridine (FUDR), cytosine arabinoside), and antifolates 
such as methotrexate. These agents are structural mimics of purines, 
pyrimidines and folates which are required for DNA synthesis and the 
antimetabolites inhibit DNA synthesis during the S phase of the cell cycle and 
this blocks cell division [135]. 
Several naturally occuring plant alkaloids, terpenoids and their synthetic 
analogs disrupt microtubule function to block cell division. These include vinca 
alkaloids,Podophyllotoxin and taxanes [136]. Vinca alkaloids are derived from 
Madagascar periwinkle, a herbaceous perennial plant, and they bind to specific 
sites on tubulin to inhibit its assembly into microtubules. Podophyllotoxin can be 
isolated from American Mayapple, and this compound prevents cells from 
entering the G1 phase and DNA replication. Paclitaxel, a prototype of the taxane 
drugs, is derived from the bark of Pacific Tew tree, and taxanes can increase the 
stability of microtubules and this prevent chromosomes from separating during 
anaphase [137].  
Topoisomerases maintain the normal topological structure of DNA, and 
inhibition of topoisomerases impairs proper DNA supercoiling and interferes with 
DNA replication and transcription [138]. Type I topoisomerase cuts one of the 
DNA strands causing relaxation, and the cut strand is then reannealed; Type II 
topoisomerase cuts both strand of the DNA, delivers another intact DNA helix 
through the broken end, and then reanneals the cut strands. Examples of type I 
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topoisomerase inhibitors include camptothecins such as irinotecan and 
topotecan; amsacrin, etoposide and etoposide are examples of type II 
topoisomerase inhibitors. These cytotoxic chemotherapeutic drugs function by 
killing rapidly dividing tumors cells and also normal cells that divide rapidly, such 
as cells in the bone marrow, digestive tract and hair follicles. This causes the 
common side effects observed in patients treated with these agents, namely, 
decreased blood cell production, inflammation of the digestive tract and hair loss 
[139]. 
1.2.3.3 Endocrine therapy 
There are two major types of endocrine therapy used for treating 
hormone receptor positive breast cancers, namely, drugs inhibit estrogen-ER 
binding, and surgery or drugs that block ovarian production of hormones and 
these therapies are discussed in the following subsections. 
1.2.3.3.1 SERMs and antiestrogens 
Estrogen is a multi-functional hormone that regulates physiological 
functions in the breast, but also in other organs including ovary, bone, 
cardiovascular system and nervous system. Thus medications that interfere with 
ER function to inhibit breast cancer may also disrupt the normal action of 
estrogen in other organs and cause undesirable side effects. Therefore, 
selective estrogen receptor modulators (SERMs) have been developed for 
breast cancer therapy and these compounds selectively modulate ER action in 
specific organs [140]. A SERM can be an ER agonist in some tissues and 
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antagonist in others, and SERMs such as tamoxifen are also called mixed ER 
agonists / antagonists [141]. Fulvestrant (ICI-182780) is a SERM that is an ER 
antagonist in most if not all tissues and only endogenous estrogen is an ER 
agonist in all tissues. 
Tamoxifen (Nolvadex) is a SERM that is an ER antagonist in mammary 
tumors and an agonist in most other tissues including the endometrium. 
Tamoxifen has been used as endocrine therapy for treatment of early and 
advanced ER+ breast cancer in both pre- and post-menopausal women [142]. 
Tamoxifen has also been approved by the Food and Drug Administration (FDA) 
for prevention of breast cancer in women at high risk of this disease, and to 
reduce the risk of breast cancer in the opposite site [143]. 
Tamoxifen is a substituted triphenylethylene derivative (Fig. 5) which has 
low affinity for the ER. Tamoxifen is metabolized in the liver by P450 isoforms 
CYP2D6 and CYP3A4 and its major metabolites, 4-hydroxytamoxifen and N-
desmethyl-4-hydroxytamoxifen (endoxifen) have 30-200 times higher affinity for 
the ER compared to tamoxifen and 4-hydroxytamoxifen is considered to be the 
“active” metabolite [144]. The activity of SERMs as ER agonists or antagonists is 
dependent on several factors including the SERM-induced conformational 
changes in the ER and subsequent interactions with coactivators, corepressors 
and other nuclear cofactors and this will also depend on tissue-specific 
expression of these proteins [145]. In mammary tumors, tamoxifen metabolites 
interact with ER, bind DNA and recruit co-repressors such as nuclear receptor  
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Figure 5. Estrogen (E2), SERMs (TAM, 4-hydroxy TAM and raloxifene) and the pure antiestrogen (ICI 182, 780). 
co-repressor (NcoR) and silencing mediator of retinoid and thyroid receptors 
(SMRT) to inhibit transcription of estrogen-responsive genes [146]. In bone and 
uterus, where tamoxifen acts as an ER agonist, the DNA-bound ER complex 
recruits co-activators such as steroid receptor co-activators (SRCs), CREB-
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binding protein (p300/CBP), p68 RNA hecilase, and ribosomal protein L7/switch 
protein for antagonists (L7/SPA) [147-149], which are more highly expressed in 
bone and uterus compared to breast cancers. Protease digestion followed by 
analysis of ligand-bound ER showed that in breast tumors, tamoxifen induces a 
conformational change of ERα that is more favorable for recruiting co-repressors 
[150]. 
During the course of tamoxifen treatment, ER-positive breast tumors often 
develop resistance, which is frequently accompanied by loss of ER [151]. In a 
number of breast cancer cases, however, tamoxifen-resistant tumor cells remain 
ER+ and this may be due to increased metabolic deactivation of tamoxifen [152], 
increased cellular kinase activities [153], and activation of the P-glycoprotein 
multidrug-resistance efflux pump [154]. 
Given its activity as an ER agonist in the bone and uterus, tamoxifen is 
also used to maintain bone density [155], and to treat infertility in women with 
anovulatory disorders [156]. With exception of these beneficial estrogenic 
effects, tamoxifen treatment is associated with adverse side-effects, including 
minor symptoms of mood disturbance, weight gain, hot flashes and atrophic 
vaginitis, increased incidence of pulmonary embolism, stroke, and deep-vein 
thrombosis. Two other tamoxifen side-effects are an increased incidence of 
endometrial carcinoma and thromboembolic phenomena in postmenopausal but 
not in premenopausal women [157]. 
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Raloxifene (LY 156758) is a newly developed SERM that has anti-
estrogenic actions on the breast and uterus and estrogenic actions on bone. 
Unlike tamoxifen, primary applications of raloxifene are not for treating breast 
cancer, but for prevention of breast cancer, cardiovascular diseases and 
osteoporosis in postmenopausal women. Raloxifene binds ER with high affinity 
but has a shorter biological half-life and is less potent than tamoxifen [158]. 
Raloxifene has some cross-resistance with tamoxifen and is barely effective for 
treating tamoxifen-resistant breast tumors [159]. 
Since raloxifene acts as an antagonist in both breast and uterus, it 
reduces the risk of breast cancer without increasing incidence of endometrial 
cancer [160]. The results from Multiple Outcomes of Raloxifene Evaluation 
clinical trials show that raloxifene increases bone mineral density in the spine, 
hip and femoral neck, and decreases vertebral fracture incidence in 
postmenopausal osteoporotic women [161]. Raloxifene decreases levels of 
serum low-density lipoprotein (LDL) and decreases the incidence of coronary 
heart disease by 40% [162].  
Arzoxifene (LY 353, 381) is a raloxifene analog that acts as an ER 
antagonist in mammary and uterine tissue but an ER agonist in bone. Arzoxifene 
has a longer biological half life and is more potent than raloxifene, and is more 
effective than raloxifene as an inhibitor of nitrosomethylurea induced rat mamm- 
  
43 
4
3
 
ary tumor formation [163]. Arzoxifene maintains bone density and lowers serum 
cholesterol more efficiently than raloxifene without causing uterotropic effects 
[164]. 
ICI 182,780 (Fulvestrant) is a pure antiestrogen with no ER agonist 
activity. ICI 182,780 induces ER downregulation and is a second-line agent after 
the failure of tamoxifen for treating ER+ metastatic breast cancer in 
postmenopausal women. Fulvestrant is administered monthly as an injection 
and this drug exhibits less cross-resistance with tamoxifen compared to other 
SERMs. For example, tamoxifen-resistant MCF-7 breast cancers respond to ICI 
182,780 [165].  
1.2.3.3.2 Ovarian ablation and aromatase inhibitors 
Inhibition of estrogen biosynthesis is also an important strategy for breast 
cancer therapy. The ovaries are the major site of estrogen synthesis in 
premenopausal women, and ovarian ablation was extensively used for treating 
breast cancer patients. Surgical ovariectomy results in a permanent and 
immediate decrease in ovarian hormone production [166]. Due to the relatively 
high rate of surgical complications from ovariectomy, current applications of 
laparoscopic surgery have significantly reduced the mortality and morbidity from 
the operation. 
Radiation is another form of ovarian ablation, in which the treatment 
algorithms range from 450 cGy in one fraction to 2000 cGy in five or six fractions 
[166]. Radiation is a simple and safe approach for ovarian ablation with a 
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disadvantage of possible incomplete ablation and reversibility in some 
individuals. 
During the past twenty years, medical ovarian ablation has also been 
extensively used and include chronic administration of analogs of luteinizing 
hormone-releasing hormone (LHRH, also known as gonadotropin-releasing 
hormone (GnRH)) and these include leuprolide and goserelin which cause 
temporary chemical castration [166]. Ovarian estrogen synthesis is controlled by 
the release of LHRH from the hypothalamus, which leads to production of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in vertebrates in 
the pituitary gland and these gonadotropins stimulate the ovarian 
steroidogenesis (Fig. 6). Binding of LHRH agonists to pituitary gondatropin 
receptors prevents binding of endogenous LHRH resulting in decreased 
secretion of gonadotropin from the pituitary gland and diminished steroid 
production in the ovaries. The major advantage of medical ovarian ablation is its 
noninvasiveness and reversibility. Comparative trials of goserelin with surgery 
and radiation have shown that the three strategies have similar effects in treating 
ER+ breast cancer patients [167], and the three approaches are often applied 
interchangeably.  
In contrast to premenopausal women, the major areas for producing 
estrogen in postmenopausal women are peripheral adipose tissue and the 
adrenal gland where androgens are converted into estrogens. An important 
strategy for treating ER+ breast cancer in postmenopausal women involves the  
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Figure 6. Sythesis of estrogen and progesterone in premenopausal and postmenopausal women (Adapted from [168]). 
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use of aromatase inhibitors, which inhibits the enzyme aromatase and block 
conversion of androgens into estrogens [169]. 
Aromatase is a cytochrome P450 and is encoded by the CYP19 gene. 
Aromatase catalyzes the conversions of androstenedione to estrone and of 
testosterone to estradiol (Fig. 7) and these are the rate-limiting steps in estrogen 
production [170]. Aromatase is highly expressed in placenta and granulosa cells 
of the ovary, and lower expression is observed in fat, muscle, subcutaneous, 
liver and normal breast tissues [171]. Aromatase inhibitors inhibit the action of 
aromatase, and hence prevent conversion of androgens into estrogens by a 
process called aromatization [172]. 
Aromatase inhibitors cannot be used for treating premenopausal women 
with breast cancers, since 95% of circulating estrogen in premenopausal women 
is produced in the ovaries, instead of the adrenal gland and inhibition of 
aromatase does not sufficiently decreases the production of estrogen [173]. In 
contrast, treatment of premenopausal women with aromatase inhibitors 
decreases estrogen levels and activates the hypothalamic-pituitary axis to 
stimulate gonadotropin secretion in the pituitary gland which in turn increases 
ovarian production of estrogen (Fig. 6). 
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Figure 7. The role of aromatase in estrogen synthesis. 
Aromatase inhibitors can be classified to two types: Type I inhibitors 
(steroidal) have an androgen structure and interact with the substrate-binding 
site of the enzyme; Type II inhibitors are azoles (non-steroidal) and associate 
with the cytochrome P450 heme moiety of the enzyme (Fig. 8) [173]. There are 
three generations of aromatase inhibitors and these include testolactone (Type I) 
and aminoglutethimide (Type II) which belong to the first generation; formestane 
(Type I) and fadrozole (Type II) are second generation aromatase inhibitors; and  
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Figure 8. Structure of aromatase inhibitors. 
exemestane (Type I), anastrozole and letrozole (Type II) belong to the third 
generation of thses compounds[174]. Type I aromatase inhibitors irreversibly 
inhibit the aromatase activity whereas type II inhibitors reversibly bind to the 
enzyme in competition with the natural substrates. 
The major side-effects of aromatase inhibitors are increased incidence of 
osteoporosis and bone fracture [175]. In contrast to tamoxifen, aromatase 
inhibitors are associated with lower incidence of endometrial cancer and 
thromboembolic phenomena. Aromatase inhibitors are used as second-line 
medication following tamoxifen treatment and these compounds are effective for 
treating tamoxifen resistant tumors. In the Intergroup Exemestane Study (IES) 
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trial, breast cancer patients who were treated with tamoxifen for 2-3 years were 
assigned to exemestane or continued tamoxifen treatment, and after a 2.5 year 
follow-up, the exemestane group exhibied a significantly decreased breast 
cancer reccurrence compared to patients treated with tamoxifen [175]. In 
postmenopausal breast cancer patients who have completed 5 years of 
tamoxifen treatment, administration of letrozole resulted in a 43% decrease in 
breast cancer incidence compared to patients using tamoxifen for 2 additional 
years [176]. 
1.2.3.3.3 Progestins and antiprogestins 
Progestins such as megestrol acetate and medrocyprogesterone acetate 
are synthetic derivatives of progesterone that have been used for treating 
metastatic breast cancers in postmenopausal women [177]. The response rates 
(30%) for progestins are comparable with that of tamoxifen, however they are 
used as a second-line therapy because of their side-effects which include weight 
gain and thromboembolic phenomena [178]. It was suggested that 
antiprogesterone therapy can also be used to treat breast cancer, since 
progesterone increases breast epithelium proliferation. Mifepristone (RU486) 
was the first antiprogestin used clinically, however there was a poor response 
rate (10.7%). Onapristone, a second generation antiprogestin was successfully 
used in early clinical trials but was discontinued due to its liver toxicity [179]. 
New antiprogestins are in development and are more selective for the 
progesterone receptor [180]. 
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1.2.3.4 Targeted therapy 
Although a number of systemic therapies are available for treating breast 
cancer, most solid tumors develop resistance to systemic agents. Targeted 
therapies have recently been developed and they are designed to specifically 
target cancer cells without affecting normal cells. Agents targeting specific 
molecules in cancer cells are highly selective, have fewer side-effects compared 
to most traditional chemotherapeutic agents, and can be used in combination 
with conventional therapies to improve treatment response. Development of 
targeted drugs for treating breast cancer requires identification of overexpressed 
or amplified molecules that are important oncogenic pathways in breast cancer. 
Growth factor receptors are important for sustaining growth and survival 
of breast cancer cells, and are important drug targets for treating breast cancer. 
The epidermal growth factor receptor (EGFR) family of tyrosine kinase receptors 
plays important roles in the pathogenesis of breast cancer and includes EGFR 
(ErbB1), ErbB2 (HER2), ErbB3 and ErbB4 receptor kinases. The EGFR is 
expressed in 14-91% of breast tumors, and overexpression of EGFR in tumors 
is associated with a more aggressive phenotype and poor prognosis [181]. 
Expression of ErbB2 occurs in 20-30% breast carcinomas, and ErbB3 and 
ErbB4 expression is also occurs frequently observed in breast tumors [181]. 
Ligand-activated ErbB interacts with adaptor proteins that activate 
intracellular signaling pathways including phosphatidylinositol 3-kinase (PI3K)/v-
akt murine thymoma viral oncogene homolog 1 (AKT) pathway and 
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Ras/Raf/mitogen-activated protein kinase kinase (MEK)/mitogen-activated 
protein kinase (MAPK) [182]. Activation of these pathways can be ErbB-
dependent or ErbB-independent due to involvement of other activated tyrosine 
kinases.  
The PI3K/AKT pathway promotes tumor proliferation, survival, invasion 
and migration [183]. Dysfunction or loss of expression of phosphatase and 
tensin homolog (PTEN), the negative regulator of PI3K signaling, and activation 
of AKT are observed in various cancers [184]. One of the important downstream 
targets of PI3K/AKT signaling is the serine/threonine kinase ammalian target of 
rapamycin (mTOR), which activates ribosomal p70S6 kinase (S6K1) and 
inactivates the eukaryotic translation initiation factor 4E-binding protein 1 (4E-
BP1) to regulate translation initiation. RPS6KB1, the gene that encodes S6K1, is 
amplified in 10% of breast tumors and the amplification is associated with ErbB2 
overexpression [185]. 
The Ras/Raf/MEK/MAPK signaling pathway regulates important events in 
tumor progression including cell growth and survival, and activation of MAPK 
signaling has been related to resistance to endocrine therapy and EGFR 
targeting drugs in breast tumors [186]. 
The protein kinase C (PKC) is a family of serine/threonine kinase that 
mediates intracellular signaling [187]. Activation of PKC through phospholipase 
Cγ (PLCγ) is induced by phosphorylation of EGFR and the vascular endothelial 
growth factor receptor (VEGFR). Activated PKC activates a series of kinases 
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including glycogen synthse kinase 3β (GSK3β), which is responsible for 
development, metabolism and apoptosis. PKC plays a role in breast cancer 
pathogenesis, and enzymatic activity of PKC is increased in breast carcinomas 
compared to normal breast tissues [188]. Therefore, PKC is also considered as 
a target for treating breast cancers. 
Src belongs to a large family of nonreceptor protein kinases, and 
activates various intracellular signaling cascades including PI3K/AKT and 
Ras/Raf/MAPK pathways. There is evidence that Src plays a role in progression 
of breast carcinomas and Src kinase activity is 4-20-fold higher in human breast 
carcinomas compared to normal breast tissues [189]; Src cooperates with EGFR 
in breast tumor progression [190] and Src increases the metastatic potential of 
tumor cells through enhancing epithelium to mesenchymal transition [191]. Thus 
Src is also a good candidate for targeted therapy in breast cancer treatment. 
Angiogenesis, namely the formation of new blood vessels, is important for 
primary tumor growth and metastasis and vascular endothelial growth factor 
(VEGF) is the major molecule that regulates tumor-related neoangiogenesis. 
The normal function of VEGF is to produce new blood vessels after injury or 
during embryonic development, and create collateral circulation to bypass 
blocked vessels [192]. VEGF binds the vascular endothelial growth factor 
receptor 1 (VEGFR-1) to activate endothelial cell differentiation and migration; 
activation of VEGFR-2 by VEGF regulates vascular permeability, endothelial cell 
survival, proliferation, invasion and migration; VEGFR-3 signaling is associated 
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with lymphangiogenesis. Overexpression of VEGF is observed in many breast 
cancers and a correlation between VEGF overexpression and poor prognosis 
and low response rate to tamoxifen was observed in advanced breast cancer 
patients [193]. 
Given the identification of numerous molecular targets in breast cancer 
therapy, these agents can be classified into three groups: 1) agents targeting 
ErbB2; 2) anti-angiogenic agents; and 3) inhibitors of specific signaling 
pathways. 
1.2.3.4.1 Anti-ErbB2 agents 
Agents that block ErbB receptor family activities have been developed 
during the past 20 years and these include monoclonal antibodies which bind 
the extracellular domain of the receptor, and tyrosine kinase inhibitors (TKIs) 
that inhibit the kinase domain activity of the receptor and some of the key agents 
are described below. 
Trastuzumab (Herceptin) is a monoclonal antibody that blocks the 
HER2/neu/ErbB2. Trastuzumab binds to the juxtamembrane portion of the 
extracellular domain of ErbB2 through its two antigen-specific sites. The 
remaining part of the antibody is the human immunoglobulin G (IgG) with a 
conserved Fc portion. Mechanisms of action of trastuzumab include interference 
with ErbB2 homodimerization and heterodimerization with other ErbB members, 
increased endocytosis and degradation of ErbB2, inhibition of ErbB2 
extracellular domain cleavage, and activation of immune responses that kill 
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tumor cells (Fig. 9) [194]. Immune deficient animals do not respond to 
trastuzumab, suggesting that trastuzumab recruits immune effector cells and 
stimulates andibody-dependent cytotoxicity [195]. Studies of ErbB2 
overexpressed in animal models of breast cancer suggest that trastuzumab also 
inhibits angiogenesis, by modulations of proangiogenic and antiangiogenic 
factors to regress the vascular structure of tumors [196]. 
Trastuzumab is used for treatment of metastatic breast cancer and 
adjuvant therapy for early-stage breast cancer. For metastatic and advanced 
HER2+ breast cancer, trastuzumab is the standard therapy, and treatment with 
trastuzumab prolongs survival of metastatic breast cancer patients [122]. 
Trastuzumab is used with or without chemotherapy for first-line treatment of 
metastatic breast cancer. Use of trastuzumab in adjuvant therapy is considered 
for women with early-stage HER+ breast cancer. Results from different trials 
show that adjuvant trastuzumab treatment improves disease-free survival (DFS) 
and overall survival (OS), but the optimal duration of use is unclear [197].  
Cardiotoxicity is one of the major complications of trastuzumab and 
approximately 7% of patients treated with trastuzumab develop cardiac 
dysfunction, and regular cardiac exams are taken during treatment with 
trastuzumab [198]. Clinical oncologists usually need to balance the risk of 
cardiac dysfunction against cancer recurrence. 
Lapatinib is a tyrosine kinase inhibitor (TKI) that binds to the adenosine 
triphosphate (ATP)-binding site of the intracellular kinase domain of EGFR and  
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Figure 9.  Mechanisms of action of trastuzumab. Trastuzumab blocks cleavage of extracellular domain of ErbB2 (B), 
inhibits dimerization and hence reduces ErbB2 signaling(C), recruits immune effector cells to activate tumor cell death 
(D), and enhances ErbB2 endocytosis and degradation (E). 
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ErbB2. This interaction inhibits the use of ATP as a cofactor for auto-
phosphorylation of the tyrosine residue and inhibits downstream signaling to 
activate PI3K/AKT and MAPK pathways [199]. Dissociation of lapatinib from the 
intracellular tyrosine kinase domain is very slow (half life≥300 min) and results in 
downregulation of EGFR and ErbB2 signaling in tumor cells [200]. Lapatinib 
reversibly inhibits EGFR and ErbB2 kinase activities with half maximal inhibitory 
concentration [IC50] values of 10.2 and 9.7 nmol/L [201], and this inhibition 
results in growth arrest and apoptosis in EGFR and ErbB2 positive breast 
tumors [202]. 
Because of its small molecular weight (580 kDa), lapatinib can pass 
through the blood-brain barrier and exhibits anti-tumor activity in the central 
nervous system (CNS) [203]. A preclinical animal model has shown that 
lapatinib inhibits metastases of breast cancer to the brain [204]. Lapatinib is also 
a substrate for P-glycoprotein and breast cancer resistance protein (BCRP), 
which work together as efflux transporters to regulate penetration of drugs 
through the blood-brain barrier. 
Lapatinib has been used to treat woman with ER+/EGFR+/HER2+ (triple-
positive) breast cancer and patients with advanced HER2+ breast cancer that 
Have not had positive responses with other chemotherapeutic agents. 
Resistance to endocrine therapy is a problem for treatment of patients with triple 
positive breast tumors and lapatinib re-sensitizes breast cancer cells to 
tamoxifen in tamoxifen-resistant breast tumor models [205], and lapatinib also  
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interacts with antiestrogens to inhibit growth of ErbB2 amplified breast cancer 
cells [206]. Lapatinib in combination with other chemotherapeutic agents, such 
as capecitabine, a prodrug of 5Fu significantly decreases progression of ErbB2 
overexpressing, trastuzumab-resistant metastatic breast cancer [207]. 
Pertuzumab is another humanized monoclonal antibody that binds to the 
extracellular domain of ErbB2. This agent inhibits homo- or hertero- dimerization 
of ErbB2, and pertuzumab is more efficient than trastuzumab for this activity 
[208], and is often used in combination with trastuzumab for their 
complementary action [209]. Frequent adverse side effects of pertuzumab 
include diarrhea, nausea, pain, skin rash and mucositis. The response rate to 
pertuzumab is approximately 18%, and the rate of disease stabilization in 
patients treated with pertuzumab is about 21% [210]. 
1.2.3.4.2 Anti-angiogenic agents 
Anti-angiogenic agents include monoclonal antibody of VEGF 
(bevacizumab) and TKIs of VEGFRs (sorafenib, sunitinib, candetanib, et al). 
Bevacizumab (trade name Avastin) is a humanized monoclonal antibody 
against VEGF-A, and was the first angiogenesis inhibitor used in the United 
States. Binding of bevacizumab to VEGF-A blocks the interaction of VEGF-A 
with VEGFR and hence leads to inhibition of VEGF-related angiogenesis. 
Bevacizumab was approved by U.S. Food and Drug Administration (FDA) in 
2008 to treat metastatic breast cancer, and it was also used as a single agent for 
treating ovarian cancer, and glioblastoma multiforme. Bevacizumab 
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demonstrated minimum activity as a single agent for treating metastatic breast 
cancer; however, combination of bevacizumab with first-line chemotherapeutic 
agents enhanced their effectiveness in phase III trials. In the E2100 trial, 
combinations of bevacizimab with paclitaxel improved the progression-free 
survival and increased the response rate compare to paclitxel alone in patients 
with metastatic breast cancer [211]. In the avastin and docetaxel (AVADO) trial, 
addition of bevacizumab to docetaxel significantly prolonged the progression-
free survival and response rate compared with docetaxel alone in patients with 
ErbB2 negative metastatic breast cancer [212]. 
Other uses of bevacizumab include its application in eye diseases such 
as macular degeneration (AMD) and diabetic retinopathy, in which VEGF-
induced over-growth of blood vessels around the retina causes retina damage 
and blindness [213]. The major side effect of bevacizumab is hypertension, 
which is induced or enhanced due to the lack of collateral circulation around 
blocked vessels and interference with new blood vessels formation in wound 
healing [214]. 
 Sorafenib is a small molecule that inhibits multiple receptor tyrosine 
kinases, including VEGFR2, VEGFR3, platelet-derived growth factor receptor 
(PDGFR)-β, and stem-cell factor receptor (c-KIT). In breast cancer cells with 
mutated K-Ras and B-Raf, sorafenib also inhibits Raf isoforms including Raf-1 
and B-Raf, and decreases activation of MAPK [215]. Sorafenib is primarily used 
for the treatment of kidney cancer and advanced liver cancer by reducing 
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angiogenesis. Sorafenib as a single agent for treating metastatic breast cancer 
exhibited limited activity, and combination of sorafenib with other 
chemotherapeutic for treating metastatic breast cancer is being investigated 
[216]. 
 Vandetanib is a TKI that targets VEGFR2, EGFR and rearranged during 
transfection (RET) receptor tyrosine kinases and minimal effects were observed 
for this compound in patients with metastatic breast cancer [113]; additional 
trials on the combination of candetanib and other TKI with chemotherapeutic 
agents are ongoing. Other anti-angiogenic TKIs include axitinib, which inhibits 
VEGFR1, 2 and 3 [217]; and pazopanib, which inhibits multiple kinases such as 
VEGFRs, PDGFR-α/β and c-KIT [218]. Their use in combination with 
themotherapeutic agents are also being investigated in various clinic trails [219]. 
1.2.3.4.3 Inhibitors of signaling pathways 
Anti-EGFR agents - Gefitinib is an EGFR TKI that extensively inhibits 
growth of EGFR positive tumors including breast carcinomas. Gefitinib binds to 
the ATP-binding pocket of EGFR and inhibits kinase activity and the Ras 
signaling pathway [220]. Gefitinib is extensively used for treating EGFR-
overexpressing non-small cell lung cancer (NSCLC) in 46 countries as an all-line 
treatment that significantly improves the progression-free survival. However, 
phase II clinical trials of gefitinib as a signal agent demonstrated minimal activity 
for treating advance breast cancer [221], and effects of gefitinib in combination 
with chemotherapy is being investigated. Resistance to gefitinib in breast cancer 
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treatment may be due to loss of dependence on EGFR in certain tumors or 
EGFR-independent activation of PI3K or MAPK signaling cascades, since 
inhibition of EGFR phosphorylation by gefitinib has been observed in 
pharmacodynamic studies [222]. 
Erlotinib is a reversible TKI for EGFR, and also inhibits ErbB2kinase 
activity through a direct interaction with the receptor [223]. Erlotinib was 
approved by FDA in 2005 for use in treatment of pancreatic cancer in 
combination with gemcitabine. Treatment with erlotinib in patients with breast 
cancer prior to the surgery dramatically reduced EGFR and ErbB2 kinase 
activities [224]. Limited activity is observed when erlotinib is used as a single 
agent or combined with chemotherapeutic agents for treatment of metastatic 
breast cancer treatment [225]. 
Cetuximab is a chimeric monoclonal antibody against the extracellular 
domain of EGFR that decreases EGFR autophosphorylation, endocytosis and 
degradation. Cetuximab demonstrates anti-tumor activity in a number of tumor 
xenografts and synergistically interacts with radiation therapy [226]. Cetuximab 
was approved by FDA in 2006 for treatment of head and neck cancer in 
combination with radiation. In a phase I trial of cetuximab with paclitaxel in 
patients with EGFR-overexpressing breast cancer, low activity was observed 
[227]. 
mTOR inhibitors - mTOR mutations and overexpression are rarely seen in 
human tumors, however, mTOR signaling is pivotal for cell growth, proliferation 
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and survival, and pathways that regulate mTOR are often deregulated in breast 
cancer. Rapamycin is the first identified mTOR inhibitor identified and 
termsirolimus and everolimus are two analogues of rapamycin being developed 
for clinical applications. Temsirolimus, a water-soluble ester derivative of 
rapamycin exhibits anti-cancer activity in various cancer models. Treatment of 
breast cancer with temsirolimus leads to G1 arrest and ER+, PTEN negative and 
/ or ErbB2 overexpressing breast cancer cell lines are sensitive to temsitolimus, 
whereas cell lines lacking of these characteristics are resistant. Temsirolimus 
also exhibits antiangiogenetic activity [228], and a phase II study in advanced 
metastatic breast cancer patients showed a 9% response rate after treatment 
with temsirolimus [229]. 
Everolimus is another mTOR inhibitor in clinical trials; in cancer cells 
lacking of PTEN expression, everolimus enhance the growth inhibitory effects of 
trastuzumab and gefitinib [230]. In 2009 everolimus was approved by the FDA 
for treating kidney cancer, and clinical trials in breast cancer patients are 
ongoing.  
Farnesyl transferase inhibitors - Farnesyl transferase (FTase) catalyzes 
addition of a farnesyl isoprenoid to the cysteine residue at the carboxyl terminal 
of proteins. Targets of FTase include Ras small GTP binding proteins, which are 
essential for cell cycle progression and are usually highly active in tumor cells. 
Therefore, FTase inhibitors (FTIs) such as tipifarnib, lonafarnib, and AZD3409 
are being developed as anti-cancer agents. 
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In preclinical studies in ER+ breast tumors, tipifarnib alone and in 
combination with 4-hydroxytamoxifen showed synergistic anticancer activity in 
ER+ breast cancers [231]. Lonafarnib exhibits anti-tumor activity in various 
mouse xenograft models [232], and preclinical studies with combination of 
lonafarnib and trastuzumab, aromatase inhibitors, or chemotherapy are ongoing. 
AZD3409 is a novel FTI that mimics the carboxyl terminus CAAX sequence of K-
Ras, which is often mutated in human tumors [233]. AZD3409 inhibits both 
FTase and geranylgeranyl transferase I (GGTI) activities, and also inhibits 
growth of gefitinib-resistant breast cancer cells [234]. 
Src inhibitors - Src plays an important role in cell growth, invasion, 
angiogenesis and metastasis. Inhibition of Src activation can prevent tumor 
progression and decrease metastasis and  Src inhibitors are being developed for 
treating breast cancers. Dasatinib is a Src kinase inhibitor and is approved for 
treating chronic myelogenous leukemia (CML). Dasatinib inhibits growth of 
breast cancer cells and this includes the more aggressive basal-like subtype 
[235]. Pharmacodynamic studies indicate that phosphorylation of Src is inhibited 
by dasatinib in dose-dependent manner [236]. 
AZD0530 is a dual inhibitor that targets the tyrosine kinase domain of Src 
and Abl. AZD0530 inhibits growth of MCF-7 breast cancer cells and tamoxifen 
plus AZD0530 exhibits synergistic activity in treating ER+ breast cancer cells, 
suggesting that inhibition of ER signaling is required for maximal activity of this 
drug combination [237]. Bosutinib is another dual inhibitor for Src and Abl 
  
63 
6
3
 
kinases that significantly inhibits growth, invasion and migration of MDA-MB-231 
breast cancer cell [238], however, side effects of this drug include asthenia, 
nausea, vomiting, diarrhea, and anorexia. 
MEK signaling inhibitors - Many MEK signaling inhibitors are in 
development, and only AZD6244 (arry-142886) is effective for treating breast 
cancer. AZD6244 specifically binds to the allosteric inhibitor-binding site of 
MEK1/2 and stabilizes it in the inactive conformation. In vivo studies show that 
AZD6244 inhibits growth of ZR-75 breast tumors in a mouse xenograft model 
[239]. Examination of tumor biopsy samples demonstrates that AZD6244 inhibits 
phosphorylation of MAPK in tumor tissues 1 hour after administration [240]. 
Side-effects of AZD6244 include diarrhea, nausea, rash, and fatigue and clinical 
trials with AZD6244 are ongoing. 
PKC inhibitors - Enzastaurin is a synthetic bisindolemaleimide that 
specifically inhibits PKCβ, which in turn regulates VEGF signaling. Blockage of 
PKC activation by enzastaurin decreases AKT and GSK3β activity, inhibits 
tumor cell growth, decreases VEGF-mediated angiogenesis, and induces cancer 
cell death [241]. A phase I study showed that administration of enzastaurin (700 
mg daily) is well tolerated, however, a phase II study with metastatic breast 
cancer patients indicated that treatment with enzastaurin as a single agent was 
not effective [242]. Breast cancer treatments with combinations of enzastaurin 
and other chemotherapeutic agents including endocrine therapy are ongoing. 
 
  
64 
6
4
 
1.2.4 ErbB2 and ErbB receptor family 
ErbB2 is an attractive target for treatment of breast cancer due to its 
overexpression and association with enhanced metastasis and poor prognosis 
[243]. ErbB2 belongs to the human epidermal growth factor receptor (EGFR, 
HER) family which includes four structurally related members: ErbB1 (EGFR, 
HER1), ErbB2 (HER2, neu), ErbB3 (HER3), and ErbB4 (HER4) [244]. The 
symbol ErbB is given to this protein family due to their homology with the 
erythroblastic leukemia viral oncogene. These four ErbB family members belong 
to the receptor tyrosine kinase (RTK) family which includes 20 subgroups, and 
the ErbB family is called the type I RTK [245]. This RTK subgroup plays 
important roles in cell survival, adhesion, proliferation, differentiation, and 
migration. 
The ErbB family of proteins contains a cysteine-rich extracellular domain, 
a transmembrane domain and an intracellular domain. The extracellular domain, 
also named ectodomain, is highly conserved and upon ligand binding the 
receptor undergoes a conformational change that results in dimerization and 
activation of kinase activity [246]. The transmembrane domain is hydrophobic 
and anchors the receptor across the plasma membrane;  the intracellular 
domain contains a highly conserved C-terminal tail with an ATP-binding pocket 
for autophosphorylation and for phosphorylation of substrates (Fig. 10) [247].  
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Figure 10. Structural similarities (A) and differences of ligands (B) for ErbB family RTKs (Adapted from [248]). 
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These receptors form hetero- or homo-dimers to activate downstream 
signaling pathways that regulate cell behavior [249]. Since ErbB2 does not have 
a ligand binding site in the extracellular domain, and ErbB3 does not possess 
the intracellular kinase activity, therefore these two receptors are not capable of 
triggering cell signaling as monomers or homodimers [250]. 
1.2.4.1 EGFR 
EGFR is a 170 kDa protein that is encoded by a gene in chromosome 
7q12.3-p12.1 [251]. The extracellular domain of EGFR is composed of four 
domains (I-IV), and domains I and III are for creating the ligand binding pocket. 
When domains II and IV are juxtaposed, the EGFR receptor is in its “closed” 
conformation and is unable to bind ligands and dimerize with other receptors; in 
contrast, when the EGFR is in the “open” conformation, ligands can bind and the 
EGFR can interact with other receptors to form dimers with exposure of domain 
II (Fig. 11) [252]. 
EGFR is important for growth, development, and differentiation of multiple 
tissues including breast, where it is required for mammary gland development in 
the late stage of pregnancy [253]. The number of EGFR molecules in normal 
cells ranges from40,000 to 100,000, whereas in breast cancer cells the number 
of EGFR molecules can be 2×106 [254]. EGFR is expressed in approximately 
30% of human carcinomas and 50% of glioblastomas and expression is strongly 
associated with poor prognosis for breast cancer patients [244]. Expression of  
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Figure 11. Ligand incuded conformational change of extracellular domain of EGFR (Adapted from [255]). 
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EGFR is particularly high in basal-like breast cancers (54% cases), and the 
EGFR is a therapeutic target for treating this type of breast cancer [256]. 
1.2.4.2 ErbB2 
ErbB2 is a 185 kDa protein encoded by a gene localized in chromosome 
17q21, and was first idenfied by Schechter and coworkers in 1984 [257]. ErbB2 
does not have a ligand binding region in the extracellular domain and there is no 
endogenous ErbB2 ligand. However, ErbB2 interacts with high affinity with other 
members of the type I RTK family as a co-receptor due to its extended 
ligand/heterodimer linkage [258]. A mutation of the ErbB2 gene at amino acid 
codon 655 is frequently observed in breast carcinomas and this mutation 
changes the transmembrane conformation to enhance homodimerization of 
ErbB2 [259]. Homodimerization of ErbB2 caused by this mutation or by ErbB2 
overexpression results in increased cancer cell growth, division, and enhances 
survival [244]. 
Overexpression of ErbB2 enhances mitosis and survival of breast cancer 
cells and this is due to activation of the MAPK and PI3K/Akt-mediated pathways 
[260]; ErbB2 also induces angiogenesis by enhancing VEGF expression [261]. 
ErbB2-dependent activation of these pathways is due, in part, to overexpression 
of cyclin-D1, and inhibition of p27Kip1, which results in inhibition of cell cycle 
progression [262]. 
ErbB2 overexpression is observed in 13%-23% of breast tumors, and is 
also involved in metastasis and the aggressive phenotype of breast cancer cells 
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 [263]. Overexpression of ErbB2 is linked with increased disease recurrence and 
poor prognosis for breast cancer patients and this receptor is clearly an 
important therapeutic target for treatment of breast cancer. 
1.2.4.3 ErbB3 
The third member of ErbB family, ErbB3, is a 145kDa protein and its gene 
is localized on chromosome 12q13 [264]. This receptor does not have active 
tyrosine kinase activity in the intracellular domain; binding of ligands to ErbB3 
does not induce phosphorylation and/or receptor activation. However, ErbB3 
interacts with other members of ErbB family that harbor the kinase activity to 
form heterodimers that activate cell proliferation and differentiation [265]. 
The intracellular tyrosine kinase region of ErbB3 possesses seven Src 
Homology 2 (SH2) domains that specifically recognize phosphorylated tyrosine 
residues on other proteins. ErbB3 has high affinity for PI3K, heterodimerizes 
with other ErbB members and activates survival pathways [266]. ErbB3 is the 
preferred heterodimeric partner of ErbB2 and overexpression of both receptors 
are frequently observed; when ErbB2 is inactivated by a neutralizing antibody, 
decreased ErbB3 signaling activity is also observed [267,268]. One study 
showed that despite the expression of EGFR and ErbB4, lack of ErbB3 
expression strongly decreased the neoplasticicy of the breast cancer cell lines, 
indicating that the ErbB2/ErbB3 heterodimer plays a critical role in tumor cell 
proliferation and survival [269,270]. 
  
70 
7
0
 
Levels of ErbB3 in breast cancer cells are significantly higher than that in 
normal breast cells, and this is due to enhanced protein translation and/or 
decreased protein degradation [271]. ErbB3 overexpression is linked to poor 
prognosis for breast, lung and ovary cancer patients, and approximately 17% of 
breast cancer patients express high levels of ErbB3 [244]. 
1.2.4.4 ErbB4 
ErbB4, is an 180kDa protein, and is encoded by a gene located in 
chromosome 2q33 [272]. The cytoplasmic domain of ErbB4 has the capacity to 
autophosphorylate and does not require other ErbB family receptors to form 
dimers to activate downstream signaling pathways [273]. There are several 
alternative splicing isoforms of ErbB4 with similar ligand binding sites and 
tyrosine kinase activities [273]. 
ErbB4 is ubiquitously expressed in breast, lung, prostate, ovarian, 
cervical, stomach and thyroid cancers [273], and ErbB4 levels in breast tumors 
are lower than EGFR and ErbB2 [274]. ErbB4 is overexpressed in the normal 
breast during pregnancy and has a function in cell differentiation and lactation 
[275]. 
Expression of ErbB4 is associated with good prognosis in a subset of 
breast cancer patients and they have longer survival times and disease-free 
intervals. This is partially due to ErbB4-mediated inhibition of ErbB2 activity and 
the promotion of apoptosis by ErbB2  [276]. 
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1.2.4.5 ErbB ligands in breast cancer 
All ErbB members, except for ErbB2, are activated by their specific 
ligands belonging to the epidermal growth factor (EGF) hormone family which 
contain an EGF-like domain, and are expressed as ten different genes [182]. 
Ligands that specifically bind EGFR include EGF, transforming growth factor-
alpha (TGF-α), and amphiregulin (AR), and these ligands do not interact with 
other members of the ErbB family. Heparin-binding EGF-like growth factor (HB-
EGF), betacellulin (BTC) and epiregulin (EPR) are ligands that bind EGFR and 
ErbB4. Both ErbB3 and ErbB4 interact with neuregulin1 (NRG1) and NRG2, 
whereas NRG3 and NRG4 only bind ErbB4 (Fig. 10) [277]. Expresssion of these 
ligands are elevated in 85% of breast carcinomas [277]. 
EGF and TGF-α both bind to domains I and III of the ectodomain of 
EGFR and exhibit 30-40% homology [252]. Expression of EGF is elevated in 
breast, pancreatic, and liver cancers, and overexpression of this ligand is linked 
to promotion of cell proliferation [278]. AR interacts only with EGFR and exhibits 
two different functions, namely to promote proliferation of normal epithelial cell 
and some cancer cell, or to inhibit growth of certain aggressive carcinoma cells 
[279]. 
Expression of HB-EGF is associated with breast cancer cells, however, in 
breast cancer patients with poor prognosis, HB-EGF level are dramatically 
decreased [280]. This ligand also inhibits the proapoptotic effects of some anti-
cancer drugs [281]. BTC triggers proliferation of breast cancer cells, and 
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stimulates differentiation of breast epithelial cells to produce neutral lipids [282]. 
NRGs are expressed in a number of carcinomas, and play an important role in 
mammary gland development, and NRGs are also highly expressed in invasive 
breast cancers [283]. 
1.2.4.6 ErbB dimerization 
In the absence of ligand binding, EGFR, ErbB3 and ErbB4 remain in their 
“tethered” conformation, in which the dimerization arm of the domain II is buried 
in domain IV [284]. When a ligand contacts one of these receptors, it binds 
domains I and III to form an extended conformation, in which the dimerization 
surfaces of domains II and IV are exposed and promote homo- or hetero-
dimerization [285]. ErbB2 does not have an endogenous ligand, and its 
dimerization arm in domain II is constitutively exposed and readily 
heterodimerizes with other ligand-bound ErbBs [286]. Upon ligand binding in the 
ectodomain, the kinase region located on the tail of these receptors is activated. 
The kinase region is composed of C and N lobes that interact to achieve the 
active conformation. Activation of the kinase requires the C lobe in the first 
receptor to contact the N lobe of the second receptor (Fig. 12) [287], and this 
results in activation of downstream pathways [288]. 
Kinase domain mutations of ErbB2 are observed in cancer cells, and this 
results in constitutive activation of the receptor [289]. Heterodimerization such as 
EGFR/ErbB2, EGFR/ErbB3, and ErbB2/ErbB3 occur frequently in aggressive 
carcinomas [290], and the EGFR/ErbB2 combination is observed in the most 
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aggressive tumors and these patients have a poor prognosis and decreased 
survival [291]. 
 
Figure 12. Ligand induced dimerization of ErbBs (Adapted from [248]). 
 
1.2.4.7 Endocytosis and recycling of ErbBs 
Normally, growth factor receptor-coupled signaling is rapidly attenuated 
by mechanisms that include dissociation of the ligand-receptor complex, 
dephosphorylation of the activated receptor, rapid internalization through 
clathrin-coated pits and degradation of active receptors in lysosomes. For ErbB 
family members, EGFR is the most well studied receptor regarding endocytosis. 
Ligand-bound EGFR is rapidly endocytosed to form early endosomes, and in the 
late endosomes the ligand is dissociated from the receptor and undergoes 
lysosomal degradation; the receptor can also be degraded or recycled back to 
the cell surface. 
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EGFR homodimers are usually degraded by lysosomes, however, ErbB2-
containing heterodimers are transported back to the cell surface and activated. 
There are several possible mechanisms that ErbB2-containing heterodimers 
avoid efficient endocytotic degradation. For example, the rate of EGF-induced 
internalization of a chimeric receptor consisting of the extracellular domain of 
EGFR and intracellular domain of ErbB2 was decreased by three- to four fold  
compared to wild type EGFR, and the lower internalization rate of the chimeric 
receptor resulted in lower rates of receptor degradation [292]. It was also 
reported that geldanamycin-induced cleavage of ErbB2 within the cytoplasmic 
domain produces a 135-kDa and 23-kDa fragments, with the former 
representing the extracellular domain and part of the cytoplasmic domain, and 
the latter the carboxyl-terminal domain; Cleavage of the C-terminal domain 
resulted in accrelerated endocytosis and degradation of the 135-kDa fragment of 
ErbB2 [293]. Both studies suggest that the C-terminal domain of ErbB2 
expresses an inhibitory signal for clathrin-coated endocytosis of the receptor. c-
Cbl protein is an E3 ubiquitin ligase that recognizes tyrosine-phosphorylated 
substrates through the SH2 domain and controls the recycling and degradation 
of proteins [294]. A number of reports have shown that upon activation of EGFR, 
c-Cbl is associated with the phosphorylated Tyr-1045 of EGFR in the early 
endosome, ubiquitinates the receptor and directs it to the lysosome; c-Cbl 
mediated ubiquitination is required for EGFR endocytosis and lysosomal 
interactions [295-300]. In contrast, interactions between c-Cbl and ErbB2 are 
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weak and ubiquitination of ErbB2 followed by activation of the receptor is barely 
observed; ErbB3 and ErbB4 do not have any affinity for c-Cbl [301,302]. 
At present, very little is known regarding the endocytosis of ErbB3 and 
ErbB4, and results of the first study indicate that internalization of these 
receptors is impaired [303]. 
1.2.4.8 Regulation of ErbB2 expression 
ErbB2 overexpression in breast cancer cells is due not only to impaired 
degradation, and gene amplification, but also to elevated gene expression. The 
human ErbB2 proximal promoter consists of typical TATA box (-22 to -26bp) and 
a CCAAT box (-71 to -75bp) (Fig. 13) and there are two transcription initiation 
regions at +1, and -69 (Fig. 13). Transcription initiation at these two sites utilizes 
two separate mechanisms, with the upstream initiation site specified as an 
initiator-like element, whereas the downstream sites require the TATA box. 
Figure 13. Cis elements and their corresponding trans-acting factors on the ErbB2 promoter. 
In ErbB2 overexpressing cells, the upstream initiation site is preferentially 
upregulated [304,305]. A number of transcription factors bind the ErbB2 proximal 
promoter, and two of these, activating protein 2 (AP-2) and E-twenty six (Ets) 
family of transcription factors are required for maximal promoter activity. The two 
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transcription factors are associated with overexpression of the gene in breast 
cancers.  
AP-2 is a member of a family of closely related transcription factors that 
regulate gene expression during early development [306-308]. There are two 
AP-2 binding sites (GCTGCAGGC) at -215 and -500 that are activated in ErbB2 
overexpressing cells [309,310], and mutations that block AP-2 binding result in 
decreased activity of promoter-reporter constructs in ErbB2 overexpressing cells 
[311]. AP-2 family proteins include AP-2α, AP-2β, and AP-2γ, all of which can 
activate the ErbB2 promoter [312], and levels of AP-2α, AP-2β, and AP-2γ 
proteins correlate with ErbB2 overexpression in tumor derived cell lines and 
primary breast tumors [312,313]. 
Ets family transcription factors contain 12 subgroups and these protein all 
contain an ETS domain, which is a conserved helix-turn-helix DNA binding 
structure that recognizes the “GGA” DNA sequence. The Ets binding site (EBS; 
GAGGAA) in the ErbB2 promoter is at -33 to -28, and mutation of these sites 
also impairs activity of ErbB2 promoter-reporter constructs [305,314]. More than 
10 different Ets proteins have been identified in breast cells, but only PEA3 
expression correlates with ErbB2 overexpression [315]. In addition, there are 
conflicting reports regarding the effects of PEA3 on the ErbB2 promoter. One 
report showed that PEA3 and ErbB2 are coordinately upregulated in human 
breast tumors and PEA3 enhanced ErbB2 promoter activity in COS cells [315]; 
However, Xing et al observed that PEA3 represses ErbB2 expression through a 
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positive regulatory motif, PEA3 suppresses growth of MDA-MB-453 breast 
cancer and SKOV3 ovarian cancer cells that overexpress ErbB2, and inhibits 
growth of ErbB2 overexpressing tumors in vivo [316]. 
Ying Yang 1(YY1) is another transcription factor that also plays a role in 
ErbB2 expression. YY1 regulates the expression of a number of genes [317], 
and this protein is composed of an activation domain, two repression domains 
and a DNA binding domain. YY1 can function as a transcriptional activator or 
repressor [318], and YY1 expression correlates with ErbB2 and AP-2 
overexpression in primary breast tumors [319,320]. Full length but not a C-
terminal truncated YY1 enhances AP-2-mediated transactivation through an AP-
2 site in the ErbB2 promoter and inhibition of endogenous YY1 expression in 
BT474 breast cancer cells decreases AP-2 responsive-promoter activity. 
Interactions of endogenous AP-2 and YY1 and their association with ErbB2 
promoter have been reported, suggesting that YY1 cooperates with AP-2 to 
activate ErbB2 transcription in breast cancer cells [321]. 
MicroRNAs (miRs) that target the 3’ untranslated region (3’ UTR) of 
ErbB2 and ErbB3 mRNAs include miR-125a and miR-125b and these two miRs 
are significantly downregulated in ErbB2 overexpressing breast cancers [322]. 
Overexpression of miR125a and miR125b in SKBR3 breast cancer cells in 
which ErbB2 is overexpressed decreases ErbB2 and ErbB3 transcripts and 
protein levels [323]. 
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1.2.4.9 Major ErbB2 signalings 
In ErbB2-overexpressing cancer cells, heterodimers between ErbB2 and 
other members of the ErbB family are predominant and the most well-
characterized ErbB2-induced signaling involves activation of Ras/MAPK, 
PI3K/Akt, and PLCγ/PKC pathways (Fig. 14). Ligand induced ErbB dimerization 
induces autophosphorylation of the intracellular kinase domain, which in turn 
phosphorylates Src homology 2-containing protooncogene (Shc). 
Phosphorylated Shc recruits adaptor protein, growth factor receptor bound 2 
(Grb2), and stimulates activation of Son of Sevenless (Sos) guanine nucleotide 
exchange factor. Activated Sos removes guanosine diphosphate (GDP) from 
Ras and adds guanosine-5'-triphosphate (GTP). GTP-bound Ras associates 
with and activates the serine/threonine kinase Raf, which in turn phophorylates 
MEK1, and activates p42/p44 MAPK (also known as extracellular signal-related 
kinase 1 and 2 (ERK1 and ERK2)). Activated MAPK phosphorylates cytoplasmic 
and nuclear substrates including other protein kinases, growth factor receptors 
and transcription factors that are involved in proliferation, differentiation and cell 
survival [324]. 
Activation of the PI3K pathway through ErbB receptors requires the p85 
regulatory subunit of PI3K, which contains an SH2 domain that recognizes and 
binds phosphorylated tyrosines that are autophosphorylated by the kinase 
activity of the receptor. The activated p110 catalytic subunit of PI3K 
phosphorylates phosphatidylinositol (PI) to produce phosphatidylinositol 4,5-bis- 
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Figure 14. Major signaling pathways of ErbB2 (Adapted from [325]). 
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phosphate(PIP2) and phosphatidylinositol (3,4,5)-trisphosphate(PIP3), These PI-
phosphates function as docking sites for pleckstrin homology (PH) domain-
containing proteins such as phosphatidylinositol dependent kinase-1(PDK1) and 
PKB/Akt which in turn transmit signals from the cell membrane into the cell. 
Akt/PKB is phosphorylated and activated by PDK1and released into the cytosol, 
where it phosphorylates target proteins and regulates cell proliferation, 
metabolism, and apoptosis. ErbB2 and EGFR do not have binding sites for 
PI3K, however, active ErbB3 contains six PI3K binding sites; therefore 
ErbB2/ErbB3 and EGFR/ErbB3 heterodimers can generate potent signals 
through the PI3K pathway. 
Activation of PLCγ by ErbB2 is initiated by recognition of the 
phosphotyrosine sites by the SH2 domain of PLCγ, then the activated PLCγ is 
recruited to the plasma membrane through the binding of its PH-domain to 
phosphatidylinositol lipids within the membrane where PLCγ hydrolyses PIP2 to 
IP3 and diacylglyerol. This reaction results in activation of PKC, 
calcium/camodulin-dependent kinases and phosphatases, which are involved in 
development, metabolism and apoptosis [326]. 
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1.3 Sp transcription factors as drug targets 
1.3.1 Introduction of Sp / KLFs  
Specificity proteins (Sps) are highly related zinc finger proteins that play 
important roles in eukayotic cell transcription through regulating expression of a 
number of genes that contain GC-rich promoters. Sp1 was the first transcription 
factor identified and was characterized in 1980 [327,328]. Other transcription 
factors that are similar to Sp1 were also identified as Sp1-like proteins and 
Krüppel-like factors (KLFs) [329]. At least 21 Sp/KLF human genes have been 
identified using different cloning approaches. The Sp/KLF family is subdivided 
into several subgroups based on their structural similarities and Sp1-Sp6 form 
subgroup I in which all members are highly related to Sp1[330]. 
1.3.1.1 Structural features 
A typical transcription factor contains a DNA-binding domain, a nuclear 
localization signal, and a transcriptional regulatory domain. The DNA-binding 
domain of Sp/KLF proteins is highly conserved and contains three tandem 
Cys2His2 zinc-finger motifs that are localized at the carboxyl terminus. The 
similarity between zinc finger motifs of Sp1 and other Sp/KLF genes is 66.7%, 
but there are differences in DNA binding specificity. For example, Sp2 has a 
leucine residue in the first zinc-finger motif, whereas Sp1 has a histidine residue 
in the same region and Sp2 preferentially binds GT-rich (5’-GGTGTGGGG-3’) 
rather than GC-rich sites which are bound by other Sp/KLF proteins [331,332]. A 
conserved nuclear localization signal adjacent to or within the zinc-finger motifs 
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is observed only in KLF1, KLF2 and KLF4 proteins which belong to subgroup II 
of the Sp/KLF protein family [333,334]. The transcriptional regulatory domains of 
Sp/KLF proteins are located in the amino-terminus and are highly variable in 
their inhibitory or activation functions. Sp1, Sp3 and Sp4 have two glutamine-rich 
domains A and B in their respective transcriptional regulatory domains and are 
essential for activation of transcription, whereas Sp2 has only one glutamine-rich 
domain. Serine/threonine rich sequences are located adjacent to the A and B 
domains. The buttonhead (Btd) box is a conserved sequence of 11 amino acid 
located in the N-terminal of the zinc-finger domain of all Sp proteins, and is 
essential for the their transactivation potential [335]. Another region of conserved 
amino acids (sequence of SPLALLAATCSR/KI) has been identified, and this 
element (Sp-box) contains an endoproteolytic cleavage site reside in the N-
terminus of these proteins that targets proteasome-dependent degradation [336] 
(Fig. 15). It is worth noting that Sp3 has a repression domain located at the 5’ 
region of the zinc-finger domain, and this inhibitory domain (ID) may function by 
interacting with other corepressor proteins such as Sp3 interacting protein (SIF-
1) [331]. 
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Figure 15. Structural features of Sp1, Sp2, Sp3 and Sp4 (Adapted from [337]). 
1.3.1.2 Distribution and functional properties of Sp1, Sp3 and Sp4 proteins 
Sp1- Sp1 is ubiquitously expressed and plays important roles in 
embryogenesis, development, proliferation and apoptosis [338,339]. Sp1 
regulates transcription of TATA-containing and TATA-less target genes through 
both proximal and distal enhancers [340]. Sp1 activates transcription 
synergistically by forming homomultimeric complexes such as tetramers, and the 
activation domain B appears to be critical for the multimerization [341]; 
synergistic activation of promoters by Sp1 through binding multiple GC-boxes 
requires the C-terminal domain D[341]. Sp1 interacts with different classes of 
nuclear proteins including general transcription machinery factors (GTFs) such 
as TATA-box binding protein (TBP) and TBP-associated factors 
TAFII110/TAFII130 and TAFII55 to stabilize the transcription initiation complex 
[342-344]. In addition, cofactors required for Sp1 activation (CRSP) complex are 
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required for Sp1-mediated transactivation. Other transcription factors that 
interacts with Sp1 to modulate transcription include GATA1, E2F, YY1, c-Jun, 
p53, pRb and many other nuclear factors [345]. Sp1 regulates transcription of 
large number of genes, such as housekeeping, tissue-specific and cell cycle 
regulated genes. 
The DNA binding ability, transactivational activity, and protein stability of 
Sp1 can be influenced by posttranslational modifications such as 
phosphorylation, glycosylation, ubiquitination, acetylation and sumoylation [345]. 
For example, phosphorylation at Thr453 and Thr739 of Sp1 by p42/p44 MAPK 
significantly increased transcriptional activity of Sp1 in activation of the VEGF 
promoter [346]; inhibition of Sp1 phosphorylation at Thr278/739 via inhibition of 
c-Jun NH2-terminal kinase 1 (JNK1) activity resulted in ubiquitination and 
degradation of Sp1 [347]. Sp1 glycosylation is through the O-linkage of the 
monosaccharide and N-acetylglucosamine and Sp1 acetylation are involved in 
self association, interaction with GTFs and proteasome-dependent degradation 
[348,349]. 
Sp3-Sp3 is ubiquitously expressed and Sp3 null mice exhibited abnormal 
tooth formation and growth retardation although the specific physiological 
functions are not well defined [350]. In some studies, Sp3, like Sp1 acts as a 
transcriptional activator [351,352], whereas Sp3 can also be a weak activator or 
a repressor [353,354]. The structure of promoters is important for determining 
the function of Sp3. Promoters with a single GC-rich Sp binding site are 
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activated by Sp3, whereas promoters with multiple Sp binding sites are 
minimally responsive to Sp3 [355,356]. Cell context is another important factor 
that determines the function of Sp3; For example, Sp3 transactivates HERV-H 
long terminal repeat in teratocarcinoma cells but acts as a repressor in Hela and 
insect cells [357]. Since the Sp1/Sp3 ratio is relatively high in endothelial cells 
and low in non-endothelial cells, it has also been suggested that the relative 
abundance of Sp1 and Sp3 in a specific cell line influences the transcriptional 
activity of Sp3. There are three isoforms of Sp3 which are transcribed from the 
same gene at different start sites [332]; another study suggests that the two 
small Sp3 isoforms act as repressors whereas the full length Sp3 isoform acts 
as an activator [358]. The molecular basis for the suppressive activity of Sp3 is 
due to the amino acid triplet KEE in the inhibitory domain (ID). Mutation of these 
amino acids to alanines changes Sp3 into a strong activator, suggesting that the 
KEE sequence is essential for the suppressive activity of Sp3 [356]. Interactions 
of Sp3 with corepressors through the ID domain may also contribute the activity 
of Sp3 as a transcriptional repressor [331]. Posttranslational modifications also 
regulate the repressor activity of Sp3. For example, modification of Sp3 by small 
ubiquitin-related modifier-1 (SUMO-1) converted Sp3 into a strong activator of 
transcription [359]. 
Sp4-Sp4 is a tissue specific member of the Sp-family the predominant 
distribution in the brain and also expression in epithelial tissues, testis and 
developing teeth [360,361]. Sp4 plays a role in postnatal survival and male 
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fertility [361]. Approximately two-thirds of the Sp4-/- mice died shortly after birth, 
and the male survivors exhibited defects in copulation and significant growth 
retardation is observed in both males and females. Like Sp1, Sp4 exhibits 
similar transactivation potential through the glutamine-rich activation domains. 
However, in contrast to Sp1, Sp4 does not act synergistically through 
interactions with Sp proteins bound to adjacent sites [362].  
1.3.2 Sp proteins as drug targets 
 Sp1-Sp4 regulate expression of multiple genes in normal tissues and in 
tumors. There is growing evidence indicating that some Sp proteins play 
important roles in growth and metastasis of a number of tumor types and this will 
be discussed in the following subsection. 
1.3.2.1 Overexpression of Sp proteins in tumors 
Sp1 is overexpressed in gastric tumors and is non-detectable in stromal 
or surrounding normal glandular cells [363]. Sp1 is also highly expressed in 
pancreatic tumors compared to normal tissues, and this overexpression is 
correlated with increased expression of VEGF which is an Sp-regulated gene 
[364]. Levels of Sp1 protein are elevated in 11 out of 14 breast carcinomas, and 
is only detectable in 1 out of 5 benign breast tumors [365], and Sp1 is also 
overexpressed in thyroid tumors but not in the normal thyroid [366]. Expression 
of DNA-dependent protein kinases Ku70 and Ku80 is regulated through Sp1 
interactions with GC-rich regions in their respective promoters, and theses 
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kinases are upregulated in colon tumors compared to surrounding normal 
tissues and this upregulation is correlated with elevated Sp1 expression [367]. 
Wang and coworkers showed that gastric tumor patients with high Sp1 
expression have lower rates of survival than patients with low Sp1 levels [363], 
and correlation of VEGF and Sp1 overexpression in gastric tumors is also 
associated with decreased survival times [368]. 
1.3.2.2 Regulation of growth promotion and cell survival genes by Sp in cancer 
cells 
The role of Sp1, Sp3 and Sp4 in Panc-1 pancreatic cancer cells was 
investigated  using RNA interference (RNAi) and knockdown of Sp1 protein in 
Panc-1 cells decreased the percentage of cells in G2/M and S phase by 5.52% 
and 5.74%, respectively, and increased the percentage in G0/G1 by 10.26% 
[369]. However, when transfected with small inhibitory RNA for Sp3, the 
percentage of Panc-1 cells in G0/G1 was increased (20.14%) and the 
percentage in S phase was decreased (17.39%). It was subsequently shown 
that knockdown of Sp3 by RNAi in Panc-1 and other pancreatic cancer cell lines 
resulted in upregulation of the cyclin-dependent kinase inhibitor p27 [369]. 
These results indicated that Sp3 promotes pancreatic cancer cell growth through 
interaction with the GC-rich region on the p27 promoter to inhibit expression of 
this gene. 
 Loss of growth inhibitory pathways is critical for oncogenesis in some 
tumors, and Sp proteins also play a role in tumorigenesis by Sp3-dependent 
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suppression of transforming growth factor β receptor (TGFβR) pathway [370-
372]. The TGFβRII promoter contains GC-rich elements and Sp1 and Sp3 are 
required for regulation of expression of this gene [370,371,373]. Late passage 
MCF-7 breast cancer cells (MCF-7L) are nonresponsive to TGFβ due to 
nondetectable expression of TGFβRI and TGFβRII, and the Sp1/Sp3 ratio in this 
cell line is lower than that in TGFβ-responsive early passage MCF-7 cells (MCF-
7E) in which TGFβR is expressed [372]. Therefore, Sp3 acts as a repressor for 
TGFβRII and blocks an important growth inhibitory pathway in breast cancer 
cells. 
 Sp1 also regulates a number of genes in breast cancer cells that are 
involved in cell cycle progression and cell growth (cyclin D1, E2F1, c-fos, TGFα) 
[374-377], purine/pyrimidine synthesis and metabolism (thymidylate synthase, 
adenosine deaminase, DNA-polymerase α, carbamylphosphate 
synthase/aspartate carbamyltransferase/dihydroorotase (CAD)) [378-381], 
angiogenesis (VEGF) [369,382], and survival (bcl-2, survivin) [383-385]. 
1.3.2.3 Strategies for targeting Sp transcription factors in cancer cells 
Sp transcription factors are highly expressed in cancer cells, and are neg- 
ative prognostic factors for patient survival and regulate expression of growth 
promoting, survival and angiogenic / metastatic genes. Approaches for targeting 
Sp –regulated genes and pathways include chemicals that inactivate GC-rich 
DNA elements, oligonucleotides and DNA-peptide nucleic acid chimeras that 
decoy the Sp1 DNA-binding domain, and compounds that regulate Sp protein 
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expression [386]. For example, treatment of cells with mithramycin, a compound 
that binds GC-rich motifs decreased Sp1-DNA binding and expression of Sp-
regulated genes [387-389]. Hedamycin also binds G-rich DNA sequences and 
this drug inhibits transcription of survivin through interacting the GC-rich Sp1 site 
on the survivin promoter [390]. Double stranded oligonucleotides with multiple 
CG-rich sequences were developed as Sp1 decoys, and transfection of Sp1 
decoys into human lung adenocarcinoma and glioblastoma cancer cell lines 
inhibited Sp1-dependent expression of VEGF and TGFβ1 [391]. Various decoys 
for Sp transcription factors and other transcription factors are being developed 
and there may be clinical application of this approach for treatment of different 
cancers [392,393]. Compounds that modulate Sp protein expression will be 
described in the following subsection. 
1.3.3 Drugs that target Sp downregulation 
1.3.3.1 NSAIDs (celecoxib, tolfenamic acid, aspirin) 
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit synthesis of 
prostaglandins through inhibiting cyclooxygenase (COX)-mediated inflammatory 
responses, and these drugs are used primarily to treat inflammation, pain, and 
fever, with specific uses including the treatment of migraines, arthritis, sports 
injuries, and menstrual cramps. Recent studies showed that COX-2 is 
overexpressed in numbers of tumor types and promotes tumorigenesis via 
enhancement of cancer cell proliferation, increased tumor angiogenesis, 
decreased tumor cell apoptosis, and enhanced tumor metastasis. NSAID-
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induced anticarcinogenic activities are due to inhibition of these processes in a 
COX-2-dependent or independent manner [394-396]. The potential use of 
NSAIDs in reducing cancer risk is supported by epidemiologic studies which 
demonstrate that low-dose and regular use of NSAIDs reduced risk of colon 
cancer [397]. NSAIDs are also effective for preventing tumorigenesis of lung, 
breast, prostate, pancreatic and esophagal cancers [398-401]. NSAIDs can be 
classified based on their chemical structures and these include propionic acid 
derivatives, acetic acid derivatives, enolic acid (oxicam) derivatives, fenamic 
acid derivatives; according to the function, some of these drugs can be grouped 
into selective COX-2 inhibitors, and non-selective COX inhibitors which inhibit 
both COX-1 and COX-2. 
Celecoxib is a selective COX-2 inhibitor that is used for treatment of pain 
and inflammation, and this compound also decreases the numbers of colon and 
rectum polyps in patients with familial adenomatous polyposis. A number of 
studies indicate that celecoxib can be used for cancer prevention and treatment. 
Epidemiologic studies showed that people taking NSAIDs such as aspirin or 
celecoxib on a daily basis have a lower risk of colon cancer; carcinogenesis 
studies in rodents show that prevents formation of intestinal cancers [402]; small 
scale clinical trials in individuals with familial adenomatous polyposis show that 
celecoxib prevents polyp growth, and large scale clinical trials show 33 to 45% 
reduction of polyp growth in people taking celecoxib regularly [403]. Celecoxib 
inhibits COX-2 and also modulates other intracellular pathways, and several 
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celecoxib analogs devoid of COX-2 inhibitory activity also exhibit anticancer 
activity, indicating that COX-2 inhibition is not required for the anticancer effects 
of celecoxib [404,405]. In addition, celecoxib decreases Sp1 and VEGF 
expression and through induction of Sp1 degradation in pancreatic cancer cells 
[406], and COX-2 inhibitors inhibit VEGF expression by decreasing Sp1 and Sp3 
levels in colon cancer cells [407]. 
Tolfenamic acid belongs to the fenamic acid subgroup of NSAIDs, and 
has been used to treat migraines [408-412]. It was also reported that tolfenamic 
acid inhibited pancreatic cancer cell and tumor growth by targeting 
downregulation of Sp1, Sp3 and Sp4 proteins [413]. In this study, tolfenamic 
acid was the most potent among 14 screened NSAIDs (COX-1 and/or COX-2 
inhibitors) for the ability to decrease Sp1, Sp3 and Sp4 protein expression in 
pancreatic cancer cells through the proteasome pathway. Tolfenamic acid also 
inhibited VEGF mRNA and protein expression in pancreatic cancer cells, and 
this inhibition was related to decreased Sp-dependent activation of the VEGF 
promoter. 
Aspirin (also known as acetylsalicylic acid, ASA) was the first NSAID 
discovered, and is one of the most widely used medications in the world. 
Approximately 40,000 tones of ASA being consumed each year as an antipyretic 
to reduce fever, as an anti-inflammatory medication, and for prevention of heart 
attacks, strokes, and formation of blood clots [414,415]. There is growing 
evidence showing the association of between aspirin use and the reduced 
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incidence in colon, breast, lung, stomach, oesophagus, bladder, ovary, prostate, 
mouth, and skin cancers [416,417]. Aspirin decreases cancer risk through 
inhibition of COX. Salicylic acid which is the main metabolite of aspirin can 
suppress COX-2 mRNA and protein expression in human endothelial cells and 
fibroblasts [418], and aspirin decreases COX-2-dependent synthesis of 
prostaglandins which enhance carcinogenesis through promotion of cell survival, 
cell proliferation and angiogenesis [419-421]. The acetyl group of aspirin trans-
acetylates serine 530 within the active site of COX-1, and inhibits COX-1 
mediated platelet aggregation, vascular homoeostasis, renal blood flow, and 
glomerular function. Acetylation of the COX-1 active site blocks the access of 
the COX-1 substrate arachidonic acid to the active site; in contrast the enzyme 
active site of COX-2 is larger than that of COX-1, and is accessible to acetylated 
substrates [422]. A second possible mechanism for the anticancer activity of 
aspirin is due to induction of apoptosis. Aspirin induces apoptosis by activation 
of caspases [423], activation of p38 MAP kinase [424], activation of ceramide 
pathway [425], release of mitochondrial cytochrome c [426], induction of a 
proapoptotic gene PAWR [427], and downregulation of antiapoptotic genes such 
as BCL2 [428]. These effects may not be observed in all cell types and the 
doses of aspirin required for these COX-independent pathways are higher than 
doses that inhibit COX-2. Aspirin also inhibits NFкβ, which is a transcription 
factor that activates anti-apoptotic genes, and this effect contributes to the 
decreased incidence of colon, breast and gynaecological cancers associated 
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with aspirin use [429]. Moreover, aspirin can upregulate tumor suppressor genes 
such as p53, p21, and BAX [428]. DNA mismatch repair protects against the 
accumulation of mutations during DNA-replication and it was also reported that 
aspirin decreases microsatellite instability in mismatch-repair deficient colon 
cancer cells [430]. In another study, aspirin increased levels of mismatch-repair 
proteins and inhibited growth of mismatch-repair-deficient colon cancer cell lines 
[431]. Other possible mechanisms of the anticancer activity of aspirin include 
inhibition of mitochondrial calcium uptake, which is an ubiquitous influx pathway 
for cell proliferation [432]; decrease in DNA damage through modulation of 
oxidative stress and glutathione peroxidase activity [433]; inhibition of 
phenolsulphotransferase, which can activates some carcinogens activator [434]; 
and prostaglandin-independent effects on angiogenesis [435]. 
1.3.3.2 Phytochemicals (betulinic acid, curcumin) 
Phytochemicals are natural biochemicals produced by plants for 
protection from insects, disease organisms, oxidation and other environmental 
hazards.  Some phytochemicals have been traditionally used for treatment or 
prevention of cancer. Examples of cancer-suppressing phytochemicals include 
curcumin, β-carotene, epigallocatechin gallate, genistein, resveratrol, gingerol, 
and capsaicin. Most of these cancer-suppressing phytochemicals act on 
signaling pathways that have been abnormally activated or silenced in tumors 
and phytochemicals that suppress cancer through repression of Sp proteins will 
be described in this subsection. 
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Betulinic acid (BA) is a natural pentacyclic triterpenoid extracted from the 
bark of several species of plants, principally the white birch (Betula pubescens) 
from which it gets the name. BA has anti-retroviral, anti-malarial, anti-
inflammatory, and anticancer properties. BA was initially reported as a potent 
antimelanoma compound in 1995, and subsequently, it was shown to be 
effective against cancer cells from other tumor types, including neuroectodermal 
tumor cells, malignant brain tumors, ovarian carcinomas, nonsmall-cell and 
small-cell lung carcinomas, cervix carcinomas [436,437]. Normal cells such as 
melanocytes were much less sensitive to the growth inhibitory effects of BA 
compared to melanoma cells [438]; BA induced apoptosis in an immortalized 
human keratinocyte cell line HaCaT, whereas BA induced differentiation of 
normal keratinocytes  into corneocytes  [439]; moreover, human skin fibroblasts 
and peripheral blood lymphocytes are highly resistant to BA [440]. The 
underlying molecular mechanisms required for the differential effect of BA on 
cancer versus normal cells are unclear. The anti-apoptotic effects of BA have 
been extensively investigated, and unlike conventional anticancer drugs which 
induce apoptosis through activation of death receptor pathways or activation of 
p53 and subsequent Bax/Bak-dependent release of cytochrome c from 
mitochondria, BA directly induces of mitochondrial damage resulting in Bax/Bak-
independent release of cytochrome c [441-443]. About 50% of human tumors 
acquire p53 mutations and most of the remaining tumors exhibit p53-deficient 
pathways, therefore anticancer therapies that are dependent on p53 activation 
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are prone to become drug resistant, and since BA directly targets mitochondria 
to induce apoptosis, this drug has great promise for overcoming drug resistance 
in tumor cells [443-445]. Treatment with BA also increases mitochondrial 
membrane permeabilization through generation of reactive oxygen species 
(ROS), and pretreatment with antioxidants can rescue cells from BA-induced 
apoptosis suggesting that ROS production is important for cell death 
[437,446,447]. BA can also activate proteasomes. One study demonstrated that 
the anticancer effects of BA were due in part to degradation of Sp1, Sp3 and 
Sp4 transcription factors. The protein synthesis inhibitor cycloheximide had no 
effect on BA-induced downregulation of Sp1, Sp3 and Sp4 protein levels in 
prostate cancer cells, however cotreatment with the proteasome inhibitor MG132 
reversed the BA-induced repression of Sp proteins, suggesting that BA induce 
proteasome-dependent degradation of Sp proteins [448]. Another study showed 
that BA directly interacted with purified proteasomes and activated 
chymotrypsin-like proteasome activity, whereas derivatives of BA with 
modifications at C-3 exhibited proteasome-inhibitory effects [449]. Other targets 
of BA include NF-кB, topoisomerases, aminopeptidase N, acetyl-CoA 
acyltransferase and diacylglycerol acyltransferase, and cell cycle related genes 
[450-459]. In vivo studies of BA showed that a dose of 50 mg/kg every 4 days 
administrated intraperitoneally was enough to prevent tumor outgrowth and six 
injections resulted in tumor regression [460]. In a prostate cancer murine 
xenograft model treatment with 10 or 20 mg/kg BA administrated orally every 
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other day significantly inhibited tumor outgrowth compared to a corn oil-treated 
control [448], suggesting that BA is active even after oral application. Similar 
activity is observed when BA is applied by intravenous injection in a human 
murine xenograft modle [461], and systemic signs of toxicity were not observed 
in these in vivo studies. 
Curcumin (diferuloylmethane) is the active component of turmeric, and is 
a polyphenolic natural product that is widely used in cooking and as a traditional 
medicine by people from southeast Asia [462-464]. The anticancer effects of 
curcumin have been extensively investigated in various cancer cells and animal 
models, and the effects are highly variable and dependent on tumor type and 
cell context. Curcumin induces apoptosis, inhibits cancer cell proliferation, and 
angiogenesis [465-474]. Curcumin inhibited growth-induced apoptosis in KU7 
and 253JB-V bladder cancer cells and this was accompanied by decreased Sp 
protein expression [475]. Curcumin induced proteasome-dependent 
downregulation of Sp1, Sp3 and Sp4, and curcumin-induced inhibition of NFкB-
dependent genes such as bcl-2, survivin and cyclinD1is also partially dependent 
on downregulation of Sp proteins. Curcumin also decreases growth of bladder 
tumor in KU7 cell mouse xenografts and this was also accompanied by 
decrease in Sp1, Sp3 and Sp4 protein levels in tumors. Subsequent studies 
showed that downregulation of Sp1, Sp3 and Sp4 by curcumin in bladder cancer 
cells is accompanied by decreased EGFR mRNA and protein levels, and it was 
shown by RNA interference studies that EGFR is an Sp-regulated gene [476]. 
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Another study showed that curcumin decreased expression of Sp proteins and 
Sp-dependent proteins in Panc28 and L3.6pL pancreatic cancer cells and 
xenograft mouse models [477]. Moreover, RNAi experiment showed that p65 
and p50 subunits of NFкB are regulated by Sp proteins and inhibition of NFкB 
expression by curcumin is also partially due to loss of Sp transcription factors. 
Curcumin also decreases mitochondrial membrane potential and induces 
reactive oxygen species (ROS), and this was essential for downregulation of Sp 
proteins in pancreatic cancer cells [477]. 
1.4 Research Objectives 
1.4.1 Objective 1: Mechanisms of TA action in breast cancer cells 
 Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug (NSAID) 
that inhibits pancreatic cancer cell and tumor growth through induction of 
proteasome dependent degradation of specificity protein (Sp) transcription 
factors [413]. In this research, it was observed that TA also inhibited growth of 
ErbB2-overexpressing BT474 and SKBR3 breast cancer cells. In contrast to 
pancreatic cancer cells, TA downregulates ErB2 but not Sp proteins. Therefore, 
the first objective of this research was to investigate the mechanisms of anti-
cancer activity of TA in BT474 and SKBR3 breast cancer cells through 
downregulation of ErbB2. TA-induced inhibition of ErbB2 gene expression will be 
determined using real-time PCR, and by transfecting the breast cancer cells with 
a construct containing the ErbB2 promoter linked to a luciferase reporter gene; 
the levels of two ErbB2 transcriptional activators AP2 and YY1 will be 
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determined by western blot analysis; ErbB2 RNA stability will be measured using 
actinomycin D in combination with TA, and mRNA levels will be determined by 
real-time PCR. Proteasome dependent degradation of ErbB2 will be investigated 
using lactacystin, a proteasome inhibitor, in combination with TA. Endocytosis of 
ErbB2 induced by TA will be determined by immunofluorescence microscopy. 
Effects of TA in vivo will use an athymic nude mouse xenograft model. 
1.4.2 Objective 2: Mechanisms of BA action in breast cancer cells 
Betulinic acid (BA) has been reported to inhibit prostate cancer cell 
growth through induction of proteasome dependent degradation of Sp1, Sp3 and 
Sp4 transcription factors [448]. BA also inhibits growth of ErbB2-overexpressing 
BT474 and MDA-MB-453 breast cancer cells; Both Sp proteins and ErbB2 are 
downregulated in BA treated breast cancer cells. The objective of this research 
will be to investigate the mechanisms of anti-cancer activity of BA in BT474 and 
MDA-MB-453 breast cancer cells through downregulation of Sp proteins and / or 
ErbB2. Proteasome dependent degradation of Sp1, Sp3, Sp4 and ErbB2 will be 
determined using lactacystin to inhibit proteasomes. ErbB2 and their 
downstream proteins will be determined by western blot analysis. Sp protein 
mRNA levels will be determined by real-time PCR. Since a putative Sp binding 
site is found localized in the promoter region of YY1, an ErbB2 transcriptional 
activator, regulation of expression of YY1 and ErbB2 by Sp proteins will be 
determined by transfecting cells with siRNAs for Sp1, Sp3, and Sp4 or 
combination of the three Sp proteins, and the level of YY1 and ErbB2 proteins 
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will be determined by western blot analysis. A recent study showed that miR 27a 
targets ZBTB10, a repressor of Sp transcription factors in breast cancer cells 
[478]. Therefore, the effects of BA on miR27a and ZBTB10 expression will be 
determined by real-time PCR. Cannabinoid receptors have been reported as 
anticancer drugs targets and we hypothesized that BA may target Sp proteins 
and ErbB2 by activating cannabinoid receptors, and this will be determined by 
cotreatment of BA with cannabinoid receptor 1 and 2 (CB1 and CB2) 
antagonists, AM251 and AM630 respectively, and effects of BA on Sps, ErbB2, 
miR27a, and ZBTB10 will be determined using techniques described as above. 
Effects of BA in vivo will be determined using athymic nude mouse xenograft 
models. 
1.4.3 Objective 3: Mechanisms of aspirin action in breast cancer cells  
Aspirin usage lowers the incidence of multiple cancers and also inhibits 
tumor recurrence of colon and breast cancer patients who use aspirin after 
cancer diagnosis [416,417]. In this research, it was observed that aspirin also 
inhibits growth of ErbB2-overexpressing BT474 and MDA-MB-453 breast cancer 
cells and both Sp1, Sp3, Sp4 and ErbB2 proteins are downregulated in aspirin 
treated breast cancer cells. Therefore, the objective of this research will be to 
investigate the mechanisms of anti-cancer activity of aspirin in BT474 and MDA-
MB-453 breast cancer cells and the contributions of aspirin-induced 
downregulation of Sp proteins and / or ErbB2 in mediating this response. Aspirin 
induced apoptosis in cells will be determined using terminal deoxynucleotidyl 
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transferase d-UTP nick end labeling (TUNEL) assay. Proteasome-dependent 
degradation of Sp1, Sp3, Sp4 and ErbB2 will be investigated using lactacystin to 
inhibit proteasomes; Sp proteins / ErbB2 and their downstream proteins will be 
detected using western blots. Phosphatase inhibitor cocktail II (PIC II) and 
sodium orthovanadate (Na3VO4) will be used to determine whether aspirin-
induced downregulation of Sp1, Sp3, Sp4 and ErbB2 are dependent on 
induction of phosphatases. mRNA levels of specific phosphatases in aspirin 
treated cells will be determined using real-time PCR. Knocking down the specific 
phosphatase by RNAi will be conducted to determine the role of induced 
phosphatases in mediating downregulation of Sp1, Sp3, Sp4 and ErbB2.
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2. THE NSAID TOLFENAMIC ACID INHIBITS BT474 AND SKBR3 
BREAST CANCER CELL AND TUMOR GROWTH BY REPRESSING 
ErbB2 EXPRESSION* 
 
2.1 Introduction 
Breast cancer is one of the major causes of premature death in women; 
however, the combination of early detection coupled with improved treatment 
has significantly improved survival from this disease [479-481].  Antiestrogens 
and aromatase inhibitors are highly effective endocrine therapies used for 
treating early stage estrogen receptor (ER)- positive breast cancer.  Compounds 
that include tamoxifen, raloxifene, fulvestrant, and their combinations or 
sequential use provide successful outcomes for patients with hormone-
responsive tumors [480-485].  Later stage or less differentiated ER-negative 
breast cancers are more aggressive; patient survival is relatively low; and 
various therapeutic regimes are less effective [486-489].  Improvements in the 
effectiveness of chemotherapies have been obtained using drug combinations 
and differences in the timing of drug delivery [489].  In addition, newer 
mechanism-based anticancer drugs that target critical kinase, survival, growth 
promoting and angiogenic pathways are also promising new chemotherapies for 
treating breast and other tumor types [488,489].   
____________ 
 *Adapted and reprinted by permission from the American Association for Cancer Research: Xinyi Liu, The 
nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and 
tumor growth by repressing ErbB2 expression., Mol Cancer Ther, 2009 ;8(5):1207-17. 
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 Epidermal growth factor receptors (EGFRs) are receptor tyrosine kinases 
overexpressed in many cancers and ErbB2/HER2/neu is an oncogene 
overexpressed in 20-30% of all breast cancers.  ErbB2-positive tumors tend to 
be aggressive with a poor prognosis for patient survival, and the recombinant 
monoclonal antibody trastuzumab (Herceptin) has been used as a single agent 
and in combination therapy for successfully treating patients with breast tumors 
overexpressing ErbB2 [490-493].  Since Herceptin targets the extracellular 
domain of ErbB2, there is a decrease in receptor tyrosine kinase activity and 
various downstream targets that are important for ErbB2-dependent tumor 
growth and survival.  For example, treatment of breast cancer cells 
overexpressing ErbB2 with Herceptin decreased ErbB2 phosphorylation and 
also mitogen-activated protein kinase (MAPK)- and phosphatidylinositol-3-kinase 
(PI3K)-dependent phosphorylation of MAPK and Akt, respectively [494]. 
 Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug (NSAID) 
used for treatment of migraine headaches and alcohol-induced hangovers [495]; 
however, recent studies have demonstrated the efficacy of this drug for cancer 
chemotherapy [413,496].  TA inhibits pancreatic cancer cell growth in vitro and 
tumor growth in vivo through inducing proteasome-dependent degradation of 
Sp1, Sp3 and Sp4 proteins which are overexpressed in these cells and tumors 
[369,413,496].  The effectiveness of TA is associated with repression of Sp 
proteins and Sp-dependent genes such as vascular endothelial growth factor 
(VEGF) and VEGF receptor 1 (VEGFR1).  The antiangiogenic activity of TA 
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correlated with the inhibition of liver metastasis in an orthotopic model for 
pancreatic cancer [495].  In this study, we show that TA also inhibits growth of 
ErbB2-overexpressing BT474 and SKBR3 breast cancer cells; however, this is 
not accompanied by a coordinate repression of Sp proteins.  Inhibition of ErbB2-
overexpressing breast cancer cell and tumor growth by TA is associated with 
downregulation of ErbB2.  This novel observation highlights the possibility that 
ErbB2-overexpressing breast tumors and tumors derived from other tissues may 
be targeted by TA and structurally-related NSAIDs that exhibit relatively low 
toxicity. 
2.2 Materials and methods 
Chemicals, antibodies, plasmids, and reagents - Tolfenamic acid, 
mefenamic acid, flufenamic acid, N-flumic acid and diclofenac were purchased 
from LKT Laboratories, Inc. (St. Paul, MN).  Lactacystin, cycloheximide and -
actin antibody were purchased from Sigma-Aldrich (St. Louis, MO).  Antibodies 
against ErbB2 (C-18), Sp1 (PEP2), Sp3 (D-20), Sp4 (V-20), Akt (H-136), p-Akt 
(Ser473), MAPK(C-14), p-MAPK (E-4), cyclin D1 (M-20), p27 (C-19), PEA3 (16), 
AP-2 (C-18 and 3B5) and YY1 (H-10) were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA); antibody against ErbB2 (Ab-3) was obtained 
from Calbiochem (San Diego, CA); and antibody against EEA1 was obtained 
from Upstate (Lake Placid, NY).  The pErbB2-500 construct was kindly provided 
by Dr. Christopher C. Benz (University of California, San Francisco, CA) and the 
full length AP-2 cDNA construct TFAP2A was purchased from Open Biosystem 
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(Huntsville, AL).  Reporter lysis buffer and luciferase reagent for luciferase 
studies were purchased from Promega (Madison, WI).  -Galactosidase (-gal) 
reagent was obtained from Tropix (Bedford, MA).  LipofectAMINE reagent was 
supplied by Invitrogen (Carlsbad, CA).  Western lightning chemiluminescence 
reagent was from Perkin-Elmer Life Sciences (Boston, MA). 
 Cell lines - Human mammary carcinoma cell lines MDA-MB-231, MCF-7, 
BT474 and SKBR3 were obtained from the American Type Culture Collection 
(Manassas, VA).  Cell lines were cultured with 10% fetal bovine serum (FBS) in 
DMEM (BT474, MDA-MB-231 and MCF-7) or McCoy’s 5A medium (SKBR3).  
Cells were maintained at 37C in the presence of 5% CO2. 
 Cell proliferation assay - Cells (2-3 x 104 per well) were plated in 12-well 
plates and allowed to attach for 24 hr.  The medium was then changed to 
DMEM/Ham's F-12 medium containing 2.5% charcoal-stripped FBS, and either 
vehicle (DMSO) or different concentrations of TA were added.  Fresh medium 
and compounds were added every 48 hr, and cells were then trypsinized and 
counted at the indicated time points using a Coulter Z1 cell counter.  Each 
experiment was done in triplicate, and results are expressed as means  SE for 
each set of experiments.  
 Western blotting - Cells were rinsed with PBS and collected by scraping 
cells from the culture plate in 200 L of lysis buffer.  The cell lysates were 
incubated on ice for 1 hr with intermittent vortex mixing and then centrifuged at 
40,000 g for 10 min at 4C.  Equal amounts of protein were separated on SDS-
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polyacrylamide gels.  Proteins were transferred to Immobilon P membranes 
(Millipore, Bedford, MA) using a Bio-Rad Trans-blot apparatus and transfer 
buffer (48 mM Tris, 39 mM glycine, 0.0375% SDS, 20% methanol).  After 
blocking in TBST-Blotto [10 mmol/L Tris-HCl, 150 mmol/L NaCl (pH 8), 0.05% 
Triton X-100, 5% nonfat dry milk] for 30 min, the membranes were incubated 
with primary antibodies overnight at 4C and then with horseradish peroxidase-
conjugated secondary antibody for 2 hr at room temperature.  Proteins were 
visualized using the chemiluminescence substrate (Perkin-Elmer Life Sciences) 
for 1 min and exposed to Kodak X-OMAT AR autoradiography film (Eastman 
Kodak, Rochester, NY).  For protein quantitation, band intensities were 
normalized to -actin (loading control) and compared to band intensities for the 
DMSO (control) set at 1.0 or 100%. 
 Quantitative real-time PCR - Total RNA was purified using RNeasy Mini 
Kit (Qiagen, Germantown, MD) and cDNA was prepared using Reverse 
Transcription System (Promega, Madison, WI).  Each PCR was carried out in 
triplicate in a 30 L volume using SYBR Green Mastermix (Applied Biosystems, 
Foster City, CA) for 15 min at 95C for initial denaturing, followed by 40 cycles of 
95C for 30 s and 60C for 1 min in the Applied Biosystems 7900HT Fast Real-
time PCR System.  The ABI Dissociation Curves software was used following a 
brief thermal protocol (95C for 15 s and 60C for 15 s, followed by a slow ramp 
to 95C) to control for multiple species in each PCR amplification.  Values for 
each gene were normalized to expression levels of TATA-binding protein (TBP).  
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Primers were obtained from Integrated DNA Technologies.  The following 
primers were used: 
hNeu(F):  5'-ACC GGC ACA GAC ATG AAG CT-3'. 
hNeu(R):  5'-AGG AAG GAC AGG CTG GCA TT-3'. 
TBP (F):  5'-TGC ACA GGA GCC AAG AGT GAA-3'.  
TBP (R):  5'-CAC ATC ACA GCT CCC CAC CA-3'. 
 DNA transfection and luciferase assays - Cells were plated in 12-well 
plates at 1 x 105 per well and cultured as described above.  After growth for 16 
to 20 hr, transfections were done by using LipofectAMINE (Invitrogen) according 
to the manufacturer's protocol.  After 5 hr of transfection, the transfection mix 
was replaced with complete media containing either vehicle (DMSO) or TA for 
20 to 22 hr. Cells were then lysed with 100 L of 1x reporter lysis buffer, and 30 
L of cell extract were used for luciferase and -gal assays.  Lumicount was 
used to quantitate luciferase and -gal activities, and the luciferase activities 
were normalized to -gal activity. 
 Immunofluorescence microscopy - Cells were fixed immediately in 4% 
paraformaldehyde, added with 0.3% Triton X-100 (Roche Molecular 
Biochemicals, Indianapolis, IN) for 10 min, permeabilized in PBS with 0.3% 
Triton X-100 for 10 min, and preincubated for 1 hr with 10% normal goat serum 
(Vector Laboratories, Burlingame, CA).  Cells were incubated with anti-ErbB2 
antibody (1:80) or anti-EEA1 antibody (1:200) overnight and incubated with 
FITC-conjugated or Cy5-conjugated secondary antibody (1:200; Chemicon, 
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Temecula, CA) for 1 hr.  The two-well chambers were mounted with mounting 
medium (Vector Laboratories).  The slides were viewed using an LSM 510 Meta 
confocal microscope (Carl Zeiss, Jena, Germany) equipped with 40X and 63X 
objectives.  Images were analyzed and processed using the LSM software v. 3.2 
(Carl Zeiss) and occasionally Adobe Photoshop 7.0. 
 Animals and orthotopic implantation of breast tumor cells - Female 
ovariectomized athymic nu/nu mice (5-7 wk old) were purchased from the 
Animal Production Area of the National Cancer Institute Frederick Cancer 
Research and Development Center (Frederick, MD).  The mice were housed 
and maintained under specific pathogen-free conditions in facilities approved by 
the American Association for Accreditation of Laboratory Animal Care and in 
accordance with current regulations and standards of the United States 
Department of Agriculture, United States Department of Health and Human 
Services, and the NIH.  Under anesthetic condition, a 0.72-mg 60-day release 
17-estradiol pellet (Innovative Research, Sarasota, FL) was implanted into the 
interscapular region of each mouse.  One day later, BT474 cells (3x106 cells) 
were injected s.c. under the mammary fat pad area of each mouse.  The tumor 
sites were monitored twice a week and when palpable (12 days), mice were 
randomized into two groups of 5 mice per group and dosed by oral gavage with 
corn oil or 25 mg/kg/d tolfenamic acid for 27 days.  The mice were weighed, and 
tumor size was measured at the indicated time with calipers to permit calculation 
of tumor volumes:  V = LW2 / 2, where L and W were length and width, 
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respectively.  Final body and tumor weights were determined at the end of the 
dosing regimen, and tumor blocks were obtained for histopathologic analysis. 
 Immunohistochemistry - Tissue sections (4-5 M thick) mounted on poly-
L-lysine-coated slide were deparaffinized by standard methods.  Endogenous 
peroxidase was blocked by the use of 2% hydrogen peroxide in PBS for 1 min.  
Antigen retrieval for ErbB2 and p-MAPK staining was done for 10 min in 10 
mmol/L sodium citrate buffer (pH 6) heated at 95C in a steamer followed by 
cooling at room temperature for 15 min.  The slides were washed with PBS and 
incubated for 30 min at room temperature with a protein blocking solution 
(VECTASTAIN Elite ABC kit, Vector Laboratories, Burlingame, CA).  Excess 
blocking solution was drained, and the samples were incubated overnight at 4C 
with one of the following:  a 1:60 dilution of ErbB2 antibody or a 1:80 dilution of 
p-MAPK, AP-2 and YY1 antibodies.  Sections were then incubated with 
biotinylated secondary antibody followed by streptavidin (VECTASTAIN Elite 
ABC kit).  The color was developed by exposing the peroxidase to 
diaminobenzidine reagent (Vector Laboratories), which forms a brown reaction 
product.  The sections were then counterstained with Gill's hematoxylin.  ErbB2, 
AP-2, YY-1 and p-MAPK expression were identified by the brown cytoplasmic 
staining.  H&E staining was determined as previously described [369,413,496]. 
2.3 Results 
TA inhibits proliferation of BT474 and SKBR3 cells - Figures 16A and 16B 
illustrate the effects of TA on proliferation of ErbB2-overexpressing BT474 and 
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SKBR3 breast cancer cell lines.  The lowest concentration of TA (25 M) had 
minimal effects, whereas 50 and 100 M TA inhibited growth of BT474 and 
SKBR3 cells and IC50 values were 41.5 and 52.5 M, respectively.  These 
results are similar to those previously reported in pancreatic cancer cells [413] 
and in ongoing studies in other cancer cell lines.  The effects of TA and other 
substituted biphenylamine-1-carboxylic acids on proliferation of BT474 and 
SKBT3 cell was also determined (Figs. 16C and 16D).  A comparison of the 
growth inhibitory effects of 50 M TA, and structurally-related mefanamic acid, 
flufenamic acid, N-flumic acid, and diclofenac indicated that mefanamic acid was 
the least active among these 5 structurally related analogs.  Differences among 
the other 4 substituted biphenyl-1-carboxylic acid NSAIDs were not large; 
however, TA was the most active compound in BT474 cells as previously 
observed for these compounds and was used as the prototype for the remaining 
studies.   
TA downregulates ErbB2 and ErbB2-dependent responses - The growth 
inhibitory activity of TA and related compounds in cancer cells has been 
correlated with downregulation of Sp1, Sp3 and Sp4 proteins [369,413,496]; 
however, results in Figures 17A and 17B show that up to 100 M TA did not 
appreciably affect Sp3 or Sp4 expression in BT474 or SKBR3 cells, and 75-100 
M TA decreased Sp1 protein only after treatment of BT474 cells for 72 hr. Sinc- 
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Figure 16. Effects of TA and related compounds on cell proliferation.  TA-mediated inhibition of BT474 (A) and 
SKBR3 (B) cell growth.  Cells were treated with different concentrations of TA for up to 6 days and the number of 
cells in each treatment group were determined as described in the Materials and Methods.  Significant (p < 0.05) 
inhibition of cell growth was observed for 50 and 100 M TA.  Inhibition of BT474 (C) and SKBR3 (D) cell 
proliferation by TA and related compounds.  Cells were treated with 50 M TA and related compounds as described 
above and significant (p < 0.05) growth inhibition is indicated (*).  Results are expressed as means  SE for at least 3 
replicate determinations for each treatment group. 
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Figure 17. Effects of TA on Sp, ErbB2 and ErbB2-dependent proteins.  Sp protein expression in BT474 (A) and 
SKBR3 (B) cells treated with TA.  Cells were treated with different concentrations of TA for up to 72 hr and whole 
cell lysates were analyzed by western blots as described in the Materials and Methods.  ErbB2 and ErbB2-dependent 
protein expression in BT474 (C) and SKBR3 (D) cells treated with TA.  Cells were treated as described in (A)/(B) and 
whole cell lysates were analyzed by western blots as described in the Materials and Methods.  Bar graphs compare 
protein expression (normalized to -actin) relative to DMSO (set at 1.0) and results are means  SE for 3 replicate 
determinations for each treatment group.  Significant (p < 0.05) decreases in protein expression are indicated (*). 
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e ErbB2 is a major driving force for the growth and survival of both cell lines, we 
also examined the effects of TA or ErbB2 protein expression (Figs. 17C and 
17D).  TA induced a time-and concentration-dependent decrease in ErbB2 
protein in BT474 cells and this was accompanied by decreased phosphorylation 
of MAPK and Akt but not their corresponding proteins.  Cyclin D1 and p27 are 
two proteins down- and upregulated by ErbB2-dependent kinases, respectively 
[494], and results in Figure 18A show that TA also decreased cyclin D1 and 
increased p27 expression in BT474 and SKBR3 cells.  Previous reports indicate 
that geldanamycin and ansamycins decrease ErbB2 protein through 
destabilizing interactions with chaperones resulting in enhanced proteasome-
dependent degradation of ErbB2 [270,497,498].  Initial studies with the 
proteasome inhibitor MG-132 gave conflictin results since MG132 alone 
decreased ErbB2 protein in BT474 and SKBR3 cells (data not shown).  Studies 
with lactacystin, another proteasome inhibitor showed that TA-induced 
downregulation of ErbB2 protein was not inhibited after cotreatment with 
lactacystin (Fig. 18B).  Treatment of BT474 and SKBR3 with 50 M TA for 2, 6 
and 12 hr resulted in a time-dependent decrease in ErbB2 mRNA levels (Fig. 
18C) and in cells transfected with pErbB2, a construct containing the -0.5 kB 
region from the ErbB2 promoter, TA also decreased luciferase activity in both 
cell lines (Fig. 18D).  The results demonstrate that TA acts, in part, by 
decreasing ErbB2 transcription in BT474 and SKBR3 cells.   
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Figure 18. TA decreases ErbB2-dependent genes and ErbB2 gene expression.  Effects of TA on cyclin D1/p27 (A) and 
ErbB2 (B) protein levels.  BT474 and SKBR3 cells were treated with TA alone or TA in combination with 2 M 
lactacystin for 48 or 72 hr as indicated, and whole cell lysates were analyzed by western blots as described in the 
Materials and Methods.  (C) TA decreases ErbB2 mRNA levels.  BT474 and SKBR3 cells were treated with DMSO 
or 50 M TA for different times and ErbB2 mRNA levels were determined by RT-PCR as described in the Materials 
and Methods.  Results are expressed as means  SE for three replicate determinations for each treatment group and 
significantly (p < 0.05) decreased mRNA levels are indicated.  (D) TA decreases luciferase activity.  Cells were 
transfected with pErbB2, treated with DMSO, or 50 M TA, and luciferase activity (relative to -gal) was determined 
as described in the Materials and Methods.  Results are expressed as means  SE for 3 replicate determinations for 
each treatment group and significant (p < 0.05) decreases in activity are indicated (*). 
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Mechanisms of ErbB2 downregulation by TA - The mechanisms of TA-
dependent inhibition of ErbB2 transcription were investigated in BT474 and 
SKBR3 cells treated with TA alone or in combination with the protein synthesis 
inhibitor cycloheximide (Fig. 19A).  Cycloheximide did not affect TA-dependent 
ErbB2 mRNA downregulation in either cell line, suggesting that TA does not 
induce an inhibitory protein that acts on erbB2 transcription.  However, in studies 
on erbB2 mRNA stability carried out in the presence or absence of the 
transcriptional inhibitor actinomycin D, TA significantly decreased erbB2 mRNA 
stability in BT474 cells over the 8 hr duration of this experiment (Fig. 19B).  In 
contrast, only minimal effects were observed in SKBR3 cells, demonstrating cell 
context-dependent effects of TA on erbB2 mRNA stability.  YY1 and AP-2 
cooperatively regulate ErbB2 expression in ErbB2 overexpressing cells [321], 
and Figure 19C summarizes the effects of TA on expression of these 
transcription factors in BT474 and SKBR3 cells.  TA decreased YY1 and AP-2 
protein levels in BT474 and SKBR3 cells and, in cells cotreated with TA plus the 
proteasome inhibitor lactacystin, levels of YY1 and AP-2 were similar to those 
observed after treatment with TA alone.  These results indicate that 
downregulation of these transcription factors was proteasome-independent. 
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Figure 19. Effects of TA on ErbB2 expression and transcriptional regulatory proteins.  Effects of cycloheximide (A) 
and actinomycin D (B) on ErbB2 mRNA levels and stability in cells treated with TA.  BT474 and SKBR3 cells were 
treated with 50 M TA alone or in combination with cycloheximide or actinomycin D and ErbB2 mRNA levels were 
determined at various time points as described in the Materials and Methods.  Results are expressed as means  SE for 
3 replicate determinations for each treatment group and significant (p < 0.05) decreases are indicated (*).  (C) Effects 
of TA on YY1/AP-2 protein levels.  BT474 and SKBR3 cells were treated with TA for the indicated times and whole 
cell lysates were analyzed by western blot analysis as indicated in the Materials and Methods.  (D)  AP-2 activates the 
ErbB2 promoter.  BT474 cells were transfected with empty vector (PGL3) or the pErbB2-luc construct, and one 
treatment group was cotransfected with AP-2 expression plasmid.  Luciferase activity was determined as described in 
the Materials and Methods.  Results are means  SE for 3 separate determinations and significant (p < 0.05) induction 
of luciferase activity by AP-2 is indicated (*).  Western blot analysis of lysates demonstrates that the AP-2 expression 
plasmid increases AP-2 protein. 
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 BT474 cells were transfected with PGL3 empty vector or the pErbB2-luc 
construct (Fig. 19D).  In cells cotransfected with an AP-2 expression plasmid, 
there was a significant induction of luciferase activity demonstrating that AP-2 
expression activates the ErbB2 promoter and demonstrates the importance of 
AP-2 for ErbB2 expression.We also investigated the effects of TA on subcellular 
localization of ErbB2 since many drugs that decrease ErbB2 protein induce 
ErbB2 delocalization from the plasma membrane into the cytoplasm [499-501].  
In solvent (DMSO)-treated SKBR3 cells, ErbB2 staining was primarily on the 
plasma membrane (Fig. 20), whereas the endosome marker, early endosome 
antigen 1 (EEA1), staining was on the endosome and did not colocalize with 
ErbB2.  After treatment with 50 M TA for 24 hr, the ErbB2 plasma membrane 
staining was observed and, in the merge of both ErbB2 and EEA1, it was 
evident that TA did not significantly induce internalization of erbB2 as reported 
for other agents  [499-501].  Similar results were observed in BT474 cells 
demonstrating that TA did not induce internalization and subsequent 
degradation of ErbB2 in the ErbB2 overexpressing breast cancer cell lines.   
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Figure 20. Immunostaining of ErbB2.  SKBR3 and BT474 cells were treated with 50 M TA for 24 hr and cells were 
fixed, immunostained with ErbB2 or EEA1 antibodies and analyzed by confocal microscope and softwares as 
described in the Materials and Methods. 
  
118 
 
 
1
1
8
 
TA inhibits tumor growth in athymic nude mice bearing BT474 xenografts 
- We also investigated the in vivo antitumorigenic activity of TA (20 mg/kg/d) 
which was administered orally by gavage to female athymic nude mice bearing 
BT474 cells injected into the mammary fat pad.  Tumor size was determined 
over the treatment period (Fig. 21A) and there was a significant decrease in 
mice treated with TA compared to those treated with the solvent alone.  In 
addition, TA also decreased mammary tumor weight compared to solvent 
treated animals (Fig. 21B).  H & E staining (Fig. 21C) shows that tumors from 
untreated mice consisted on nests of cells in a semi-organized fashion with 
nuclear molding and high nuclear to cytoplasmic ratio.  In addition, cells with 
marked atypical features such as anisocytosis, anisokaryosis, and multiple 
variably sized nucleoli were also noted.  Tumors from tolfenamic acid-treated 
mice consisted of neoplastic cells similar to that noted from the untreated mice.  
However, the nests of tumor cells were highly disorganized with multiple nuclear 
fragmentations and condensations; in addition, epithelial atypia was decreased.  
Treatment of mice with TA also decreased expression of ErbB2, phospho- 
MAPK, AP-2 and YY-1 in tumors compared to levels in tumors from mice treated 
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Figure 21. TA inhibits tumor (BT474 xenografts) growth.  Inhibition of tumor volume (A) and weight (B).  Athymic 
nude mice bearing BT474 cells as xenografts were treated with TA (25 mg/kg/d) and tumor volumes and weights were 
determined as described in the Materials and Methods.  Significantly (p < 0.05) decreased tumor weights are indicated 
(*).  (C) H&E staining and immunostaining.  Tumors from vehicle control (corn oil)- and TA-treated mice were fixed 
and stained (H&E) and immunostaining for ErbB2, phospho-MAPK, YY1 and AP-2 as described in the Materials and 
Methods.  (D) A schematic model summarizing the effects of TA on ErbB2 in BT474 and SKBR3 cells. 
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with corn oil (Fig. 21C).  Thus, results of both in vivo and in vitro data show that 
TA inhibits tumor and cancer cell growth through downregulating ErbB2 
expression, suggesting that this relatively non-toxic NSAID may represent a 
novel clinical approach for treatment of cancers that overexpress this oncogene. 
 As a control for this experiment, we also observed that TA significantly 
decrease growth of MDA-MB-231 and MCF7 breast cancer cells (Fig. 22A), and 
mefanamic acid decreased ErbB2 and phosphorylation of MAPK and Akt but at 
higher concentrations than required for TA (Fig. 22B).  Thus, TA specifically 
decreased expression of ErbB2 protein and ErbB2-dependent phosphorylation 
pathways in BT474 and SKBR3 cells.  We also observed some treatment-
related changes in MAPK and Akt proteins (Fig. 22C) in BT474 cells and this 
was particularly evident for MAPK (but not Akt) after treatment for 72 hr.  
Previous studies show that the transcription factor PEA3 suppresses ErbB2 
expression [316,502]. Therefore, we investigated the effects of TA on PEA3 
expression in BT474 and SKBR3 cells (Fig. 22D) and did not observe any 
changes in expression of this transcription factor.   
 
  
121 
 
 
1
2
1
 
 
 
Figure 22. Supplemental figure for chapter 2. A.  The dose- and time-dependent effects of TA on proliferation of 
MDA-MB-231 and MCF-7 cells. B.  The effects of 50 M mefanamic acid on proliferation of BT474 cells and the 
effects of higher concentrations on ErbB2 protein and phosphorylation of Akt and MAPK. C.  Quantitation of specific 
bands in Figure 17C. D.  Effects of TA on PEA3 protein expression in BT474 and SKBR3 cells. 
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2.4 Discussion 
The development of Herceptin as a biotherapy for ErbB2-overexpressing 
breast cancer patients has been an important innovation for treating this subset 
of individuals [490-493].  Moreover, combination therapy of Herceptin plus other 
drugs including paclitaxel are also being used as adjuvant therapy for breast 
cancer.  Herceptin is not without side effects, and cardiotoxicity has been 
reported in a small number of patients [493].  Based on the success of targeting 
ErbB2 for cancer chemotherapy, other chemotherapeutic agents have been 
developed for blocking activity of this receptor, and these include both selective 
and non-selective tyrosine kinase inhibitors, geldanamycin and compounds that 
interfere with chaperones such as heat shock protein 90, fatty acid synthase 
(FAS) inhibitors, and orlistat, a drug used in weight loss [220,270,492-494,497-
501,503-508].  These compounds all block activation of ErbB2 and ErbB2-
dependent downstream responses, although their overall mechanisms of action 
are highly variable.  TA is a relatively non-toxic NSAID used for treatment of 
migraine headaches in humans, and TA has multiple applications in veterinary 
medicine.  Development of this drug for cancer chemotherapy is promising due 
to the relatively low toxicity of TA and related compounds.  Previous studies in 
this laboratory reported that the anticancer activity of TA in pancreatic cancer 
cell lines is associated with their repression of Sp proteins and Sp-dependent 
genes [369,413,496], and we hypothesized that TA may be effective in treatment 
of ErbB2-positive breast cancer through a comparable mechanism. 
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 Sp proteins are overexpressed in ER-positive and ER-negative breast 
cancer cell lines including SKBR3 and BT474 cells [478], and Figure 16 shows 
that TA inhibits growth of both cell lines with potencies similar to that observed 
for this compound in pancreatic cancer cells [369,413,496].  However, treatment 
of SKBR3 and BT474 cells with TA did not appreciably affect Sp1, Sp3 and Sp4 
protein levels, although we did observe a consistent 20-30% decrease in Sp1 in 
BT474 cells treated with 75-100 M TA for 3 days.  These results contrast to 
ongoing studies in pancreatic and other cancer cell lines where TA decreases 
Sp1, Sp3 and Sp4 proteins (data not shown).  However, further analysis of 
protein expression in BT474 or SKBR3 cells treated with TA showed that ErbB2 
protein expression was decreased (Fig. 17) and these results are consistent with 
the growth inhibitory effects of TA in cells, where their growth and survival are 
ErbB2-dependent.  Herceptin and other classes of drugs that block phospho-
ErbB2 formation/activation or degrade ErbB2 exhibit similar effects on ErbB2-
dependent downstream responses including decreased phosphorylation of Akt 
and MAPK, downregulation of cyclin D1 and induction of p27 [220,494,499-
501,503-508].  Figures 17C, 17D and 18A illustrate that TA also exhibits an 
identical pattern of responses in BT474 and SKBR3 cells which is consistent 
with TA-dependent downregulation of ErbB2 protein. 
 We also compared the effects of TA with other agents that block ErbB2 
signaling.  Tyrosine kinase inhibitors such as ZD1839 may or may not affect 
ErbB2 expression but, in the short term, their effects are primarily on decreased 
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ErbB2 phosphorylation [220,494,503-505].  In contrast, ansamycins, proteasome 
inhibitors such as bortezomib, and FAS synthase inhibitors all decrease ErbB2 
protein expression in BT474 and/or SKBR3 cells [270,497-501,506-508], and 
similar responses were observed for TA (Figs. 17C and 17D).  However, in 
contrast to FAS inhibitors [508], TA did not induce PEA3 which inhibits ErbB2 
expression at the transcriptional level (Fig. 19C).  Ansamycins such as 
geldanamycin induce proteasome dependent degradation of ErbB2 [270,497-
499], whereas TA-induced repression of ErbB2 protein was proteasome-
independent (Fig. 18A).  Interestingly, geldanamycin, the proteasome inhibitor 
bortezomib (Valcade), and the reversible tyrosine kinase inhibitor CI-1033 
decrease ErbB2 expression and this is associated, in part, with intracellular 
localization of ErbB2 from the cell membrane and this process is related to the 
subsequent decrease in ErbB2 protein [499,500].  In contrast, treatment with TA 
did not induce translocation of cell membrane ErbB2 into the cell (Fig. 20), 
indicating that the mechanism of TA-dependent downregulation of ErbB2 is 
different from these classes of drugs. 
 TA clearly affected ErbB2 transcription and decreased ErbB2 mRNA 
levels (Fig. 18C) and promoter activity in BT474 and SKBR3 cells transfected 
with the pErbB2 constructs that contained a -0.5 kB promoter insert (Fig. 18D).  
The protein synthesis inhibitor cycloheximide did not affect TA-induced 
repression of ErbB2 mRNA levels (Fig. 19A), suggesting that an induced 
"inhibitory" protein was not involved.  These results were consistent with the 
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failure of TA to induce PEA3 (Fig. 22D) which inhibits ErbB2 expression 
[316,502] and plays a role in the reported downregulation of ErbB2 gene 
expression by inhibitors of FAS cells [506-508].  A previous study showed that 
YY1 and AP-2 transcription factors cooperatively regulate ErbB2 expression in 
BT474 and other cancer cell lines [321].  Figure 19C illustrates that TA 
decreased expression of YY1 and AP-2 transcription factors in both BT474 and 
SKBR 3 cells after treatment for 48 hr, and this response was not reversed by 
the proteasome inhibitor lactacystin.  The role of AP-2 in basal expression of 
ErbB2 in BT474 cells is illustrated in Figure 19D showing that overexpression of 
AP-2 activates the ErbB2 promoter.  Thus, TA-induced downregulation of ErbB2 
protein and mRNA levels was due to the effects of this compound on AP-2 and 
YY1 expression in both cell lines, and decreased ErbB2 mRNA stability (Fig. 
19B) also contributed to these effects in BT474 cells.  It is also possible that TA 
affects expression of other factors in BT474 and SKBR3 cells that decrease 
ErbB2 transcription and these are currently being investigated. 
 The effects of TA on SKBR3 and BT474 cell growth and on ErbB2 in vitro 
were also observed in athymic nude mice injected with BT474 cells into 
mammary fat pads (Fig. 21).  TA decreased tumor growth and weight and 
downregulated ErbB2 protein and ErbB2-dependent responses (phospho-
MAPK).  TA also decreased immunostaining of both AP-2 and YY-1 in TA-
treated tumors (compared to corn oil-treated) and these in vivo results 
complemented the cell culture studies.  Thus, the anticarcinogenic activity of TA 
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is associated with downregulation of Sp transcription factors in some cell lines 
[369,413,496] and repression of the oncogene ErbB2 in breast cancer cell lines 
overexpressing this oncogene.  The mechanisms of action of TA are, in part, cell 
context-dependent since this NSAID decreases ErbB2 mRNA stability in BT474 
and not SKBR3 cells and this may involve differential effects on factors that 
control mRNA stability (Fig. 21D).  However, the critical TA-dependent effects in 
both cell lines involves downregulation of YY1 and AP-2 (which regulate ErbB2 
expression), whereas proteasome-dependent degradation of ErbB2, induction of 
a repressor such as PEA3 or enhanced ErbB2 endocytosis are not involved in 
downregulation of ErbB2 by TA (Fig. 21D).  The mechanisms of TA-induced 
repression of YY-1 and AP-2 and the potential clinical applications for TA in 
treatment of ErbB2 overexpressing cancers are currently being investigated. 
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3. BETULINIC ACID INHIBITS ErbB2-OVEREXPRESSING BREAST 
CANCER CELL AND TUMOR GROWTH BY ACTIVATION OF 
CANNABINOID RECEPTOR-DEPENDENT REPRESSION OF Sp 
TRANSCRIPTION FACTORS 
 
3.1 Introduction 
Naturally-occurring triterpenoids and triterpenoid-derived compounds 
have been widely used in traditional medicines and for treatment of various 
diseases [509-511]. Activities of these compounds are structure-dependent, 
however many triterpenoids and their synthetic derivatives are potent anti-
inflammatory agents and exhibit anticancer activities against several tumor 
types. For example, 2-cyano-1,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and 
related compounds are synthesized from oleanolic acid, a triterpenoid found in 
various plants and herbs, and are potent anti-inflammatory drugs and anticancer 
agents [510,512]. Betulinic acid (BA) is a component of bark extracts and is 
readily synthesized from betulin which can constitute up to 30% by weight of 
birch bark [444,513]. BA and several derivatives exhibit a broad spectrum of 
pharmacological properties including antiviral, antibacterial, anti-inflammatory, 
antimalarial and anticancer activities [444,513]. 
 BA is relatively non-toxic in rodent studies and highly effective against 
melanoma in both in vivo and in vitro assays [460]. Subsequent research in 
several laboratories indicates that BA inhibits growth of multiple tumor types 
128 
 
 
1
2
8
 
including breast cancer [444,513]. Studies in this laboratory show that BA 
inhibits prostate cancer cell and tumor growth in a xenograft model and one of 
the underlying mechanisms of action is due to BA-induced proteasome-
dependent degradation of specificity protein (Sp) transcription factors Sp1, Sp3 
and Sp4 [448]. These proteins are highly expressed in several different cancer 
cell lines and tumors [413,448,475,478,514,515] whereas Sp1 levels in non-
tumor tissue of rodents and humans is relatively low and decreases with age 
[516,517]. Results of RNA interference studies have identified several Sp-
regulated genes and these include vascular endothelial growth factor (VEGF) 
and its receptors (VEGFR1 and VEGR2), epidermal growth factor receptor 
(EGFR, HER1), p65 unit of NFkB, survivin and hepatocyte growth factor 
receptor (c-MET) [369,475-477,496,515,518] and these genes are themselves 
individual targets for new mechanism-based drugs. Ongoing studies have 
identified several other anticancer agents that downregulate Sp transcription 
factors in cancer cells and these include the non-steroidal anti-inflammatory drug 
(NSAID) tolfenamic acid, arsenic trioxide, curcumin, the methyl ester of CDDO 
(CDDO-Me) [519] and a structurally-related compound synthesized from 
glycyrrhetinic acid, methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate 
(CDODA-Me) [369,407,413,475-478,496,514,515,518-520]. The mechanisms of 
action of these anticancer drugs involve both proteasome-dependent and 
independent pathways which depend on the specific agent and cell context. 
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 In this study we have used BA as a model to investigate the effect of Sp1, 
Sp3 and Sp4 downregulation on BT474 and MDA-MD-453 breast cancer cells 
that express the oncogene EGFR2 (ErbB2, HER2). BA inhibited cell and tumor 
growth in a xenograft model (BT474 cells) and BA also decreased expression of 
Sp1, Sp3, Sp4, ErbB2 and ErbB2-regulated kinases. Unlike EGFR, ErbB2 is not 
directly regulated by Sp transcription factors however BA-mediated repression of 
ErbB2 was due to downregulation of YY-1, an Sp-regulated gene that activates 
ErbB2 expression. In addition, we show for the first time that BA-mediated 
downregulation of Sp transcription factors and ErbB2 is dependent on activation 
of the cannabinoid receptor (upstream), downregulation of miR-27a and 
induction of ZBTB10, an Sp repressor which has previously been identified as 
an inhibitor of Sp1, Sp3, Sp4 and Sp regulated gene expression 
[478,514,519,521]. 
3.2 Materials and methods 
Chemicals, antibodies, plasmids, and reagents - Betulinic acid, lactacystin 
were purchased from Sigma-Aldrich (St. Louis, MO). AM 251, AM 630, 
capsazepine and WIN-55,212-2 were purchased from Tocris Bioscience 
(Ellisville, MO). Antibodies against ErbB2 (C-18), p-ErbB2 (Try 1248)-R, Sp1 
(PEP2), Sp3 (D-20), Sp4 (V-20), Akt (H-136), p-Akt (Ser473), MAPK(C-14), p-
MAPK (E-4), β-actin (C4), AP-2 (C-18 and 3B5), YY1 (H-10), CB1 (H-150) and 
CB2 (H-60) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
Antibodies against cleaved-PARP (D214) and survivin were purchased from Cell 
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Signaling Technology (Danvers, MA). The YY1 promoter plasminds (YY-1 p-
1729 Luc and YY-1 p-277 Luc) was kindly provided by Dr. Ed Seto (University of 
South Florida, Tampa, FL). The ZBTB10 expression vector and empty vector 
(pCMV6-XL4) were purchased from Origene (Rockville, MD). The wild-type (wt) 
or mutated (mt) miR-27a target sequence from the 3’-UTR of ZBTB10 was 
cloned into NotI and XhoI sites of psiCHECK2 dual luciferase reporter construct 
(Promega, Madison, WI) as described [522]. Reporter lysis buffer, luciferase 
reagent and Dual-Luciferase Reporter Assay Kit for luciferase studies were 
purchased from Promega (Madison, WI).  -Galactosidase (-gal) reagent was 
obtained from Tropix (Bedford, MA).  LipofectAMINE 2000 was supplied by 
Invitrogen (Carlsbad, CA).  Western lightning chemiluminescence reagent was 
from Perkin-Elmer Life Sciences (Boston, MA). 
Cell lines - Human mammary carcinoma cell lines BT474 and MDA-MB-
453 were obtained from the American Type Culture Collection (Manassas, VA).  
Cell lines were cultured with 10% fetal bovine serum (FBS) in DMEM and were 
maintained at 37C in the presence of 5% CO2. 
 Cell proliferation assay - Cells (2-3 x 104 per well) were plated in 12-well 
plates and allowed to attach for 24 hr. Then cells were treated with either vehicle 
(DMSO) or different concentrations of betulinic acid for up to 4 days.  Fresh 
medium and compounds were added every 48 hr, and cells were then 
trypsinized and counted at the indicated time points using a Coulter Z1 cell 
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counter.  Each experiment was done in triplicate, and results are expressed as 
means  SE for each set of experiments. 
 Western blotting - Cells were rinsed with PBS and collected by scraping 
cells from the culture plate in 200 L of lysis buffer.  The cell lysates were 
incubated on ice for 1 hour with intermittent vortex mixing and then centrifuged 
at 40,000 g for 10 min at 4C.  Equal amounts of protein were separated on 
SDS-polyacrylamide gels.  Proteins were transferred to Immobilon P 
membranes (Millipore, Bedford, MA) using a Bio-Rad Trans-blot apparatus and 
transfer buffer (48 mM Tris, 39 mM glycine, 0.0375% SDS, 20% methanol).  
After blocking in TBST-Blotto [10 mmol/L Tris-HCl, 150 mmol/L NaCl (pH 8), 
0.05% Triton X-100, 5% nonfat dry milk] for 30 min, the membranes were 
incubated with primary antibodies overnight at 4C and then with horseradish 
peroxidase-conjugated secondary antibody for 2 hr at room temperature.  
Proteins were visualized using the chemiluminescence substrate (Perkin-Elmer 
Life Sciences) for 1 min and exposed to Kodak X-OMAT AR autoradiography 
film (Eastman Kodak, Rochester, NY).  For protein quantitation, band intensities 
were normalized to -actin (loading control) and compared to band intensities for 
the DMSO (control) set at 1.0 or 100%. 
TUNEL assay - Cells were plated in Lab-Tek II Chamber Slide System 
(Nalge Nunc International, Naperville, IL) and allowed to attach for 24 hr.  Cells 
were then treated with either vehicle (DMSO) or different concentrations of BA 
for 24 hr, TUNEL staining was performed using the DeadEnd™ Fluorometric 
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TUNEL System (Promega, Madison, WI) following manufacture’s protocol. The 
slides were analyzed using a Nikon ECLIPSE 80i confocal microscope (Japan). 
Real-time PCR analysis of mRNAs and miRNAs - Total mRNA was 
isolated using the RNeasy Protect Mini kit (Qiagen) according to the 
manufacturer’s protocol. RNA was reverse transcribed using Transcription 
System (Promega, Madison, WI) according to the manufacturer’s protocol. Each 
PCR was carried out in triplicate in a 30 L volume using SYBR Green 
Mastermix (Applied Biosystems, Foster City, CA) for 15 min at 95C for initial 
denaturing, followed by 40 cycles of 95C for 30 s and 60C for 1 min in the 
Applied Biosystems 7900HT Fast Real-time PCR System.  The ABI Dissociation 
Curves software was used following a brief thermal protocol (95C for 15 s and 
60C for 15 s, followed by a slow ramp to 95C) to control for multiple species in 
each PCR amplification.  Values for each gene were normalized to expression 
levels of TATA-binding protein (TBP). Total miRNA was extracted using the 
mirvana miRNA isolation kit (Ambion). Quantification of miRNA (RNU6B, 
miRNA-27a) was done using the Taqman miRNA kit (Applied Biosystems) 
according to the manufacturer’s protocol with real-time PCR. U6 small nuclear 
RNA was used as a control to determine relative miRNA expression. Primers for 
Sp3 and Sp4 were purchased from Qiagen. Other primers were obtained from 
Integrated DNA Technologies: 
Sp1 (F):  5'-TCA CCT GCG GGC ACA CTT-3'. 
Sp1 (R):  5'- CCG AAC GTG TGA AGC GTT -3'. 
133 
 
 
1
3
3
 
ZBTB10 (F):  5’-GCT GGA TAG TAG TTA TGT TGC-3’ 
ZBTB10 (R):  5’-CTG AGT GGT TTG ATG GAC AGA-3’ 
TBP (F):  5'-TGC ACA GGA GCC AAG AGT GAA-3'.  
TBP (R):  5'-CAC ATC ACA GCT CCC CAC CA-3'. 
 DNA and siRNA transfection - Cells were plated in 12-well plates at 1 x 
105 per well and cultured as described above.  After growth for 16 to 20 hr, 
transfections were carried out using Lipofectamin 2000 (Invitrogen) according to 
the manufacturer's protocol.  Transfection reagent was not removed from the 
cells and siRNA transfected cells were incubated for 72 hr; DNA or antisense 
RNA transfected cells were incubated for 48 hr at 37°C before experimentation. 
The negative control siRNA was purchased from Ambion (Austin, TX). siRNAs 
for Sp1 (Sp1-1: SASI_Hs02_00363664; Sp1-2: SASI_Hs01_00070994), Sp3 (5’-
GCG GCA GGU GGA GCC UUC ACU TT-3'), Sp4 (5’-GCA GUG ACA CAU UAG 
UGA GCT T-3')  and YY1 (YY1-1: SASI_Hs01_00155071, YY1-2: SASI_Hs01_--
155072) were purchased from Sigma-Aldrich (St. Louis, MO). iLamin (5’-CUG 
GAC UUC CAG AAG AAC ATT-3’), miR-27a mimic and as-miR-27a were 
purchased from Dharmacon RNA Technologies (Lafayette, CO). 100nM siRNAs 
were used in this study. 
Luciferase assay - Transfected cells were lysed with 100 L of 1x reporter 
lysis buffer, and 30 L of cell extract were used for luciferase and -gal assays.  
Lumicount was used to quantitate luciferase and -gal activities, and the 
luciferase activities were normalized to -gal activity. 
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Animals and xenograft study - Female ovariectomized athymic nu/nu 
mice (5-7 wk old) were purchased from the Harlan Laboratories (Indianapolis, 
IN).  The mice were housed and maintained under specific pathogen-free 
conditions in facilities approved by the American Association for Accreditation of 
Laboratory Animal Care and in accordance with current regulations and 
standards of the United States Department of Agriculture, United States 
Department of Health and Human Services, and the NIH.  Under anesthetic 
condition, BT474 cells (1x106) were implanted with matrigel (BD Biosciences, 
San Jose, CA) s.c. into the flank of each mouse.  Ten days later, mice were 
randomized into two groups of 6 mice per group and dosed by oral gavage with 
corn oil or 20 mg/kg/d of betulinic acid every other day for 28 days (14 doses).  
The mice were weighed, and tumor size was measured at the indicated time 
with calipers.  Final body and tumor weights were determined at the end of the 
dosing regimen, and tumor blocks were obtained for histopathologic analysis. 
 Immunohistochemistry - Tissue sections (4-5 M thick) mounted on poly-
L-lysine-coated slide were deparaffinized by standard methods.  Endogenous 
peroxidase was blocked by the use of 2% hydrogen peroxide in PBS for 1 min.  
Antigen retrieval for ErbB2 and Sp1 staining was done for 10 min in 10 mmol/L 
sodium citrate buffer (pH 6) heated at 95C in a steamer followed by cooling at 
room temperature for 15 min.  The slides were washed with PBS and incubated 
for 30 min at room temperature with a protein blocking solution (VECTASTAIN 
Elite ABC kit, Vector Laboratories, Burlingame, CA).  Excess blocking solution 
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was drained, and the samples were incubated overnight at 4C with one of the 
following:  a 1:60 dilution of ErbB2 antibody or a 1:100 dilution of Sp1 antibody. 
Sections were then incubated with biotinylated secondary antibody followed by 
streptavidin (VECTASTAIN Elite ABC kit).  The color was developed by exposing 
the peroxidase to diaminobenzidine reagent (Vector Laboratories), which forms 
a brown reaction product.  The sections were then counterstained with Gill's 
hematoxylin.  ErbB2 and Sp1 expression were identified by the brown staining. 
 Competitive receptor binding - Membrane proteins (100 or 25 g) 
prepared from mouse brain or CHO-hCB2 cells were used in each binding 
assay, respectively.  Increasing concentrations of the non-radioactive test 
ligands were incubated with 0.2 nM of the non-selective CB1/CB2 agonist [3H] 
CP-55,940 for 90 min at room temperature, and reactions were terminated by 
rapid vacuum filtration through Whatman GF/B glass fiber filters followed by 
three washes with ice-cold binding buffer as described previously [523]. Analysis 
of the binding data was performed using the non-linear regression (Curve Fit) 
function of GraphPad Prism v4.0b to determine the concentration of the drug 
that displaced 50% of [3H]CP-55,940 (IC50), and measure of affinity (Ki) was 
derived from the IC50 values utilizing the Cheng-Prushoff equation [524]. 
3.3 Results 
BA inhibits growth, induces apoptosis and downregulates Sp1, Sp3 and 
Sp4 in BT474 and MDA-MB-453 cells - BT474 and MDA-MB-453 cells 
overexpress ErbB2 and these cell lines are widely used as models for 
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understanding the molecular mechanisms associated with drugs that target 
cancer cells expressing high levels of ErbB2. BA inhibited proliferation of both 
BT474 and MDA-MB-453 cells and the overall decrease in cell number was both 
concentration-(1, 5 and 10 µM) and time-(2 or 4 days) dependent and MDA-MB-
453 cells were less responsive to BA than BT474 cells (Figs. 23A and 23B). The 
growth inhibitory effects of BA were also accompanied by induction of cleaved 
PARP, a marker of apoptosis and decreased expression of survivin an inhibitor 
of apoptosis was also observed (Fig. 23C). Induction of apoptosis by BA in 
BT474 and MDA-MB-453 was also confirmed in a TUNEL assay in which BA 
increased TUNEL staining in both cell lines (Fig. 23D). 
 The growth inhibitory effects of BA in LNCaP prostate cancer cells have 
been linked, in part, to activation of proteasome-dependent degradation of Sp1, 
Sp3 and Sp4 proteins [448] and results illustrated in Figures 24A and 24B show 
that after treatment of BT474 and MDA-MB-453 cells with 10 µM BA for 48 hr. 
there was a decrease in expression of Sp1, Sp3, Sp4 and survivin (an Sp-
regulated gene) proteins in both cell lines. The proteasome inhibitor MG132 
alone was cytotoxic to BT474 and MDA-MB-453 cells and MG132 alone 
decreased Sp proteins whereas lactacystin was not toxic and did not affect Sp 
protein expression (data not shown). Treatment of BT474 or MDA-MB-453 cells 
with 10 µM BA plus 1 µM lactacystin for 48 hr. resulted in decreased expression  
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Figure 23. Effects of BA on cell proliferation and apoptosis. BA-mediated inhibition of BT474 (A) and MDA-MB-
453 (B) cell growth. Cells were treated with different concentrations of BA for up to 4 days and the number of cells in 
each treatment group was determined as described in the Materials and Methods. Significant (p < 0.05) growth 
inhibition is indicated (*). Results are expressed as means  SE for at least 3 replicate determinations for each 
treatment group. C. Effects of BA on cleaved-PARP and survivin. Cells were treated with 10 M BA for 48 hr and 
whole cell lysates were analyzed by western blots as described in the Materials and Methods. D. BA induces apoptosis 
in cancer cells. Cells were treated with DMSO or 10 M BA for 24 hr and analyzed with a TUNEL assay as described 
in the Materials and Methods.  
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of Sp1, Sp3 Sp4 and survivin proteins that was not blocked after cotreatment 
with lactacystin suggesting that BA-mediated downregulation of Sp proteins was 
proteasome-independent. Therefore the effects of 10 µM BA on Sp1, Sp3 and 
Sp4 mRNA levels were investigated and after treatment of BT474 and MDA-MB-
453 for 16 hr there was a significant decrease in Sp1, Sp3 and Sp4 mRNA 
levels (Fig. 24B), suggesting that the mechanism of action of BA involved 
transcriptional repression. 
BA downregulates ErbB2 and ErbB2-regulated genes - Since ErbB2 
plays a major role in the proliferation of BT474 and MDA-MB-453 cells the 
effects of BA alone and in combination with lactacystin on ErbB2, MAPK, Akt 
and their phosphorylated analogs were investigated. BA alone decreased 
ErbB2, p-ErbB2, and downstream kinases MAPK, p-MAPK, Akt and p-Akt 
expression (Fig. 24C) and these effects were not reversed after co-incubation 
with the proteasome inhibitor lactacystin. We also investigated the effects of BA 
alone and BA-plus lactacystin on expression of YY-1 which is a key upstream 
regulator of ErbB2 in breast cancer cells overexpressing this oncogene [321]. 
The results showed that BA decreased expression of YY1 in both cell lines in the 
presence or absence of lactacystin (Fig. 24C). The linkage between Sp 
transcription factors and ErbB2 could be due to regulation of YY1 by Sp 
transcription since the YY1 promoter contains multiple GC-rich Sp binding sites 
[525]. We also investigated the effects of BA on YY1 promoter activity. In MDA-
MB-453  cells  transfected  with YY1 p-277  Luc  or p-1729  Luc,  two   luciferase 
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Figure 24. Effects of BA on Sp1, Sp3, Sp4, ErbB2 and ErbB2 dependent proteins. BA decreases Sp protein and 
survivin levels in BT474 and MDA-MB-453 cells (A). Cells were treated with 10 M BA alone or in combination 
with 1 M lactacystin for 48 hr, and whole cell lysates were analyzed by western blots as described in the Materials 
and Methods. B. BA decreases mRNA levels of Sp proteins. Cells were treated with 10 M BA for 16 hr, and mRNA 
levels were determined as described in the Materials and Methods. Results are expressed as means  SE for 3 replicate 
determinations for each treatment group and significant (p < 0.05) decreases are indicated (*). C. BA decreases protein 
levels of ErbB2 and ErbB2 dependent proteins. Cells were treated with 10 M BA alone or in combination with 1 M 
lactacystin for 48 hr, and whole cell lysates were analyzed by western blots as described in the Materials and Methods. 
D. BA decreases YY1 promoter activity. MDA-MB-453 cells were transfected with empty vector (PGL2), the YY1 p-
277-luc or the YY1 p-1729-Luc construct, cells were then treated with 5 or 10 M BA for 24 hr. Luciferase activity 
was determined as described in the Materials and Methods.  Results are means  SE for 3 separate determinations and 
significant (p < 0.05) induction of luciferase activity by AP-2 is indicated (*).  
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reporter constructs containing the -277bp and -1729bp region from the YY1 
promoter, treatment with BA for 24 hr resulted in a dose-dependent decrease in 
luciferase activity (Fig. 24D). RNA interference was used to investigate the 
potential role of Sp proteins in mediating basal expression of YY1 in BT474 and 
MDA-MB-453 cells. Figures 25A and 25B illustrate the effect of siRNAs against 
Sp1 (iSp1), Sp3 (iSp3), Sp4 (iSp4) and their combination (iSp1/3/4) on 
expression of Sp proteins, YY1 and ErbB2. Transfection of BT474 cells with two 
siRNAs for Sp1, iSp3, iSp4 and iSp1/3/4 resulted in specific knockdown of the 
target Sp proteins and Sp1, iSp3, iSp4 and iSp1/3/4 and also decreased 
expression of YY1 and ErbB2 proteins. In a second set of experiments the 
oligonucleotides were also transfected in MDA-MB-453 cells (Fig. 25B). The 
siRNAs for Sp1 and Sp4 proteins were highly specific however iSp3 decreased 
expression Sp3 and Sp4 proteins; iSp1, iSp4 and iSp1/3/4 decreased levels of 
both YY1 and ErbB2 whereas Sp3 knockdown had minimal effects on either 
YY1 or ErbB2 proteins. Previous RNA interference studies showed that 
knockdown of YY1 also decreased expression of ErbB2 and in this study we 
also observed that YY1 knockdown decreased ErbB2 in both cell lines (Fig. 
25C). 
Role of cannabinoid receptors - BA-induced downregulation of Sp 
transcription factors was proteasome-independent (Fig. 24) and these effects 
were also not reversed by ROS inhibitors (data not shown) as previously 
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Figure 25. Role of Sp proteins in regulating level of YY1 protein. Knock down of Sp1, Sp3, Sp4 or Sp1 / Sp3 / Sp4 in 
combination decreases protein levels of YY1 and ErbB2 in BT474 (A) and MDA-MB-453 (B) cells. Cells were 
transfected with siRNAs for Sp1, Sp3, Sp4 or Sp1 / Sp3 / Sp4 in combination for 72 hr, and whole cell lysates were 
analyzed by western blots as described in the Materials and Methods. C. Knock down of YY1 decreases protein levels 
of ErbB2 in BT474 and MDA-MB-453 cells. Cells were transfected with siRNA for YY1 for 72 hr, and whole cell 
lysates were analyzed by western blots as described in the Materials and Methods.  
  
142 
 
 
1
4
2
 
reported for CDDO-Me [519]. Since preliminary studies in other cancer cell lines 
show that cannabinoids (CBs) decrease Sp proteins (data not shown), the 
effects of CB1 and CB2 receptor antagonists AM251 and AM630 respectively 
and capsazepine (vanilloid receptor antagonists) on BA-mediated repression of 
Sp1, Sp3 and Sp4 and survivin were also determined in BT474 and MDA-MB-
453 cells (Figs. 26A and 26B). In BT474 and MDA-MB-453 cells cotreatment of 
BA with either AM251 or AM630 attenuated the effects of BA downregulation of 
Sp1, Sp3 and Sp4 whereas capsazepine inhibited the effects of BA only in MDA-
MB-453 cells. The effects of AM251, AM630 and capsazepine on BA-mediated 
downregulation of ErbB2 and ErbB2-regulated kinases were also determined in 
BT474 (Fig. 26C) and MDA-MB-453 (Fig. 26D) cells. In BT474 cells, the CB1 
and CB2 receptor antagonists inhibited BA-mediated downregulation of ErbB2, 
P-ErbB2, p-MAPK, p-Akt and YY1; similar results were observed in MDA-MB-
453 cells confirming a role for the cannabinoid receptors in mediating the effects 
of BA on Sp and Sp-regulated genes. Treatment of these cells with AM251 or 
AM630 alone does not affect levels of these proteins (Fig. 26B). Moreover, in 
MDA-MB-453 cells capsazepine was also active as an inhibitor. Both the CB1 
and CB2 receptors are expressed in BT474 and MDA-MB-453 cells (Fig. 26D) 
however, competitive binding of BA to the CB1 and CB2 receptors using the 
non-selective radioligand [3H] CP-55, 940 showed that BA at concentrations up 
to 10 µM did not displace the radioligand. Enhanced binding of [3H] CP-55,940 
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Figure 26. Role of cannabinoid receptors on effects of BA. Effects of AM251, AM630 and capsazepine on BA-
mediated repression of Sps and survivin proteins in BT474 (A) and MDA-MB-453 (B) cells. Effects of AM251, 
AM630 and capsazepine on BA-mediated downregulation of ErbB2 and ErbB2-regulated kinases in BT474 (C) and 
MDA-MB-453 (D) cells and expression of CB receptors (D). Cells were pretreated with or without 6 M AM251, 6 
M AM630 or 2 M capsazepine for 1 hour, and then DMSO or 10 M BA were added to the medium for 48 hr, and 
whole cell lysates were analyzed by western blots as described in the Materials and Methods.  
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to both receptors was observed after coincubation with 100 µM BA and since 
similar effects were observed for both CB receptors, this may be due to non-
specific interactions (Fig. 27A). As a positive control the synthetic cannabinoid 
WIN-55,212-2 displaced the radioligand from both the CB1 and CB2 receptors 
(Fig. 27B). Since potential BA-mediated inhibition of fatty acid amide hydrolase 
(FAAH) would increase production of endocannabinoids to produce a CB1/CB2-
dependent downregulation of Sp transcription factors,  we investigated the 
effects of FAAH knockdown by RNA interference on expression of Sp proteins 
and ErbB2 (Fig 27C). The results show that FAAH knockdown does not affect 
expression of Sp1 or ErbB2, suggesting that the effects of BA are not due to 
elevated levels of endocannabinoids acting at CB1 or CB2 receptors resulting 
from direct inhibition of FAAH. 
 Previous studies showed that drug-induced repression of Sp1, Sp3 and 
Sp4 mRNA levels was due to downregulation of miR-27a and induction of 
ZBTB10, a transcriptional repressor of Sp1, Sp3 and Sp4 gene expression 
[478,514,519]. Treatment of BT474 and MDA-MB-453 cells with 5 or 10 µM BA 
resulted in significant downregulation of miR-27a in both cell lines and 
cotreatment with AM251 or AM630 inhibited this response (Fig. 28A) which was 
most pronounced in BT474 cells. Downregulation of miR-27a in cells treated 
with BA was accompanied by induction of ZBTB10 mRNA levels in both cell 
lines and cotreatment with AM251 or AM630 inhibited the induction response 
(Fig. 28B). A > 6-fold induction of ZBTB10 was observed in BT474 cells whereas   
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Figure 27. Supplemental figure for chapter 3. Competitive binding of BA (A) and WIN-55,212-2 (B) to the CB1 and 
CB2 receptors. C. Effects of FAAH knockdown by RNA interference and the FAAH inhibitor CAY10401 on 
expression of Sp proteins and ErbB2. Cells were transfected with FAAH siRNA or treated with CAY10401 for 48 hr 
and western blots were performed as described in Materials and Methods. 
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Figure 28. Effects of BA on miR-27a and ZBTB10, and the role of cannabinoid receptors on BA-mediated effects. 
Downregulation of miR-27a (A) and induction of ZBTB10 (B) mRNA levels with BA treatment in BT474 and MDA-
MB-453 cells. Cells were pretreated with or without 6 M AM251 or 6 M AM630 for 1 hour, and then DMSO 5 M 
or 10 M BA were added to the medium for 24 hr. Total RNA was extracted and miR-27a and ZBTB10 RNA levels 
were determined as described in the Materials and Methods.  Results are expressed as means  SE for 3 replicate 
determinations for each treatment group and significant (p < 0.05) decreases or inductions are indicated (*). C. Effects 
of ZBTB10 overexpression and antisense miR-27a on Sp protein levels, YY1 and ErbB2 proteins. Cells were 
transfected with 1 g / ml pCMV6-XL4-ZBTB10 plasmid or empty vector, 50 nM antisense miR-27a (as-miR-27a) or 
control, and whole cell lysates were analyzed by western blots as described in the Materials and Methods. D. Effects 
of miR-27a mimic or as-miR-27a on luciferase activity in ZBTB10 3’UTR-luc construct transfected cells. miR-27a 
mimic (50 nM) or as-miR-27a were transfected into BT474 and MDA-MB-453 cells as described in the Materials and 
Methods, and a dual luciferase reporter assay was performed according to the manufacturer’s instructions. Results are 
expressed as means  SE for 3 replicate determinations for each treatment group and significant (p < 0.05) decreases 
or inductions are indicated (*). 
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ZBTB10 was induced >2.5-fold in MDA-MB-453 cells treated with 5 or 10 µM 
BA. The effects of antisense-miR-27a (as-miR-27a) and ZBTB10 overexpression 
on levels of Sp1, Sp3 and Sp4 , YY1 and ErbB2 proteins were also determined 
in BT474 and MDA-MB-453 cells (Figs. 28C and 28D) and both treatments 
decreased expression of Sp and Sp-regulated gene products. The effects of a 
miR-27a mimic and as-miR-27a on luciferase activity in BT474 and MDA-MB-
453 cells transfected with ZBTB10 (UTR)-luc construct containing a miR-27a 
binding site resulted in decreased (miR-27a mimic) and increased (as-miR-27a) 
luciferase activity. In contrast, the mimic or antisense oligonucleotide did not 
affect luciferase activity in cells transfected with a construct [ZBTB10 (mUTR)-
luc] containing a mutation in the miR-27a binding sites, confirming interactions of 
miR-27a with the target sequence in the 3’-UTR of ZBTB10. 
 The in vivo effects of BA on tumor growth were also investigated in 
athymic nude mice bearing BT474 cells as xenografts. BA was administered 
over a period of 28 days at a dose of 20 mg/kg/d and tumor volumes and tumor 
weight were significantly inhibited and BA also decreased expression of Sp1, 
Sp3 and Sp4 proteins in tumors (Figs. 29A and 29B). Figure 29C illustrates that 
immunostaining of ErbB2 and Sp1 proteins were also decreased in fixed tumor 
tissue from BA-treated mice compared to control (corn oil) treat animals and 
these in vivo data complement the results of in vitro studies. 
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Figure 29. BA inhibits tumor (BT474 xenografts) growth. Inhibition of tumor size (A) and weight (B). Athymic nude 
mice bearing BT474 cells as xenografts were treated with BA (20 mg/kg/d) and tumor sizes and weights were 
determined as described in the Materials and Methods.  Significantly (p < 0.05) decreased tumor sizes and weights are 
indicated (*). C. BA decreases expression of Sp1, Sp3 and Sp4 proteins in tumors. Whole cell lysates from corn oil 
and BA-treated tumors were analyzed by western blot as described in Materials and Methods. D, immunostaining for 
ErbB2 and Sp1. Fixed tumor tissue from corn oil and BA-treated mice were stained with ErbB2 and Sp1 antibodies as 
described in Materials and Methods. 
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3.4 Discussion 
Endocrine therapies with antiestrogens and aromatase inhibitors for 
women with early stage ER-positive breast cancer has been one of the most 
successful cancer treatments in terms of patient prognosis and survival 
[481,482,485]. In contrast, patients with ER-negative or ErbB2-overexpressing 
tumors must undergo more aggressive treatment and their overall prognosis and 
survival are much lower than patients with early stage breast cancer [486-489]. 
The development of more mechanism-based drugs such as Herceptin for the 
treatment of ErbB2 overexpressing breast tumors has provided some treatment 
benefits for a sub-set of patients with these aggressive tumors [491-494]. 
Herceptin is a monoclonal antibody that binds the extracellular domain of ErbB2 
to decrease the tyrosine kinase activity and this results in inhibition of 
downstream phosphatidylinositol-3-kinase-and mitogen activated protein kinase-
dependent phosphorylation of Akt and MAPK respectively [491-494]. Although 
Herceptin has been successfully used alone and in combination therapy, there is 
concern regarding cardiotoxic side-effects of this antibody and development of 
other agents including tyrosine kinase inhibitors is being actively pursued for 
treatment of tumors which overexpress ErbB2 and other growth factor receptors 
[526]. 
 TA is an NSAID that has been used for treatment of inflammatory 
conditions in humans and veterinary medicine [527] and in pancreatic cancer 
cells and tumors TA inhibited growth and metastasis and induced proteasome-
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dependent degradation of Sp1, Sp3, Sp4 and Sp-regulated genes such as 
VEGF [413,496]. TA also exhibited similar responses in other cells and tumors 
[515] however, in ErbB2-overexpressing breast cancer cells, the role of Sp 
protein downregulation in mediating the anticancer activity of TA was cell 
context-dependent [528]. This was particularly true in BT474 cells where TA 
inhibited cell and tumor growth but this was accompanied by only 20-30% 
repression of Sp1, Sp3 and Sp4. Therefore, in order to determine the effects of 
drug-induced Sp downregulation on ErbB2 overexpressing breast cancer cells 
and tumors we investigated the effects of BA in BT474 and MDA-MB-453 cells 
since previous studies with this compound showed that BA inhibited proliferation 
and induced proteasome-dependent degradation of Sp1, Sp3 and Sp4 in 
prostate cancer cells [448]. 
 BA also inhibited growth and induced apoptosis in both breast cancer cell 
lines (Fig. 23) and this was accompanied by downregulation of Sp1, Sp3 and 
Sp4 protein and mRNA levels (Fig. 24). Moreover, BA also inhibited tumor 
growth and downregulated Sp1, Sp4 and Sp in tumors from athymic nude mice 
bearing BT474 cells as xenografts (Fig. 29). The effects of BA on Sp proteins in 
BT474 and MDA-MB-453 cells were not inhibited after cotreatment with the 
proteasome inhibitor lactacystin (Fig. 24A) and this was in contrast to the 
proteasome-dependent degradation of Sp proteins in LNCaP prostate cancer 
cells treated with BA [448]. In ongoing studies with BA, and other compounds 
that repress Sp proteins we have observed different mechanisms that are cell 
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context-dependent [448]. For example, BA decreases Sp proteins in bladder 
cancer cells and these effects were proteasome-independent [476]. In BT474 
and MDA-MB-453 breast cancer cells BA decreased expression of ErbB2 p-
ErbB2 and downstream ErbB2-dependent kinases p-MAPK/MAPK and p-Akt/Akt 
(Fig. 25) suggesting that ErbB2 downregulation may also be due to repression of 
Sp proteins. However, unlike the EGFR which is an Sp-regulated gene [476], 
ErbB2 expression is dependent on other transcription factors including YY1 
which contains multiple GC-rich promoter sites that bind Sp proteins [525]. BA 
decreased YY1 protein expression in BT474 and MDA-MB-453 cells (Figs. 25A 
and 3B) and not surprisingly knockdown of Sp proteins (individually and 
combined) decreased expression of YY1 and ErbB2 (Figs. 25C and 25D). 
Moreover YY1 knockdown by RNA interference also decreased ErbB2 (Fig. 
25D) demonstrating that BA-mediated downregulation of ErbB2 is linked to 
decreased expression of Sp1, Sp3, Sp4 and Sp-regulated YY1. Previous studies 
with TA in BT474 cells and BA in bladder cancer cells show that both 
compounds repress total Akt and MAPK protein levels [476,528]; similar effects 
were observed in this study and the mechanisms associated with these 
responses are currently being investigated. 
 Previous studies with CDDO-Me in pancreatic cancer cells and CDODA-
Me in colon cancer cells showed that repression of Sp mRNA and proteins was 
due to downregulation of miR-27a in pancreatic, colon and breast cancer cell 
lines [478,514,519]. Mir-27a regulates expression of ZBTB10, an Sp-repressor, 
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and BA-dependent repression of miR-27a results in the induction of ZBTB10 
[478,514,519]. Results summarized in Figure 27 show that BA also decreased 
miR-27a and induced ZBTB10 in BT474 and MDA-MB-453 cells suggesting that 
the critical downstream effects of BA on the miR-27a:ZBTB10 complex are 
similar to those observed in previous studies with the synthetic triterpenoids 
CDDO-Me and CDODA-Me [514,519]. CDDO-Me mediated downregulation of 
miR-27 in pancreatic cancer cells was dependent on upstream disruption of 
mitochondria and induction of ROS however, in contrast to these results BA did 
not induce ROS in BT474 and MDA-MB-453 cells and the antioxidant 
glutathione did not modulate effects of BA on Sp1, Sp3, Sp4 (data not shown). 
 Ongoing studies in this laboratory with cannabinoids show that these 
compounds also downregulate Sp1, Sp3 and Sp4 in cancer cell lines (data not 
shown) and these effects were inhibited after cotreatment with CB1 and CB2 
receptor antagonists AM251 and AM630 respectively. Results in Figures 26 and 
28 show that AM251 and AM630 inhibited BA-induced miR-27a 
(downregulation), ZBTB10 (induction), Sp1, Sp3, Sp4, YY1 and ErbB2 
(downregulation) and confirm that this pathway involves initial BA-dependent 
activation of CB1 and CB2 receptors by BA. These results demonstrate for the 
first time that the effects of BA on BT474 and MDA-MB-453 cells on Sp 
transcription factors and ErbB2 are mediated through activation of the CB1 and 
CB2 receptors which subsequently modulate the miR-27a:ZBTB10-Sp axis. CB1 
and CB2 receptors are expressed in both cell lines and these receptors are 
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expressed in human breast cancer cells and tumors and one study showed a 
correlation between CB2 receptor and ErbB2 expression in human mammary 
tumors [529]. However, since BA does not bind the CB1 and CB2 receptors 
(Figs. 27A, 27B) and since inhibition of FAAH does not affect expression of Sp 
proteins or ErbB2, the mechanisms associated with activation of CB receptors 
by BA are unknown and are currently being investigated. 
 In summary, this study demonstrates that BA inhibits ErbB2-
overexpressing breast cancer cell and tumor growth and this accompanied a 
cascade of events involving activation of the CB1 and CB2 receptors. This 
results in modulation of the miR-27a:ZBTB10-Sp transcript-factor axis, 
downregulation of the Sp-dependent gene YY1 and the YY1-dependent gene 
ErbB2. This pathway does not necessarily define all the anticancer activities of 
BA but significantly contributes to the effects of this compound as an inhibitor of 
ErbB2-overexpressing breast cancer cell and tumor growth. Current studies are 
focused on the mechanistic link between activation of the CB receptors and 
modulation of miR-27a:ZBTB10 and the efficacies and mechanism of action of 
other agents that repress Sp transcription factors. These data demonstrate a 
novel pathway for targeting ErbB2 and suggest new therapeutic approaches for 
treating breast cancer patients that overexpress this oncogene. 
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4. MECHANISM OF ACTION OF ASPIRIN AS AN ANTICANCER 
AGENT IN BREAST CANCER 
 
4.1 Introduction 
Acetylsalicylic acid (ASA) or aspirin is a non-steroidal anti-inflammatory drug 
(NSAID) widely used for treatment of pain, fever and other inflammatory 
conditions [530] and the role of ASA and other NSAIDs in cancer has been 
extensively investigated [417,531-533]. There is evidence for the association of 
ASA use and decreased risk for colorectal, breast, esophageal, lung, stomach 
and ovarian cancer, whereas effects on the incidence of other cancers are 
uncertain [417,531-533]. Several studies consistently show that aspirin is a 
chemopreventive agent for breast and colon cancer [534-541] and there is also 
evidence that aspirin exhibits remarkable chemotherapeutic activity for these 
cancers. For example, a hazard ratio of 0.53 (for mortality) was observed in 
colorectal cancer patients who did not use the drug prior to diagnosis and this 
value decreased to 0.39 for a subset of patients overexpressing 
cyclooxygenase-2 (COX-2) [541]. Several studies have demonstrated the 
protective effects of aspirin in breast cancer incidence [542-550]. A recent report 
on breast cancer patients from the prospective Nurses’ Health Study showed 
that the adjusted relative risks for breast cancer patients using aspirin 1, 2-5 or 
6-7 days/wk were 0.91, 0.57 and 0.40, respectively [550]. These dramatic 
chemotherapeutic effects of aspirin for colorectal and breast cancer demonstrate 
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the potent anticancer activity of this drug and the potential chemotherapeutic 
efficacy for applications of aspirin in drug combinations. 
The effects of aspirin on cancer cells in culture and in in vivo models 
demonstrate the anticancer activity of this compound in multiple tumor types and 
there is evidence for induction of apoptosis, inhibition of cell proliferation and 
angiogenesis [435,551-559]. These aspirin-induced responses are somewhat 
variable among cancer cell types and have been linked to decreased expression 
or activity of NFkB, bcl-2, vascular endothelial growth factor (VEGF) and Wnt/β-
catenin. 
Research in this laboratory has been focused on development of anticancer 
agents that downregulate specificity protein (Sp) transcription factors Sp1, Sp3 
and Sp4 that are overexpressed in many tumor types. Several different classes 
of compounds repress Sp transcription factors and Sp-regulated genes and 
these include betulinic acid and synthetic triterpenoid analogs, curcumin, arsenic 
trioxide non-steroidal antiinflammatory drugs (NSAIDs) and a nitro-NSAID 
derivative [407,413,448,475-477,496,514,515,519,520,528,560-563]. The 
rationale for targeting Sp proteins is due to the importance of Sp-regulated gene 
products many of which are individually targeted by tyrosine kinase inhibitors or 
neutralizing antibodies. Sp-regulated genes that are decreased by anticancer 
drugs and by RNA interference (Sp knockdown) include epidermal growth factor 
receptor (EGFR), hepatocyte growth factor receptor (c-MET) survivin, bcl-2, 
cyclin D1, VEGF and its receptors (VEGFR1/R2) and pituitary tumor 
157 
 
 
1
5
7
 
transforming gene-1 (PTTG-1) [369,448,475-477,518-520]. Recent studies show 
that the NO-NSAID ethyl 2-[(2,3-bis (nitrooxy) propy] disulfanyl benzoate (GT-
094) inhibits colon cancer cell growth and this is due, in part, to downregulation 
of Sp1, Sp3, Sp4 and Sp-regulated genes [562] and in this report we 
investigated the effects of aspirin on ErbB2-overexpressing BT474 and MDA-
MB-453 breast cancer cells. The results show the aspirin decreased expression 
of Sp1, Sp3, Sp4 and several Sp-regulated genes including YY1 and this latter 
response resulted in decreased expression of ErbB2 which is regulated by YY1. 
4.2 Materials and methods 
 
Chemicals, antibodies and reagents - Aspirin, camptothecin, lactacystin, 
phosphatase inhibitor cocktail II, sodium orthovanadate and MKP-5 (D7944) 
antibody were purchased from Sigma-Aldrich (St. Louis, MO). Antibodies against 
ErbB2 (C-18), p-ErbB2 (Try 1248)-R, Sp1 (PEP2), Sp3 (D-20), Sp4 (V-20), Akt 
(H-136), p-Akt (Ser473), MAPK(C-14), p-MAPK (E-4), β-actin (C4), β-tubulin (H-
235), VEGF (A20), AP-2 (C-18) and YY1 (H-10) were obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA); Antibodies against cleaved-PARP (D214) 
and survivin were obtained from Cell Signaling Technology (Danvers, MA). The 
negative control siRNA (4613) siRNA for MKP-5 and MKP-1 was purchased 
from Ambion (Austin, TX). Western lightning chemiluminescence reagent was 
from Perkin-Elmer Life Sciences (Boston, MA). Lipofectamin 2000 was 
purchased from Invitrogen. 
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 Cell lines - Human mammary carcinoma cell lines MDA-MB-453, and 
BT474 were obtained from the American Type Culture Collection (Manassas, 
VA).  Cell lines were cultured with 10% fetal bovine serum (FBS) in DMEM and 
were maintained at 37C in the presence of 5% CO2. 
 Cell proliferation assay - Cells (2-3 x 104 per well) were plated in 12-well 
plates and allowed to attach for 24 hr.  Then cells were treated with either vehicle 
(DMSO) or different concentrations of aspirin for 48 hr, and cells were then 
trypsinized and counted using a Coulter Z1 cell counter.  Each experiment was 
done in triplicate, and results are expressed as means  SE for each set of 
experiments. 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling - 
Cells were plated in Lab-Tek II Chamber Slide System (Nalge Nunc 
International, Naperville, IL) and allowed to attach for 24 hr.  Then cells were 
treated with either vehicle (DMSO) or different concentrations of aspirin for 24 hr, 
TUNEL staining was performed using the DeadEnd™ Fluorometric TUNEL 
System (Promega, Madison, WI) following manufacture’s protocol. The slides 
were analyzed using a Nikon ECLIPSE 80i confocal microscope (Japan). 
Cell migration assay - Cells were seeded 70% confluent in triplicates in 
six-well collagen IV–coated plates and then treated with selected concentration 
of aspirin for 24 hours, then a scratch through the central axis of the plate was 
gently made using a sterile 200 ul pipette tip. Cells were then washed with 
medium and treated with the DMSO control or different concentration of aspirin. 
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Migration of the cells into the scratch was observed at nine preselected points 
(three points per well) at 0, 24, and 48 hour. Results of this study were obtained 
at a 48 hour time point. 
 Western blotting - Cells were rinsed with PBS and collected by scraping 
cells from the culture plate in 200 L of lysis buffer.  The cell lysates were 
incubated on ice for 1 hr with intermittent vortex mixing and then centrifuged at 
40,000 g for 10 min at 4C.  Equal amounts of protein were separated on SDS-
polyacrylamide gels.  Proteins were transferred to Immobilon P membranes 
(Millipore, Bedford, MA) using a Bio-Rad Trans-blot apparatus and transfer 
buffer (48 mM Tris, 39 mM glycine, 0.0375% SDS, 20% methanol).  After 
blocking in TBST-Blotto [10 mmol/L Tris-HCl, 150 mmol/L NaCl (pH 8), 0.05% 
Triton X-100, 5% nonfat dry milk] for 30 min, the membranes were incubated 
with primary antibodies overnight at 4C and then with horseradish peroxidase-
conjugated secondary antibody for 2 hr at room temperature.  Proteins were 
visualized using the chemiluminescence substrate (Perkin-Elmer Life Sciences) 
for 1 min and exposed to Kodak X-OMAT AR autoradiography film (Eastman 
Kodak, Rochester, NY). 
 Quantitative real-time PCR - Total RNA was purified using RNeasy Mini 
Kit (Qiagen, Germantown, MD) and cDNA was prepared using Reverse 
Transcription System (Promega, Madison, WI).  Each PCR was carried out in 
triplicate in a 30 L volume using SYBR Green Mastermix (Applied Biosystems, 
Foster City, CA) for 15 min at 95C for initial denaturing, followed by 40 cycles of 
160 
 
 
1
6
0
 
95C for 30 s and 60C for 1 min in the Applied Biosystems 7900HT Fast Real-
time PCR System.  The ABI Dissociation Curves software was used following a 
brief thermal protocol (95C for 15 s and 60C for 15 s, followed by a slow ramp 
to 95C) to control for multiple species in each PCR amplification.  Values for 
each gene were normalized to expression levels of TATA-binding protein (TBP).  
Primers were obtained from Integrated DNA Technologies.  The following 
primers were used: 
MKP-5(F):  5'-ATC TTG CCC TTC CTG TTC CT-3'. 
MKP-5(R):  5'-ATT GGT CGT TTG CCT TTG AC-3'. 
MKP-1(F): 5'-CTC CAT GCT CCT TGA GAG GAG-3'. 
MKP-1(R): 5'-GGT AGG TAT GTC AAG CAT GAA-3'. 
FAP-1(F): 5'-GAA TAC GAG TGT CAG ACA TG-3'. 
FAP-1(R): 5'-AGG TCT GCA GAG AAG CAA GA-3'. 
PTP-1B(F): 5'-ACG AAT CCT GGA GCC ACA CAA TG-3'. 
PTP-1B(R): 5'-AGC CCA CGC ACA TGT TGA CCA GGA-3'. 
Se-PAP(F): 5'-GGC AGA TGA TGC TTT GAG AAC-3'. 
Se-PAP(R): 5'-TCA TCC AAA GCC CAT TTT CC-3'. 
TM-PAP(F): 5'-TCT CAG TGG TGC CGC ATC TA-3'. 
TM-PAP(R): 5'-CAG GGT GTG AGG ATG GCA A-3'. 
TBP (F):  5'-TGC ACA GGA GCC AAG AGT GAA-3'.  
TBP (R):  5'-CAC ATC ACA GCT CCC CAC CA-3'. 
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siRNA transfection - Cells at 50% confluency in 60 mm collagen-coated 
dishes were transfected with 50 nmol of negative control or MKP-5 / MKP-1 
specific siRNA using Lipofectamin 2000. Transfection with siRNA was 
accomplished according to the manufacturer’s instructions. Transfection reagent 
was not removed from the cells and transfected cells were incubated for 72 
hours at 37°C before experimentation. 
4.3 Results 
BT474 AND MDA-MB-453 cells were treated with 1 – 10 mM aspirin for 48 
hr.; cell growth was inhibited by 1.5 and 10 mM aspirin and IC50 values were 4.1 
and 2.13 mM respectively (Fig. 30A). Similar results were observed in estrogen 
receptor (ER)-negative SKBR3 and MDA-MB-231 cells (data not shown). MDA-
MB-453 and BT474 cells were also treated with DMSO (solvent control), 2.5 and 
5.0 mM aspirin for 24 hr. and analyzed for apoptosis in a TUNEL assay (Fig. 
30B). After staining with DAPI and FITC there was increased TUNEL staining in 
both cells and similar results were observed after treatment of BT474 cells with 
0.2 ug/ml camptothecin which served as a positive control for this experiment 
(Fig. 30B). The effects of 1 or 2.5 mM aspirin of cell migration were also 
investigated in MDA-MB-453 and BT474 cells (Fig. 30C). Treatment for 48 hr. 
inhibited cell growth in both cell lines; however migration was inhibited only in 
MDA-MB-453 cells. Under the conditions used in this experiment neither cell line 
exhibited high levels of migration and BT474 cells did not significantly migrate in 
the solvent (DMSO) control group. 
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Figure 30. Effects of aspirin on cell proliferation, apoptosis and migration. A. Aspirin-mediated inhibition of BT474 
and MDA-MB-453 cell growth. Cells were treated with solvent (DMSO) or different concentrations of aspirin for 2 
days and the number of cells in each treatment group were determined as described in the Materials and Methods. Cell 
survival is expressed as the percentage of aspirin-treated cells remaining compared to DMSO (set at 1). Significant (p 
< 0.05) growth inhibition is indicated (*). Results are expressed as means  SE for at least 3 replicate determinations 
for each treatment group. B. Aspirin induces apoptosis in cancer cells. Cells were treated with DMSO, 2.5, 5.0 mM 
aspirin or 0.2 ug / ml camptothecin for 24 hours and analyzed with TUNEL as described in the Materials and Methods. 
C. Cell migration assay. MDA-MB-453 and BT474 cells were treated with DMSO, 1 mM or 2.5 mM aspirin for 48 
hours, migration of cells were determined as described in the Materials and Methods. 
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Figure 31A shows that aspirin-induced growth inhibition and apoptosis 
observed in BT474 cells (Fig. 30) is accompanied by induction of cleaved PARP 
and downregulation of the survival protein survivin and VEGF (Fig. 31A). 
Moreover, aspirin also decreased phosphorylation of ErbB2 which is a critical 
growth/survival-promoting factor in BT474 cells. However, this was also 
accompanied by decreased expression of ErbB2 (total) protein (Fig. 31C). We 
also observed decreased phosphorylation of AKT and MAPK and this was also 
accompanied by decreased expression of total AKT protein but much less 
pronounced changes in total MAPK protein were observed. In a parallel set of 
experiments in MDA-MB-453 cells, treatment with aspirin also decreased 
expression of survivin and VEGF and induced PARP cleavage (Fig. 31B) and 
the effects on phospho- and total ErbB2, AKT and MAPK proteins (Fig. 31D) 
were similar to those observed in BT474 cells. 
Results of ongoing and published studies from this laboratory show that 
downregulation of Sp1, Sp3 and Sp4 proteins by various agents or by RNA 
interference can lead to the changes in protein expression observed in Figure 31 
[448,475-477,514,515,519,520] and therefore the effects of aspirin on Sp1, Sp3 
and Sp4 expression were investigated. Aspirin induced a concentration- and 
time-dependent decrease in Sp1, Sp3 and Sp4 protein levels in BT474 and 
MDA-MB-453 cells (Fig. 32A). Some agents that induce downregulation of Sp 
proteins activate the proteasome pathway [448,475] and results in Figure 32B 
show 
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Figure 31. Effects of aspirin on survival proteins, cleaved-PARP, ErbB2 and ErbB2-dependent proteins. VEGF, 
survivin and c-PARP expression in BT474 (A) and MDA-MB-453 (B) cells treated with aspirin. Cells were treated 
with different concentrations of aspirin for 24 or 48 hours and whole cell lysates were analyzed by western blots as 
described in the Materials and Methods. ErbB2 and ErbB2-dependent protein expression in BT474 (C) and MDA-
MB-453 (D) cells treated with aspirin. Cells were treated as described in (A), (B) and whole cell lysates were analyzed 
by western blots as described in the Materials and Methods. 
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show that aspirin-induced downregulation of Sp1, Sp3 and Sp4 proteins in 
BT474 and MDA-MB-231 cells was partially reversed after cotreatment with the 
proteasome inhibitor lactacystin. These results were obtained after treatment of 
the cells with 2.5 mM aspirin and 1 M lactacystin for 48 hr. and higher 
concentrations of either compound were cytotoxic. Thus aspirin-mediated 
downregulation of Sp1, Sp3 and Sp4 was due in part to activation of the 
proteasome pathway as previously observed for the NSAID tolfenamic acid and 
betulinic acid in pancreatic and prostate cancer cells respectively [448,475]. 
YY1 regulates ErbB2 expression in BT474 [319] and MDA-MB-453 [564] 
and recent studies in this laboratory have demonstrated by RNA interference 
that YY1 is also an Sp-regulated gene in both cell lines [564]. Figures 32C and 
32D show that aspirin also decreased YY expression in both cell lines and this 
effect is reversed in cells cotreated with aspirin plus the proteasome inhibitor 
lactacystin. AP2 is a transcription activator of ErbB2. Therefore expression of 
AP2 was also investigated. AP2 expression was not changed in BT474 and 
MDA-MB-453 cells treated with aspirin for 24 hr and a slight decrease was 
observed when cells are treated with 5 mM aspirin for 48 hr (Fig. 32C); and this 
effect was not reversible in cells cotreated with aspirin plus lactacystin (Fig. 
32D). 
Phosphorylation of Sp1 increases Sp-1 dependent transactivation[565] and 
also protects against proteasome-dependent degradation of Sp1 [347] 
suggesting that aspirin-induced proteasome-dependent degradation of Sp1, Sp3 
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Figure 32. Effects of aspirin on Sp, YY1 and AP2 proteins. Sp1, Sp3 and Sp4 expression in BT474 and MDA-MB-
453 cells treated with aspirin alone (A) or in combination with lactacystin (B). Cells were treated with different 
concentrations of aspirin (A) or pretreated with 1 uM lactacystin for 1 hour followed by addition of aspirin (B) for 48 
hours and whole cell lysates were analyzed by western blots as described in the Meterials and Methods. YY1 and AP2 
expression in BT474 and MDA-MB-453 cells treated with aspirin alone (C) or in combination with lactacystin (D). 
Cells were treated as described in (A), (B) and whole cell lysates were analyzed by western blots as described in the 
Meterials and Methods. 
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and Sp4 may be due to induction of phosphatases. Results in Figure 33A show 
that PICII, a commercial mixture of phosphatase inhibitors (sodium 
orthovanadate, sodium molybdate, sodium tartrate and imidazole) inhibited 
aspirin-induced downregulation of Sp1, Sp3 and Sp4 in BT474 cells whereas 
another mixture of phosphatase inhibitors (PIC I) had minimal effects (data not 
shown). Results of preliminary screening of PICII components indicated that 
sodium orthovanadate (SOV) was the most active inhibitor (Fig. 33A) and the 
aspirin-induced effects on Sp proteins were inhibited by PICII and SOV in BT474 
cells. In MDA-MB-453 cells aspirin-induced downregulation of Sp1, Sp3 and Sp4 
were also inhibited by PICII and SOV (Fig. 33B). SOV was used as an inhibitor 
of aspirin-induced downregulation of survivin and induction of PARP cleavage in 
BT474 and MDA-MB-453 cells and the effects of aspirin were reversed by SOV 
(Fig. 33C). Moreover, SOV also inhibited aspirin-induced downregulation of 
ErbB2 (total) and phosphorylated ErbB2, AKT and MAPK (Fig. 33D) and the 
effects of aspirin illustrated in Figures 33C and 33D were also inhibited by PICII 
(data not shown). 
Several different classes of anticancer agents including curcumin, a 
compound that also decreases expression of Sp1, Sp3 and Sp4 in cancer cells 
[475,477] also induce phosphatase gene expression [566-571] and Figures 34A 
and 34B summarize the effects of aspirin on induction of 6 phosphatases in 
BT474 and MDA-MB-453 cells respectively. Like curcumin [566], aspirin induces 
MKP-5 and also MKP-1 in both cell lines; soluble prostatic acid phosphatase (s- 
168 
 
 
1
6
8
 
      
 
Figure 33. PIC II or Na3VO4 reverses the effects of aspirin on Sp, survival proteins, ErbB2 and ErbB2-dependent 
proteins. Expression of Sp1, Sp3 and Sp4 proteins in BT474 (A) and MDA-MB-453 (B) cells treated with aspirin with 
or without PIC II or Na3VO4. Cells were pretreated with or withour 1:50 diluted PIC II or 5 mM Na3VO4 for 1 hour 
followed by addition of different concentrations of aspirin for 48 hours and whole cell lysates were analyzed by 
western blots as described in the Materials and Methods. Expression of survivin, c-PARP (C), ErbB2 and ErbB2-
dependent (D) proteins in BT474 and MDA-MB-453 cells treated with aspirin with or without 5 mM Na3VO4. Cells 
were pretreated with or without Na3VO4 followed by addition of aspirin as described in (A, B) and whole cell lysates 
were analyzed by western blots as described in the Materials and Methods. 
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Figure 34. Effects of aspirin on phosphatases. Effects of aspirin on MKP-5, MKP-1, Se-PAP, TM-PAP, FAP-1 and 
PTP-1B mRNA levels in BT474 (A) and MDA-MB-453 (B) cells. Cells were treated with 5 mM aspirin for up to 16 
hr (a), or treated with different concentration of aspirin for 24 hr (b), and phosphatase mRNA levels were determined 
by real time PCR as described in the Materials and Methods.  Results are expressed as means  SE for 3 replicate 
determinations for each treatment group and significant (p < 0.05) inductions are indicated (*). Roles of MKP-5 (C) 
and MKP-1 (D) in aspirin-induced downregulation of Sp proteins, ErbB2 and YY1.  Cells were transfected with 
control siRNA, siRNAs for MKP-5 or  MKP-1, then DMSO or 5 mM aspirin was added to the medium and cells were 
incubated in 37 C for 48 hr. Whole cell lysates were analyzed by western blots as described in the Materials and 
Methods. 
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Figure 34. (Continued) 
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PAP) was not induced by aspirin and cellular PAP (c-PAP) was induced in MDA-
MB-453 but not BT474 cells. Two additional phosphatases (FAP-1 and PTP-1B) 
were not induced in either cell lines. Since aspirin and curcumin decrease 
expression of Sp1, Sp3, and Sp4 and Sp-regulated gene products (Figs. 31-32) 
and also induce MKP-5 mRNA we hypothesized that MKP-5-dependent 
dephosphorylation of Sp proteins may be important for activation of the 
proteasome pathway. Results in Figure 34C demonstrate that aspirin-induced 
downregulation of Sp1, Sp3 and Sp4 are accompanied by induction of MKP-5 
protein and in cells transfected with an oligonucleotide (siMKP5) that knocks 
down MKP-5 by RNA interference the effects of aspirin on Sp1, Sp3 and Sp4 
are reversed. MKP1 protein level was induced in BT474 but not in MDA-MB-453 
cells when treated with aspirin, and knockdown of MKP1 in BT474 cells does not 
reverse aspirin-induced downregulation of Sp1, Sp3 and Sp4 (Fig. 34D). This 
demonstrates for the first time a linkage between a drug-induced phosphatase 
and Sp downregulation and is consistent with studies by Hung, Chang and 
coworkers showing that phosphorylation stabilizes Sp1 [347]. 
4.4 Discussion 
Sp transcription factors are overexpressed in multiple tumor types and Sp1 
is a negative prognostic factor for survival of gastric and colon cancer cell lines 
[368,572]. Although most Sp transcription factors are critical in embryonic and 
early postnatal development [573] there is evidence in rodents and humans that 
Sp1 expression decreases with age [516,517,574] in mouse tumor xenograft 
172 
 
 
1
7
2
 
studies expression of Sp1, Sp3 and Sp4 is low in most organs and high in 
tumors[413,448,477]. Lou and coworkers reported that carcinogen-induced 
transformation fibroblasts that formed tumors in xenograft experiments exhibited 
an 8- to 18-fold increase in Sp1 expression in the transformed cells [575]. 
Moreover, knockdown of Sp1 in the transformed cells resulted in the loss of 
tumor formation of these cells in animal models thus demonstrating the pro-
oncogenic activity of Sp1. 
The importance of Sp1, Sp3 and Sp4 as targets for anticancer drugs is due 
primarily to Sp-regulated growth promoting (cyclin D1, p65, c-MET and EGFR), 
antiapoptotic (survivin and bcl-2) and angiogenic (VEGF, VEGFR1/R2 and 
PTTG-1) genes. Studies in this laboratory have identified several anticancer 
agents that induce proteasome-dependent or –independent downregulation of 
Sp1, Sp3 and Sp4 regulated gene products, and the mechanism of action of 
these responses are cell context- and compound-dependent. Nevertheless, the 
development and mechanism of action of compounds such as curcumin, arsenic 
trioxide, NSAIDs, betulinic acid and synthetic triterpenoids that decrease Sp1, 
Sp3, Sp4 and Sp-regulated genes is important for the future clinical applications 
of these drugs alone and in combination therapies. 
NSAIDs such as tolfenamic acid target Sp proteins in most but not all cell 
lines and the NO-NSAID GT-094 also exhibits similar activity in colon cancer 
cells [413,496,561,562]. Since aspirin exhibits chemotherapeutic and 
chemopreventive activity in breast cancer patients [542-550] we hypothesized 
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that this compound may act by targeting Sp transcription in breast cancer cells. 
Recent studies in this laboratory showed that betulinic acid decreased 
expression of Sp1, Sp3, Sp4 and Sp-regulated gene products in ErbB2-
overexpressing breast cancer cells (BT474 and MDA-MB-453), and it was 
demonstrated that decreased expression of ErbB2 was due to downregulation of 
YY1 an Sp-regulated gene that is important for ErbB2 expression [319,564]. 
Aspirin inhibited BT474 and MDA-MB-453 cell growth and induced apoptosis 
(Figs. 30A and 30B) at low mM concentrations as reported in other cancer cell 
lines [319]. Moreover, aspirin decreased expression of Sp1, Sp3 and Sp4 
proteins and surviving, and this was accompanied by induction of cleaved PARP 
in both cell lines as previously described for betulinic acid in these same cell 
lines [564] and for other agents that target Sp transcription factors. 
The growth inhibitory effects of BA in BT474 and MDA-MB-453 cells was 
due, in part, to downregulation of ErbB2, phospo-ErbB2 and ErbB2-regulated 
genes [564] and this was also observed for aspirin in these cell lines (Fig. 31). 
Moreover like BA [564] aspirin also decreased expression of the Sp-regulated 
gene YY1 (Figs. 32C and 32D) and this is consistent with the downregulation of 
ErbB2 which is regulated by YY1. The effects of BA in breast cancer cells and 
GT-094 (NO-NSAID) in colon cancer cells were proteasome independent and 
involved disruption of microRNA:ZBTB10 interactions resulting in enhanced 
expression of the transcriptional repressor ZBTB10, an Sp repressor that 
decreases expression of Sp and Sp-regulated genes [562]. In contrast, the 
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effects of aspirin on Sp1, Sp3 and Sp4 are due to activation of proteasomes and 
these effects can be blocked by the proteasome inhibitor lactacystin (Fig. 32B) 
and this pathway has previously been observed for tolfenamic acid and betulinic 
acid in pancreatic and colon cancer cells respectively [448,475]. The mechanism 
of this response has not been determined. However a recent study showed that 
phosphorylation of Sp1 stabilized this protein and inhibited ubiquitination and 
proteasome-dependent degradation [347]. Not surprisingly phosphatase 
inhibitors such as PICII and SOV inhibited aspirin-induced downregulation of 
Sp1, Sp3, Sp4 and Sp regulated genes (Fig. 33), suggesting a role for 
phosphatases in mediating decreased expression of Sp proteins. 
Previous studies in colon cancer cells show that aspirin inhibited protein 
phosphatase 2A activity [553]. However it has also been reported that curcumin 
induced MKP5 in prostate cancer cells [566] and we have previously showed 
that curcumin decreased Sp transcription factors in bladder and pancreatic 
cancer cells and tumors [475,477]. Aspirin also induces MKP-5 and other 
phosphatases in BT474 and MDA-MB-453 cells (Figs. 34A and 34B) and 
knockdown of MKP-5 inhibited aspirin-induced effects on Sp proteins (Fig. 34C). 
These results suggest that for aspirin in BT474 and MDA-MB-453 cells, a key 
event in downregulation of Sp1, Sp3 and Sp4 is associated with induction of 
MKP-5 and phosphatase activity. These effects may be cell context-specific and 
current studies are focused on the induction and role of other phosphatases in 
mediating downregulation of Sp1, Sp3 and Sp4 and on identification of other 
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factors such as ubiquitin ligases that may also be required for activating 
proteasomes pathways that primarily target Sp1, Sp3 and Sp4. Our results 
identify for the first time that the mechanisms of action of aspirin as a 
chemotherapeutic agent for treatment of breast cancer is due, in part, to 
activating proteasomes that targeted Sp1, Sp3 and Sp4 transcription factors and 
this is accompanied by decreased expression of growth promoting, antiapoptotic 
and angiogenic Sp-regulated genes. These effects include downregulation of 
YY1 and ErbB2 (a YY1-regulated gene) and illustrate a novel pathway for 
targeting ErbB2 and also demonstrate why aspirin is a highly effective 
chemotherapeutic agent for treatment of breast cancer. These results also 
suggest that other agents that decrease Sp1, Sp3 and Sp4 transcription factors 
may also be effective for breast cancer chemotherapy, and our ongoing 
research is focused on characterization and clinical applications of these 
compounds. 
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5. SUMMARY 
 
Treatment of patients with ER-positive breast cancer with endocrine 
therapies such as SERMs and aromatase inhibitors has been highly successful 
in terms of improving patient survival [481,482,485]. However, approximately 20 
to 30 percent of breast cancer patients overexpress ErbB2 and treatment for 
women with ER-negative or ErbB2-positive breast tumors is relatively more 
intractable and the overall prognosis and survival of this sub-set of patients are 
much lower than patients with early stage ER-positive breast cancer [486-489]. 
The development of Herceptin for treatment of ErbB2 overexpressing breast 
tumors has brought significant benefits to this subset of patients. Herceptin is a 
monoclonal antibody that binds to the extracellular domain of ErbB2 to block 
dimerization which results in increased endocytosis and degradation of ErbB2 
resulting in inhibition of downstream activation of PI3K and MAPK signaling. 
Although Herceptin has been successfully used alone and in combination with 
other drugs, cardiotoxicity and fetal-toxicity have been reported as side-effects 
[493,576]. Development of other agents that target ErbB2 include other 
monoclonal antibodies (Pertuzumab), tyrosine kinase inhibitors (Lapatinib), 
ansamycin antibiotics (geldanamycin), proteasome inhibitors (bortezomib), and 
FAS inhibitors [220,270,492-494,497-501,503-508]. Although the mechanisms of 
action of these compounds are highly variable, all the compounds block 
activation of ErbB2 and downstream responses. 
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Sp transcription factors are over expressed in multiple tumor types 
compared to normal tissues and Sp1 is a negative prognostic factor for survival 
of gastric and colon cancer patients [368,572]. Sp transcription factors have 
been investigated as important anticancer drug targets, and this is due in part to 
regulation of pro-oncogenic factors by Sp transcription factors and these include 
genes involved in growth promotion (cyclin D1, E2F1, c-fos, p65, c-MET and 
EGFR) [374-377], cell survival (survivin, bcl-2) [383-385] and angiogenesis 
(VEGF, VEGFR1 /R2, PTTG-1) [369,382]. 
TA is a relatively non-toxic NSAID used in humans for treatment of 
migraines and as an anti-inflammatory drug in veterinary medicine. Development 
of TA exhibits relatively low toxicity and previous studies reports show that TA 
inhibited growth and metastasis of pancreatic cancer cells and tumors through 
inducing proteasome-dependent degradation of Sp1, Sp3, Sp4 and Sp-regulated 
genes such as VEGF [413,496]. TA also exhibited similar effects in esophageal 
cancer cells and tumors; however the effects on Sp downregulation were 
proteasome-independent in these cells [515]. In this study, TA inhibited growth 
of ErbB2-overexpressing BT474 and SKBR3 breast cancer cells. However, in 
contrast to pancreatic cancer cells, TA induced downregulation of ErbB2 but not 
Sp proteins.  TA-induced ErbB2 downregulation was accompanied by decreased 
ErbB2-dependent kinase activities, induction of p27, and decreased expression 
of cyclin D1.  TA also decreased ErbB2 mRNA expression and promoter activity, 
and this was due to decreased mRNA stability in BT474 cells and, in both cell 
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lines, TA decreased expression of the YY1 and AP-2 transcription factors 
required for basal ErbB2 expression.  In addition, TA also inhibited tumor growth 
in athymic nude mice in which BT474 cells were injected into the mammary fat 
pad. In contrast to mechanisms of other ErbB2-targeting drugs, downregulation 
of ErbB2 by TA is not due to enhanced ErbB2 degradation, induction of ErbB2 
repressors or increased ErbB2 endocytosis (Fig. 35A). Thus, the anticancer 
activity of TA is associated with downregulation of Sp transcription factors in 
some cell lines [369,413,496]. However repression of the oncogene ErbB2 in 
ErbB2-positive breast cancer cell lines was independent of effects on Sp 
transcription factors. It is possible that the effects of TA on expression of other 
factors that regulate YY1 and AP2 in BT474 and SKBR3 cells are important for 
downregulation of ErbB2 and the mechanisms of this response and potential 
clinical applications of TA for treatment of ErbB2-overexpressing cancers are 
currently being investigated. 
BA is a natural pentacyclic triterpenoid which exhibited selective 
cytotoxicity against a number of specific tumors, a variety of infectious agents 
such as HIV, malaria and bacteria, and the inflammatory process [445]. 
Biological activity of BA was first demonstrated in melanoma cell lines and was 
confirmed in mice bearing human melanoma cells as xenografts [460]. These in 
vivo studies demonstrated a favorable safety margin for BA, as systemic side 
effects were not observed at any dose up to 500 mg per kg body weight 
[440,460]. Previous studies in this laboratory reported that BA inhibited prolifera- 
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Figure 35. Model of mechanisms of TA (A), BA (B) and aspirin (C). 
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tion and induced proteasome-dependent degradation of Sp1, Sp3 and Sp4 in 
prostate cancer cells [448]. BA also decreases Sp proteins in bladder cancer 
cells and these effects were proteasome-independent [476]. In this study, 
treatment of ErbB2 overexpressing BT474 and MDA-MB-453 breast cancer cells 
with 1-10 M BA inhibited cell growth and induced apoptosis through 
downregulation of both Sp proteins and ErbB2; this effect was proteasome-
independent as observed for BA in bladder cancer cells but contrasted to BA-
induced proteasome-dependent degradation of Sp1, Sp3 and Sp4 in prostate 
cancer cells [448]. In this study, BA also induced downregulation of survivin, a 
Sp-regulated gene, ErbB2-regulated kinases, YY1 and luciferase activity in cells 
transfected with a construct containing the GC-rich YY1 promoter linked to a 
luciferase reporter gene. Knockdown of Sp1, Sp3, Sp4 and their combination by 
RNA interference was also accompanied by decreased expression of ErbB2 and 
YY1. However, unlike the EGFR which is an Sp-regulated gene, ErbB2 
expression is dependent on other transcription factors including YY1 which 
contains multiple GC-rich promoter sequences that bind Sp proteins [525], 
suggesting indirect regulation of ErbB2 by Sp transcription factors. BA-
dependent repression of Sp1, Sp3, Sp4 and Sp regulated genes was due in part 
to induction of the Sp repressor ZBTB10 and down regulation of microRNA-27a 
(miR-27a) which constitutively inhibits ZBTB10 expression. The effects of BA on 
the miR-27a:zBTB10-Sp transcription factor axis were inhibited in cells cotreated 
with the cannabinoid 1 (CB1) and CB2 receptor antagonists AM251 and AM630 
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respectively (Fig. 35B). However, in vitro binding studies with ≤ 10 M BA and a 
radiolabeled cannabinoid did not indicate competitive binding of BA to the CB1 
and CB2 receptors, suggesting a possible role for other CB-like G protein-
coupled receptors. In the athymic nude mice xenograft studies, BA not only 
inhibited tumor growth but also decreased expression of Sp1, Sp3, Sp4 and 
ErbB2 in the tumors. Previous studies with TA in BT474 cells and BA in bladder 
cancer cells show that both compounds repress total Akt and MAPK protein 
levels [510,511]; similar effects were observed in this study and the mechanisms 
associated with these responses are currently being investigated. 
Aspirin is a widely used NSAID for relieving minor aches, reducing fever 
and as an anti-inflammatory agent. Although aspirin induces considerable side-
effects such as gastrointestinal ulcers, stomach bleeding, and tinnitus in higher 
doses, prolonged use of aspirin results in chemotherapeutic and 
chemopreventive activity in breast cancer patients [542-550] and this prompted 
us to investigate the effects and mechanism of action of aspirin in ErbB2-
overexpressing breast cancer cells. Aspirin inhibited growth, induced apoptosis 
and inhibited migration of BT474 and MDA-MB-453 breast cancer cells that 
overexpress the ErbB2 oncogene. Aspirin also downregulated ErbB2 expression 
in these cells and this was accompanied by inhibition of downstream kinases 
including phospho-Akt and phospho-mitogen-activated protein kinase (p-MAPK). 
Aspirin also decreased expression of Sp1, Sp3, Sp4 and survivin, and this effect 
was inhibited in part by proteasome inhibitor lactacystin and phosphatase 
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inhibitors including sodium orthovanadate (SOV), suggesting a role for 
proteasomes and phosphatases in aspirin-induced downregulation of Sp 
proteins (Fig. 35C). These results were consistant with induction of several 
phosphatases by aspirin in BT474 and MDA-MB-453 cells and these include 
MKP-5 and MKP-1. Aspirin-induced downregulation of Sp1, Sp3 and Sp4 were 
reversed in cells transfected with an oligonucleotide (siMKP5) that knocks down 
MKP5 by RNA interference demonstrating for the first time a linkage between a 
drug-induced phosphatases and Sp downregulation and this is consistent with 
studies showing that phosphorylation stabilizes Sp1 [347]. Aspirin-induced 
induction of MKP-1 mRNA was not accompanied by increased MKP-1 protein 
level in MDA-MB-453 cells suggesting possible enhanced degradation or 
repression of translation of MKP-1 in this cell line. Knockdown of MKP-1 in 
BT474 cells did not affect aspirin-induced downregulation of Sp proteins and 
ErbB2 implicates that induction of MKP-1 mRNA and protein levels were not 
accompanied by increased activity of this protein. These results demonstrated 
that aspirin-induced downregulation of Sp1, Sp3 and Sp4 is due to induction of 
MKP and the role of MKP2 in destabilizing Sp proteins and facilitating 
degradation by proteasomes is currently being investigated. 
In summary, these studies demonstrated that TA, BA and aspirin inhibited 
ErbB2-overexpressing breast cancer cell and tumor growth by targeting Sp / 
ErbB2 through different mechanisms. Results of these studies do not 
necessarily define all the anticancer activities of TA, BA and aspirin but identify 
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important pathways that significantly contribute to the effects of these 
compounds as inhibitors of ErbB2-overexpressing breast cancer cell and tumor 
growth. 
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